---
document_datetime: 2023-09-21 20:18:34
document_pages: 134
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/blincyto-h-c-3731-ii-0030-epar-assessment-report-variation_en.pdf
document_name: blincyto-h-c-3731-ii-0030-epar-assessment-report-variation_en.pdf
version: success
processing_time: 193.5394858
conversion_datetime: 2025-12-30 00:55:31.473635
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

15 October 2020 EMA/CHMP/37563/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## BLINCYTO

International non-proprietary name: blinatumomab

Procedure No. EMEA/H/C/003731/II/0030

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................8           |
| 2.1.2. About the product............................................................................................10      |                                                                                                         |
| 2.1.3. General comments on compliance with GLP, GCP.................................................10                      |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11          |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                             |
| 2.2.2. Discussion on non-clinical aspects......................................................................11           |                                                                                                         |
| 2.2.3. Conclusion on the non-clinical aspects................................................................11             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11    |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................14      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................18         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................19      |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................19             |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................19              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................19    |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................20                     |
| 2.4.2. Main study(ies)                                                                                                      | ...............................................................................................21       |
| 2.4.3. Discussion on clinical efficacy............................................................................66        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................72          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................73  |
| 2.5.1. Introduction....................................................................................................73   |                                                                                                         |
| 2.5.2. Clinical safety in adult RR Phi + ALL patients.......................................................75              |                                                                                                         |
| 2.5.3. Clinical safety in peadiatric RR Phi + ALL patients ..............................................                   | 109                                                                                                     |
| 2.5.4. Clinical safety in adult MRD Phi + ALL patients ..................................................                   | 110                                                                                                     |
| 2.5.5. Safety related to drug-drug interactions and other interactions                                                      | ........................... 110                                                                         |
| 2.5.6. Post marketing experience..............................................................................              | 110                                                                                                     |
| 2.5.7. Discussion on clinical safety ............................................................................           | 111                                                                                                     |
| 2.5.8. Conclusions on clinical safety                                                                                       | .......................................................................... 115                          |
| 2.5.9. PSUR cycle                                                                                                           | ................................................................................................... 115 |
| 2.6. Risk management plan......................................................................................             | 115                                                                                                     |
| 2.7. Update of the Product information ......................................................................               | 126                                                                                                     |
| 2.7.1. User consultation...........................................................................................         | 126                                                                                                     |
| 3. Benefit-Risk Balance............................................................................126                      |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 126           |
| 3.1.1. Disease or condition.......................................................................................          | 126                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 127                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 127             |
| 3.2. Favourable effects                                                                                                     | ............................................................................................ 128        |

<div style=\"page-break-after: always\"></div>

3.3. Uncertainties and limitations about favourable effects  ........................................... 128

3.4. Unfavourable effects  .........................................................................................  129

3.5. Uncertainties and limitations about unfavourable effects ....................................... 130

3.6. Effects Table  ....................................................................................................  131

3.7. Benefit-risk assessment and discussion  ............................................................... 133

3.7.1. Importance of favourable and unfavourable effects  ............................................ 133

3.7.2. Balance of benefits and risks  ...........................................................................  133

3.7.3. Additional considerations on the benefit-risk balance ......................................... 133

3.8. Conclusions .....................................................................................................  133

4. Recommendations ...............................................................................  133

5. EPAR changes  ......................................................................................  134

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ACS American Cancer Society ADR adverse drug reaction ALL acute lymphoblastic leukemia ALT alanine aminotransferase AMQ Amgen-defined MedDRA query AST aspartate aminotransferase BiTE bispecific T-cell engager bcr-abl fusion gene 9 and 22 [t(9;22) (q34:q11)] genetic mutation/translocation CCyR complete cytogenetic response CI confidence interval cIV continuous intravenous infusion CHR complete hematologic remission CL clearance CML chronic myeloid leukemia CNS central nervous system Css steady state concentration CR complete response/remission CrCL creatinine clearance CRi complete response with incomplete recovery of peripheral blood counts CRh* complete response with partial recovery of peripheral blood counts CRS cytokine release syndrome CSR Clinical study report ECG electrocardiogram ECOG   Eastern Cooperative Oncology Group EMA European Medicines Agency EOI event of interest EPAR European Public Assessment Report EU European Union FDA Food and Drug Administration FISH fluorescence in-situ hybridization HR hazard ratio HSCT   hematopoietic stem cell transplantation

<div style=\"page-break-after: always\"></div>

ICH International Council on Harmonisation IPTW inverse probability of treatment weights MAA marketing authorization application MaCyR  Major cytogenetic response/remission MaHR   major hematologic response/remission MedDRA Medical Dictionary for Regulatory Activities MRD minimal residual disease NCCN National Comprehensive Cancer Network NE not estimable OS overall survival PBRER  Periodic Benefit Risk Evaluation Reports PCR polymerase chain reaction PD pharmacodynamics PFS progression-free survival Phi + Philadelphia-positive Phi-neg Philadelphia-negative PK pharmacokinetics PPS Per Protocol Set PSUR Periodic Safety Update Reports RFS relapse-free survival RMP Risk Management Plan SD standard deviation SmPC   Summary of Product Characteristics SMQ Standardized MedDRA Query TKI tyrosine kinase inhibitor TLS Tumor lysis syndrome TTHR time to hematologic relapse TTO time to onset ULN upper limit of normal US United States WBC white blood cell

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Amgen Europe B.V. submitted to the European Medicines Agency on 31 July 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

To modify the approved therapeutic indication to include the treatment of Philadelphia chromosome positive CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adult and paediatric patients with relapsed or refractory ALL and adult patients in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the PL are updated accordingly. The updated RMP version 10.0 has also been submitted.

The variation requested amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

BLINCYTO, was designated as an orphan medicinal product EU/3/09/650 on 24 July 2009. BLINCYTO was designated as an orphan medicinal product in the following indication: treatment of acute lymphoblastic leukaemia.

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  EMA  Decision P/0014/2016  (PIP  Modification:  EMEA-000574-PIP02-12-M02,  dated  19  December  2017) on  the acceptance of a modification of an agreement of a paediatric investigation plan (PIP).

At  the  time  of  submission  of  the  application,  the  PIP  P/0014/2016  was  not  yet  completed  as  some measures were deferred.

The PIP targets paediatric patients from 1 month to less than 18 years of age with first high-risk relapse of  B-cell  precursor  ALL  and  includes  2  clinical  studies  and  1  pharmacokinetics/  pharmacodynamics (PK/PD) analysis.

The EMA/PDCO Partial Compliance check, dated 16 December 2016 confirmed that Study 1 (Protocol MT103 205) and Study 3 (Protocol 120391) were completed in compliance with the PIP. A subsequent PIP modification (PIP Modification: EMEA-000574-PIP02-12- M02, dated 19 December 2017) to the key elements of the ongoing PIP Study 2 (Protocol 20120215) did not affect the completion date of Study 2 which is deferred to July 2023. Therefore, the current Partial Compliance Check Report (EMA/740953/2016, adopted on 16 December 2016) is still considered valid.

<div style=\"page-break-after: always\"></div>

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Protocol assistance

The MAH did not seek Protocol Assistance at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Alexandre Moreau

Co-Rapporteur:

Daniela Melchiorri

| Timetable                                            | Actual dates      |
|------------------------------------------------------|-------------------|
| Submission date                                      | 31 July 2019      |
| Start of procedure:                                  | 17 August 2019    |
| CHMP Rapporteur Assessment Report                    | 11 October 2019   |
| CHMP Co-Rapporteur Assessment Report                 | 21 October 2019   |
| PRAC Rapporteur Assessment Report                    | 19 October 2019   |
| PRAC members comments                                | 23 October 2019   |
| PRAC Outcome                                         | 31 October 2019   |
| CHMP members comments                                | 4 November 2019   |
| Updated CHMP Rapporteur(s) (Joint) Assessment Report | 8 November 2019   |
| Request for supplementary information (RSI)          | 14 November 2019  |
| CHMP Rapporteur Assessment Report                    | 8 June 2020       |
| PRAC Rapporteur Assessment Report                    | 10 June 2020      |
| PRAC members comments                                | 3 June 2020       |
| PRAC Outcome                                         | 11 June 2020      |
| CHMP members comments                                | 15 June 2020      |
| Updated CHMP Rapporteur Assessment Report            | 19 June 2020      |
| Request for supplementary information (RSI)          | 25 June 2020      |
| CHMP Rapporteur Assessment Report                    | 16 September 2020 |
| PRAC Rapporteur Assessment Report                    | 18 September 2020 |
| PRAC members comments                                | 23 September 2020 |
| Updated PRAC Rapporteur Assessment Report            | 24 September 2020 |

<div style=\"page-break-after: always\"></div>

| Timetable                                 | Actual dates    |
|-------------------------------------------|-----------------|
| PRAC Outcome                              | 1 October 2020  |
| CHMP members comments                     | 5 October 2020  |
| Updated CHMP Rapporteur Assessment Report | 8 October 2020  |
| Opinion                                   | 15 October 2020 |

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

In the European Union (EU), blinatumomab (BLINCYTO®) is currently indicated for the treatment of adults  and  children  greater  than  1  years  old  with  Philadelphia  chromosome-negative  relapsed  or refractory B-cell precursor acute lymphoblastic leukemia (ALL) and for the treatment of adults in first or second hematologic complete remission (CR) with Philadelphia chromosome-negative minimal residual disease (MRD)-positive ALL.

The purpose of this variation application is to widen the indication to include:

- 1) The treatment of adult patients with Philadelphia chromosome-positive relapsed/refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

This extension is based on the results from a phase 2, single-arm study (Study 20120216). A historical control study (Study 20160462) and a propensity score analysis were conducted to estimate the effects of  blinatumomab compared with standard of care ALL therapy for treatment of Philadelphia-positive relapsed/refractory ALL.

- 2) The treatment of paediatric patients with Philadelphia-positive relapsed/refractory ALL who have failed treatment with at least 2 TKIs and have no alternative treatment options.

Available data are presented for 3 Philadelphia-positive subjects from Study MT103-205 who were &lt; 18 years of age.

- 3) The treatment of adult patients in first or second hematologic CR with Philadelphia-positive MRDpositive ALL.

Results from the assessment of MRD response are presented for adult subjects with Philadelphia-positive relapsed/refractory  ALL  from  Study  20120216  and  from  the  subset  of  adult  subjects  (N  =  10)  in hematologic CR with Philadelphia-positive MRD-positive ALL from the MRD-positive ALL studies MT103203 and MT103-202.

## Disease or condition

Acute lymphoblastic leukemia is a rare aggressive cancer of the blood and bone marrow. In the EU, more

<div style=\"page-break-after: always\"></div>

than 7,200 new cases are diagnosed annually (Gatta et al, 2011) with approximately 3,000 diagnoses occurring in adults (Inaba et al, 2013). The majority of ALL cases are B-lineage, Philadelphia-negative ALL.

The Philadelphia chromosome is characterized by a reciprocal translocation between the long arms of chromosome 9 and 22 [t(9;22) (q34:q11)] leading to the formation of the bcr-abl fusion gene. This translocation occurs in 3% to 5% of children and 20% to 30% of adults with B-cell precursor ALL.

## Epidemiology and risk factors

The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related variations (0.53 at 4554 years, ∼ 1.0 at 55-74 years and 1.45 at 75-99 years) and that of Burkitt leukaemia/lymphoma is between 0.17 and 0.33 in the same age groups (Sant, 2010). These figures qualify ALL as a rare disease in adults, making assessment and care at qualified centres highly desirable. Predisposing risk factors for adult ALL are not known, contrary to childhood ALL (Inaba, 2013). In Europe, 5-year overall survival (OS) improved from 29.8% in the years 1997-1999 to 41.1% in 2006-2008 (P &lt; 0.0001), still as a function of age. Compared with the reference group (age 15 -54 years: OS &gt;50%), OS was &lt;30% in the 55 -64 years age group (hazard ratio 2.05) and &lt;20% in the ≥ 65 years age group (hazard ratios 2.71 and 3.75) (Sant, 2014).

## Management

Allogeneic hematopoietic stem cell transplantation (HSCT) is recommended in first remission for patients with Philadelphia-positive ALL. Since the introduction of TKIs, the objective response rates are similar between subjects with Philadelphia-negative ALL and subjects with Philadelphia-positive ALL (Thomas et al, 2004; Yanada and Naoe, 2006); however, duration of response and relapse-free survival (RFS) have remained short in ALL Phi+ patients.

Treatment of Philadelphia-positive ALL patients who are resistant to or relapse after first-line therapy remains challenging. For this population, in the absence of a clinical study with a novel agent, treatment with an alternative TKI (ie, different from the TKI used as part of induction therapy, typically dasatinib or ponatinib) with or without additional chemotherapy could be considered and is recommended with allogeneic HSCT if a second remission is achieved (National Comprehensive Cancer Network [NCCN] Guidelines, 2018; Fielding, 2015; Fielding, 2011). For subjects who received an allogeneic HSCT in first remission, donor lymphocyte infusion or second allogeneic HSCT can be considered.

Recently, 2 non-TKI treatments were approved for the treatment of relapsed or refractory ALL that included Philadelphia-positive ALL subjects in the pivotal trials. Inotuzumab ozogamicin (Besponsa) is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor ALL (Besponsa SmPC, 2017); adult patients with Philadelphia-positive relapsed or refractory B-cell  precursor ALL should have failed treatment with at least 1 TKI. Tisagenlecleucel (Kymriah) is indicated for the treatment of pediatric and young adult patients up to 25 years of age with B-cell ALL that is refractory, in relapse post-transplant, or in second or later relapse (Kymriah SmPC, 2018).

The use of molecular remission may bridge the gap between hematologic and cytogenetic remission and long-term survival as it is a harbinger of poor outcome (Ravandi, 2011; Radich, 2002).

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

Blinatumomab is a bispecific T-cell engager antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells.

In the European Union (EU), blinatumomab (BLINCYTO ® ) is currently indicated for the treatment of adults  and  children  greater  than  1  years  old  with  Philadelphia  chromosome-negative  relapsed  or refractory B-cell precursor acute lymphoblastic leukemia (ALL) and for the treatment of adults in first or second hematologic complete remission (CR) with Philadelphia chromosome-negative minimal residual disease (MRD)-positive ALL.

## Mechanism of action

BLINCYTO  is a single chain antibody construct of the bispecific T-cell engager (BiTE  ) class. Blincyto utilizes a patient's own T cells to kill CD19-positive B cells, including malignant B-cells. T cells are bound by its  anti-CD3 moiety, whereas malignant and normal B cells are bound by the anti-CD19 moiety. Blincyto is designed to transiently connect CD19-positive cells with T cells; as part of this action, Blincyto causes the formation of a cytolytic synapse between the T cell and the tumor cell, releasing the poreforming  protein  perforin  and  the  apoptosis-inducing  proteolytic  enzymes  granzyme  A  and  B.  The subsequent serial lysis of multiple malignant cells by a single T cell closely resembles a natural cytotoxic T-cell  reaction.  Blincyto-mediated  T-cell  activation  involves  the  transient  release  of  inflammatory cytokines and the proliferation of T cells.

Figure 1: T-cell Mediated Tumor Cell Lysis Through Formation of a Cytolytic Immunological Synapse Induced by Blincyto

<!-- image -->

BiTE = bispecific T-cell engager.

BLINCYTO,  was  designated  as  an  orphan  medicinal  product  EU/3/09/650  on  24  July  2009,  for  the treatment of acute lymphoblastic leukaemia.

## 2.1.3. General comments on compliance with GLP, GCP

N/A

<div style=\"page-break-after: always\"></div>

## 2.2. Non-clinical aspects

No new clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

No updated Environmental Risk Assessment (ERA) has been submitted

## 2.2.2. Discussion on non-clinical aspects

The  CHMP  Guideline  on  the  Environmental  Risk  Assessment  of  Medicinal  Products  for  Human  Use (EMEA/CHMP/SWP/4447/00; December 2006) states that medicinal products consisting of substances occurring naturally in the environment such as vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids are exempted '…because they are unlikely to result in significant risk to the environment,' and consequently do not need to be accompanied by an environmental risk assessment.

Blinatumomab is a recombinant non-glycosylated protein, consisting of 504 amino acids with a molecular weight of approximately 55 kDa. As the molecule is a sequence of amino acids, blinatumomab meets the guideline criterion for compounds that are exempt from testing because of their chemical structure and constituents that should degrade into their constituent elements in the environment. Although, the extension of indication may result in an increase in the total amount of blinatumomab used, as per the above guidance, this will not lead to any environmental risks.

## 2.2.3. Conclusion on the non-clinical aspects

The Marketing Authorisation Holder (MAH) has justified the lack for an updated Environmental Risk Assessment (ERA) on the ground that blinatumomab is a recombinant protein and is exempted from environmental impact evaluations. This is agreed.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

Table 1: Listing of Clinical Studies

<!-- image -->

| Type of Study                                                                                                    | Protocol No.                                                                                                     | Study Objective(s)                                                                                               | Study Design and Type of Control                                                                                 | Test Products; Dosage Regimen; Route of Administration                                                                                                                                                                                          | Number of Subjects                                                                                               | Key Entry Criteria                                                                                                                                                                                                                                                          | Duration of Treatment                                                                                                                                                       | Study Status: Type of Report; Data Cut-off Date; Report Location                                                                                                                               |
|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL) | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL) | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL) | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL) | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL)                                                                                                                                | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL) | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL)                                                                                                                                                            | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL)                                                            | Study Reports of Uncontrolled Clinical Studlies (Adult Philadelphia-chromosome Positive Relapsed/Refractory ALL)                                                                               |
| Efficacy                                                                                                         | 20120216                                                                                                         | Safety PK                                                                                                        | Phase 2 - Non- randomized .Non- controlled  Open-label . Multicenter                                             | Blin 9 μg/day cIV (wk 1, cycle 1) followed by 28 μg/day for remaining period, 4 wks on / 2 wks off                                                                                                                                              | 45                                                                                                               | Adult subjects with R/R Ph+ B-cell precursor ALL, refractory to at least relapsed or 1 second generation or later TKl, or intolerant to second generation TKI, and intolerant or refractory to imatinib mesylate                                                            | Up to 5 cycles. blin clV                                                                                                                                                    | Study completed; PA CSR: 20 May 2015; Module 5.3.5.4, MRD- positive ALL Variation Application (EMEA/H/C/003731/I/0011) FA CSR: 26 May 2017 Module 5.3.5.4                                      |
| OtherClinical StudyReports(Other Indications)                                                                    | OtherClinical StudyReports(Other Indications)                                                                    | OtherClinical StudyReports(Other Indications)                                                                    | OtherClinical StudyReports(Other Indications)                                                                    | OtherClinical StudyReports(Other Indications)                                                                                                                                                                                                   | OtherClinical StudyReports(Other Indications)                                                                    | OtherClinical StudyReports(Other Indications)                                                                                                                                                                                                                               | OtherClinical StudyReports(Other Indications)                                                                                                                               | OtherClinical StudyReports(Other Indications)                                                                                                                                                  |
| Efficacy                                                                                                         | 00103311                                                                                                         | Efficacy Safety                                                                                                  | Phase 3 ·Randomized • Open-label  Multicenter Controlled                                                         | Blin 9 μg/day clV (wk 1, cycle 1)followed remaining period, 4 by 28 μg/day for wks on/2 wks off 1 of 4 S0C regimens: 1) FLAG-based regimen 2) HiDAC-based regimen 3) HDMTX-based combination regimen 4) clofarabine/ clofarabine-based regimens | 405 randomized (271 blin; 134 500)                                                                               | Adults with Ph- B-cell precursor R/R blasts in bone ALL, >5% any of the following: refractory to primary induction or salvage therapy. untreated first relapse with first remission duration ≤ 12 months, untreated second or greater relapse. relapse any time after aHSCT | Up to 9 cycles blin (4 wks clV treatment followed by 2 wks treatment- free; for maintenance, up to 4 additional cycles [4 wks treatment followed by 8-wks treatment- free]) | Study completed; PA CSR; 04 January 2016: EMEA/H/C/003731/I/0009 FA CSR: 29 August 2017 EMEA/H/C/003731/I1/0009, Sequence 0061                                                                 |
| Efficacy                                                                                                         | MT103-211                                                                                                        | Efficacy. Safety PK/PD                                                                                           | Phase 2 - Non- randomized - Non-  Open-label - Multicenter                                                       | Blin 9 μg/day clV (wk 1. cycle 1) followed by 28 μg/day for remaining period, 4 wks on/2 wks off                                                                                                                                                | 225 (189 under protocol v3.0;36 under protocol V4)                                                               | Adults with Ph- B-cell precursor R/RALL,210% blasts in bone marrow, and any of the following: refractory or relapsed with first remission duration S12 months in first salvage, relapsed or refractory after first salvage therapy.relapsed within 12 months of aHSCT       | Up to 5 cycles blin clV                                                                                                                                                     | Study completed; PA CSR (N= 189): 10 0ctober 2013; Module5.3.5.2,Initial MAA (EMEA/H/C/003731) SA CSR (N= 225): 20 June 2014: Initial MAA, Day 181 Response to CHMP List of Outstanding Issues |
| Efficacy                                                                                                         | MT103-206                                                                                                        | Efficacy Safety QTc evaluation PK/PD                                                                             | Phase 2 - Non- randomized * Open-label - Non-  Multicenter - Dose ranging                                        | Blin 5/15/30 μg/m2/day clV, 4 wks on/2 wks off                                                                                                                                                                                                  | 36                                                                                                               | Adults with B-cell precursor ALL relapsed after at or with refractory least induction and consolidation, disease; >5% blasts in bone marrow                                                                                                                                 | Up to 5 cycles blin clV                                                                                                                                                     | Study completed; PACSR; 15 0ctober 2012: (EMEA/H/C/003731) Module5.3.5.2,Initial MAA                                                                                                           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

Study 20120216 provided additional PK Data.

## Study 20120216

## Study design

Study 20120216 was a phase 2, single-arm, open-label, multicenter study designed to evaluate the efficacy and safety of blinatumomab in adult subjects (≥ 18 years of age) with Philadelphia -positive relapsed/refractory B-cell precursor ALL.

The study comprised a screening period, an induction treatment period (2 cycles of blinatumomab), a consolidation treatment period (up to 3 additional cycles of blinatumomab for subjects who achieved a CR/CRh*/complete remission with incomplete hematologic recovery (CRi) within 2 induction cycles of treatment), and a safety follow-up visit 30 days after treatment discontinuation.

One  of  the  secondary  objectives  was  to  evaluate  pharmacokinetics  (PK)  of  blinatumomab  in  adult subjects with relapsed/refractory Ph-positive B-precursor ALL

In the first induction cycle, the initial dose of blinatumomab was 9 μg/day cIV infusion for the first 7 days of treatment which was increased (dose step) to 28 μg/day starting o n day 8 (week 2) through day 29 (week 4). For all subsequent cycles (beginning with the second induction cycle through 3 consolidation cycles for applicable subjects), the administered dose was 28 μg/day throughout 4 weeks of continuous treatment.

PK samples were taken at steady state in Cycles 1 and 2.

## PK and statistical analysis

The following PK parameters of blinatumomab were estimated based on individual serum blinatumomab concentrations:

- The  steady  state  serum  concentration  (Css),  summarized  as  the  observed  concentrations collected  after  approximately  6  hours  or  later  of  cIV  infusion  start  for  cycle  1  and  cycle  2, respectively, for each dose level.
- Serum clearance (CL) calculated as CL = R0/Css; where R0 is the infusion rate (microg/hr) and Css is the dose normalized average Css. Css values used for the calculation of CL were collected after approximately 6 hours or later of cIV infusion start for each dose level.

Actual doses administered and actual sampling times were used for presentation in graphs and nominal times  were  used  to  present  data  in  tables.  Blinatumomab  concentrations  below  the  lower  limit  of quantification (LLOQ) (50.0 pg/mL) were set to 0 before data analysis. All descriptive statistics were presented to 3 significant figures, except for % coefficient of variance (CV), which was reported to 1 decimal place.

## Analytical method

CD69 activation assay (bioassay) was validated to demonstrate that it is reliable and reproducible for the intended use.

A total of 69 test items (excluding d1 samples taken prior of treatment for the determination of the baseline) were analyzed for their content of blinatumomab andall fulfilled the acceptance criteria for the quality control samples.

<div style=\"page-break-after: always\"></div>

7  study  samples  (taken  during  blinatumomab  treatment)  were  reanalyzed  in  a  second  independent experiment. The recovery rates of all samples were within the specification (80-120% from initial value obtained from the first measurement). The recovery rates ranged from 85% to 109%.

Assay linearity was investigated in 4 samples. Dilution series (five 1:2 dilution steps) were prepared in pooled human serum which was used for the preparation of the calibration standard curve. Linearity with a  R²  value  of  1.0  and  a  slope  of  0.9  to  1.1  of  the  calculated  versus  the  expected  blinatumomab concentrations was shown in a range from 62 to 1322 pg/mL.

## Population handing

The PK analysis included all subjects who received blinatumomab and had at least 1 PK sample collected.

Enrollment in to Study 20120216 was initiated 03rd January 2014 and was completed January 2015. A total of 45 subjects received blinatumomab in this phase 2 study.

Sex was evenly balanced (53.3% males; 46.7% females), while the majority of subject were white (86.7%), without Hispanic/Latino ethnicity (95.6%), and had an ECOG performance status score of 0 or 1 (80%). The median age (range) was 55.0 years (23 to 78 years); 10 subjects (22.2%) were between the ages of ≥ 65 years and &lt; 75 years and 2 subjects (4.4%) were ≥ 75 years of age.

Table 2: Summary of Analysis set for Study 20120216

|                                                            | Blinatumomab (N = 45) n (%)   |
|------------------------------------------------------------|-------------------------------|
| Subjects in Full Analysis Set                              | 45 (100.0)                    |
| Subjects in Safety Analysis Set                            | 45 (100.0)                    |
| SubjectsinPer Protocol AnalysisSet                         | 40 (88.9)                     |
| Subjects excluded from Per Protocol Analysis Set           | 5 (11.1)                      |
| Received anexcluded concomitant treatment                  | 2 (4.4)                       |
| Entered study even though entry criteria was not satisfied | 4 (8.9)                       |
| Subjects in Pharmacokinetic Analysis Set                   | 42 (93.3)                     |
| Subjects excluded from Pharmacokinetic Analysis Set        | 3 (6.7)                       |
| Did not have at least one PK sample                        | 3 (6.7)                       |

Safety analysis set was the same as the full analysis set.

Full analysisset:all subjectswhoreceived anyinfusionof blinatumomab

Note:Reasons for exclusion from an analysis set are not mutually exclusive.

Source:ModifiedfromTable14-2.3

## PK results

The estimated mean (SD) Css values were 673 (613) pg/mL and 791 (555) pg/mL for the 28 μg/day doses,  respectively,  in  cycles  1  and  2,  and  mean  (SD)  CL  was  4.11  (4.30)  L/hr.  The  results  were consistent with those reported in the primary analysis CSR.

<div style=\"page-break-after: always\"></div>

Table 3: Serum Blinatumomab Css and CL after continuous IV infusion for Study 20120216

| SummaryStatistic   |   Kep/brl 6 Cycle 1 Css (pg/mL) |   28 μg/day Cycle 1 Css (pg/mL) |   28 μg/day Cycle 2 Css (pg/mL) |   CL (L/hr) |
|--------------------|---------------------------------|---------------------------------|---------------------------------|-------------|
| N                  |                             6   |                            28   |                            20   |      37     |
| Mean               |                           190   |                           673   |                           791   |       4.11  |
| SD                 |                            99.7 |                           613   |                           555   |       4.3   |
| Min                |                            76   |                            63   |                            73   |       0.526 |
| Median             |                           172   |                           534   |                           554   |       2.23  |
| Max                |                           328   |                          2490   |                          1890   |      18.5   |
| CV%                |                            52.4 |                            91.1 |                            70.2 |     104.7   |
| GeometricMean      |                           168   |                           452   |                           598   |       2.64  |
| Geometric Mean CV% |                            61.4 |                           122   |                           102.7 |     119.3   |

Source:PKS/20120216 SAS CDISC /Base ScenarioFA (version 3)

Anti-blinatumomab-binding antibody was evaluated with a validated blinatumomabanti-drug antibody assay with the electrochemiluminescence detection technology. Paired samples from pre- and post-dose were available for 31 subjects. All the samples were classified as negative for the presence of antiblinatumomab antibodies.

## Absorption

Exposure values Mean (SD) Css regardless of the Philadelphia chromosome status at the clinical doses of 9 mcg/day and 28 mcg/day for the treatment of relapsed/ or refractory ALL, the mean (SD) Css were 228 (356) pg/mL and 616 (537) pg/mL respectively.

Table 4 . Mean (SD) Css of Blinatumomab in Subjects With Relapsed/Refractory ALL Who Received 9 μg/day and 28 μg/day Doses

|                                           | Mean (SD) Css (pg/mL) (u)   | Mean (SD) Css (pg/mL) (u)   |
|-------------------------------------------|-----------------------------|-----------------------------|
| Study                                     | 9 μg/day                    | 28 μg/day                   |
| MT103-211 (Philadelphia-negative R/R ALL) | 246 (305) (n=178)           | 632 (510) (n=188)           |
| 00103311 (Philadelphia-negative R/R ALL)  | 211 (413) (n=156)           | 592 (553) (n=191)           |
| 20120216 (Philadelphia-p0sitive R/R ALL)  | 155 (106) (n=8)             | 673 (614) (n=28)            |
| Overall                                   | 228 (356) (n=342)           | 616 (537) (n=407)           |

ALL = acute lymphoblastic leukemia; Css=steady state concentration, Css in cycle 1 of each studies are presented, n = number of subjects; R/R = relapsed/refractory; SD = standard deviation.

Source: Study MT103-211 Secondary Analysis CSR (Initial MAA, Day 181 Response to CHMP List of

Outstanding Issues), Study 20120216 Primary Analysis CSR (Module 5.3.5.4, MRD-positive ALL Variation

Application),and Study 00103311 Primary Analysis CSR (EMEA/H/C/003731/ll/0009)

<div style=\"page-break-after: always\"></div>

## Distribution

Mean (SD) volume of distribution based on terminal phase (Vz) value regardless of the Philadelphia chromosome status and across studies was 4.35 (2.45) L with the continuous intravenous infusion of blinatumomab.'

Table 5: Blinatumomab PK parameters following cIV infusion in adult subjects with NHL, MRD positive ALL, and relapsed / refractory ALL

|                   |               | Clearance (CL) (L/hr)   | Clearance (CL) (L/hr)   | Clearance (CL) (L/hr)   | Clearance (CL) (L/hr)   | Volume of distribution (Vz (L)   | Volume of distribution (Vz (L)   | Volume of distribution (Vz (L)   | Volume of distribution (Vz (L)   | Terminal half-life (t sa)(hr)   | Terminal half-life (t sa)(hr)   | Terminal half-life (t sa)(hr)   | Terminal half-life (t sa)(hr)   |
|-------------------|---------------|-------------------------|-------------------------|-------------------------|-------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| Study             | Disease       | N                       | Mean (SD)               | Geo mean (CV%)          | Median (range)          | N                                | Mean (SD)                        | Geo mean (CV%)                   | Median (range)                   | N                               | Mean (SD)                       | Geo mean (CV%)                  | Median (range)                  |
| MT103-104         | NHL           | 66                      | 2.25 (1.17)             | 2.03 (46.9)             | 1.98 (0.714 -6.32)      | 33                               | 4.56 (2.50)                      | 4.04 (51.4)                      | 3.95 (1.86 -11.6)                | 33                              | 2.44 (1.62)                     | 2.07 (59.4)                     | 1.93 (0.906 -8.31)              |
| MT103-208         | NHL           | 23                      | 1.96 (0.961)            | 1.75 (52.0)             | 1.64 (0.683 - 4.41)     |                                  | NA                               | NA                               | NA                               |                                 | NA                              | NA                              | NA                              |
| MT103-202         | MRD+ ALL      | 19                      | (0.596) 1.83            | (30.2) 1.75             | (1.12 - 3.51) 1.66      | 18                               | (2.36) 3.98                      | (57.8) 3.45                      | (1.47-10.8) 3.20                 | 18                              | (0.530) 1.47                    | (39.0) 1.38                     | (0.660 -2.54) 1.42              |
| MT103-203         | MRD+ ALL      | 32                      | 2.27 (3.02)             | 1.75 (63.9)             | 1.65 (0.815 - 18.4)     |                                  | NA                               | NA                               | NA                               |                                 | NA                              | NA                              | NA                              |
| MT103-206         | Ph(-) R/R ALL | 36                      | 2.49 (1.18)             | 2.30 (39.4)             | 2.16 (1.27 -7.03)       |                                  | NA                               | NA                               | NA                               |                                 | NA                              | NA                              | NA                              |
| MT103-211         | Ph(-) R/R ALL | 210                     | 3.14 (3.31)             | 2.25 (89.2)             | 2.13 (0.356 - 20.5)     |                                  | NA                               | NA                               | NA                               |                                 | NA                              | NA                              | NA                              |
| 00103311          | Ph(-) R/R ALL | 222                     | 3.63 (3.12)             | 2.73 (89.7)             | 2.82 (0.157 - 22.9)     |                                  | NA                               | NA                               | NA                               |                                 | NA                              | NA                              | NA                              |
| 20120216          | Ph(+) R/R ALL | 38                      | 4.09 (4.04)             | 2.69 (117.0)            | 2.28 (0.526 - 19.0)     |                                  | NA                               | NA                               | NA                               |                                 | NA                              | NA                              | NA                              |
| All adult studies | combined      | 646                     | (2.98) 3.11             | (82.4) 2.34             | (0.157 - 22.9) 2.21     | 51                               | (2.45) 4.35                      | (53.8) 3.82                      | (1.47-11.6) 3.63                 | 51                              | (1.41) 2.10                     | (56.9) 1.80                     | (0.660 -8.31) 1.58              |

distributionbasedonteminalphase.

ALL=acutelymphoblastic leukemia;clV=continuous IV:CL=clearance;CV%=coefficient of variance;Geomean=geometric mean;hr=hour, L=liter, MRD+= minimal residual disease positive; NA=not available; NHL = non-Hodgkin lymphoma; SD = standard deviation; ti2 = teminal half-life; Vz = volume of

Source:Ifilesrv01IPCBard-RAWIQPDatalAMG10312014Filingl2.7Summaryof ClinicalPhamacologyiAMG103FilingSupport.phxproj

## Elimination

The estimated mean (SD) systemic clearance with continuous intravenous infusion in patients receiving blinatumomab across clinical studies was 3.11 (2.98) L/hour. The mean (SD) half-life was 2.10 (1.41) hours.

## Dose proportionality and time dependencies

There was no change.

## Special populations

With data added from Study MT103-205 (Table below), the inter-patient variability in PK in the renal impairment section was adjusted from 95.6% to 96.8%

<div style=\"page-break-after: always\"></div>

Table 6: Summary of Blinatumomab clearance by renal function groups

|                               | Blinatumomab Clearance (L/hr)   | Blinatumomab Clearance (L/hr)   | Blinatumomab Clearance (L/hr)   | Blinatumomab Clearance (L/hr)   | Blinatumomab Clearance (L/hr)   |
|-------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
| CrCL                          | N                               | Median (Range)                  | Mean                            | SD                              | %CV                             |
| Normal(CrCL:≥90mL/min)        | 506                             | 2.25 (0.157- 22.9)              | 3.25                            | 3.14                            | 96.8                            |
| Mild (CrCL: 60-89 mL/min)     | 137                             | 1.97 (0.278-18.4)               | 2.53                            | 2.37                            | 93.8                            |
| Moderate (CrCL: 30-59 mL/min) | 45                              | 1.38 (0.254- 4.90)              | 1.77                            | 1.16                            | 65.4                            |

Note:Clearancevaluesestimatedfromnon-compartmentalanalysisaresummarizedinthistable. Source:IIfilesrv01\\PCBard-RAWIQPDatalAMG103lsBLAFilingMay2016IAMG103sBLAFiling Supp0rt.phxproj;MT103-104,MT103-202,MT103-203,MT103-205,MT103-206,MT103-208,MT103-211, and20120216clinicalstudyreportsandMT103-311interimclinicalstudyreport

## Use in paediatric patients

An extrapolation exercise was submitted by the MAH in the context of a claim for a paediatric indication. A Bayesian extrapolation from adult subjects (source) to paediatric subjects (target) was performed. Three  different  Bayesian  models  were  used.  The  source  data  come  from  adult  Philadelphia-positive relapsed/refractory ALL subjects available from Amgen-sponsored studies (20120216 and 20160441). The target data come from pediatric Philadelphia-positive relapsed/refractory ALL subjects available from Amgen-sponsored studies (MT103-205, 20130320, and 20160441). In total, 30 of 78 adult subjects achieved a CR (38.0%; 95%CI: 27.3% to 49.6%), and 5 of 8 pediatric subjects achieved a CR (62.5%; 95% CI: 24.5% to 91.5%)

Table 7: Source and Target Data Used in Bayesian Extrapolation

|                    | #of CRs/ #of Subjects   | CR Rate (95% Cl)     |
|--------------------|-------------------------|----------------------|
| Adults (source)    |                         |                      |
| 20120216           | 16/45                   | 35.6% (21.9%, 51.2%) |
| 20160441           | 14/34                   | 41.2% (24.7%, 59.3%  |
| Total              | 30/79                   | 38.0% (27.3%, 49.6%) |
| Pediatric (target) |                         |                      |
| MT103-205          | 2/3                     | 66.7% (9.4%, 99.2%)  |
| 20130320           | 2/3                     | 66.7% (9.4%, 99.2%)  |
| 20160441           | 1/2                     | 50.0% (1.3%, 98.7%)  |
| Total              | 5/8                     | 62.5% (24.5%, 91.5%) |

Cl = confidence interval; CR = complete remission

## 2.3.3. Pharmacodynamics

No new PD data was included in this submission.

<div style=\"page-break-after: always\"></div>

## 2.3.4. PK/PD modelling

No new data have been submitted.

## 2.3.5. Discussion on clinical pharmacology

From a PK standpoint, data from new study are sufficient and compatible with previous observations.

Mean (SD) Css at the clinical doses of 9 mcg/day and 28 mcg/day for the treatment of relapsed/ or refractory  ALL,  the  mean  (SD)  Css  are  now  reported  as  228  (356)  pg/mL  and  616  (537)  pg/mL respectively. Mean (SD) volume of distribution based on terminal phase (Vz) value is now reported as 4.35 (2.45) L with the continuous intravenous infusion of blinatumomab. The estimated mean (SD) systemic  clearance  with  continuous  intravenous  infusion  in  patients  receiving  blinatumomab  is  now reported 3.11 (2.98) L/hour and the mean (SD) half-life as 2.10 (1.41) hours. Accordingly the interpatient variability reported in the renal impairment section of Special population is adjusted with data added from Study MT103-205 from 95.6% to 96.8%.

Regarding clinical pharmacology aspects (PK and E-R analysis) on the extrapolation for pediatric subjects with Ph+ from adults Ph+, it is important to highlight that using an extrapolation exercise suggesting that the indication exists in the adult population and sufficient PK (full extrapolation) or PK/PD (partial extrapolation) data were provided in the target population in paediatrics. According to the applicant, since PD data do not exist in the paediatric population, the applicant rely on a full extrapolation approach. However, PK data from only 2 patients in this indication were available from which no conclusion on the PK similarity between both populations can be drawn.

Satisfactory updates of the SmPC section 5.2 were implemented. Data on exposure, distribution and elimination in section 5.2 of the SmPC are updated to reflect values in relapsed/refractory ALL subjects regardless of the Philadelphia chromosome and across studies given that the values were comparable between the two subject populations.

No new PD data were included in this submission, which is acceptable.

## 2.3.6. Conclusions on clinical pharmacology

As a result of the proposed extension of indication, section 5.2 of the SmPC was updated. Clinical pharmacology aspects are well described. No changes in sections 4.2 and 4.6 were based on pharmacokinetics. Proposed changes in section 5.2 are considered acceptable based on the data presented.

## 2.4. Clinical efficacy

The purpose of this variation application is to extend the indication to include:

- -The treatment of adult patients with Philadelphia chromosome-positive relapsed/refractory ALL who have  failed  treatment  with  at  least  2  tyrosine  kinase  inhibitors  (TKIs)  and  have  no  alternative treatment options.
- -The treatment of paediatric patients with Philadelphia-positive relapsed/refractory ALL who have failed treatment with at least 2 TKIs and have no alternative treatment options.
- -The treatment of adult patients in first or second hematologic CR with Philadelphia-positive MRDpositive ALL.

<div style=\"page-break-after: always\"></div>

Clinical efficacy results are being presented for each of the three claimed extensions of indication

A. The treatment of adult patients with Philadelphia chromosome-positive relapsed/refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

## 2.4.1. Dose response study(ies)

Treatment  effect  of  blinatumomab  in  adults  with  Philadelphia-positive  relapsed/refractory  ALL  was evaluated in Study 20120216. A fixed dose regimen (9-28 µg/day) was tested under cIV infusion over 4 weeks per cycle followed by a 2-week drug-free period between cycles. In this study, blinatumomab showed single-agent activity in subjects with Ph+ R/R ALL, predictable Css, and a manageable safety profile at a target dose of 28 μg/day.

The regimen tested in subjects with Ph+ R/R ALL was the same regimen as that tested in subjects with Ph- R/R ALL (Study MT103-211 and Study 00103311). Step-dosing was included for management of cytokine release syndrome events. The rationale for the clinical dose selection for the treatment of Ph+ R/R ALL was the same as that for the treatment of Ph- R/R ALL, as the pharmacokinetics of blinatumomab was not affected by the status of Philadelphia chromosome.

In Study 20120216, the mean (SD) blinatumomab Css values at 9 and 28 µg/day doses during cIV infusion in cycle 1 are provided in below, together with the mean (SD) Css values in studies MT103-211 and 00103311 (Ph- R/R ALL).

Table 8.  Mean (SD) Css of Blinatumomab in Subjects With Relapsed/Refractory ALL Who Received 9 µg/day and 28 µg/day Doses

|                                           | Mean (SD) C ss (pg/mL) (n)   | Mean (SD) C ss (pg/mL) (n)   |
|-------------------------------------------|------------------------------|------------------------------|
| Study                                     | 9 µg/day                     | 28 µg/day                    |
| MT103-211 (Philadelphia-negative R/R ALL) | 246 (305) (n=178)            | 632 (510) (n=188)            |
| 00103311 (Philadelphia-negative R/R ALL)  | 211 (413)                    | 592 (553)                    |
|                                           | (n=156)                      | (n=191)                      |
| 20120216 (Philadelphia-positive R/R ALL)  | 155 (106) (n=8)              | 673 (614) (n=28)             |
|                                           | 228 (356) (n=342)            | 616 (537) (n=407)            |
| Overall                                   |                              |                              |

ALL = acute lymphoblastic leukemia; Css=steady state concentration, Css in cycle 1 of each studies are presented, n = number of subjects; R/R = relapsed/refractory; SD = standard deviation.

Source: StudyMT103-211 Secondary Analysis CSR (Initial MAA, Day 181 Response to CHMP List of Outstanding Issues), Study 20120216 Primary Analysis CSR (Module 5.3.5.4, MRD-positive ALL Variation Application), and Study00103311 Primary Analysis CSR (EMEA/H/C/003731/II/0009)

The Css values were comparable between Ph+ and Ph- R/R ALL subjects.

No pharmacodynamic data were collected in Study 20120216.

<div style=\"page-break-after: always\"></div>

## 2.4.2. Main study(ies)

Study 20120216:  Alcantara; A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive Bprecursor Acute Lymphoblastic Leukemia

## Methods

The figure below illustrates the study design and treatment schedule.

<!-- image -->

Figure 2: Study Design and Treatment Schema for Study 20120216

## Study participants

## Key inclusion criteria

- -Patients with Ph+ B-precursor ALL, with any of the following:

Relapsed or refractory to at least one second generation TKI (dasatinib, nilotinib, bosutinib, ponatinib)

OR intolerant to second generation TKI and intolerant or refractory to imatinib mesylate

- -Greater than 5% blasts in the bone marrow
- -Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

<div style=\"page-break-after: always\"></div>

- -Age ≥ 18 years of age, at the time of informed consent.

## Key Exclusion Criteria

- -History of malignancy other than ALL within 5 years prior to start of protocol-required therapy (refer to study protocol for the list of exceptions)
- -History  or  presence  of  clinically  relevant  CNS  pathology  as  epilepsy,  childhood  or  adult  seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis

With the exception of CNS leukemia that is well controlled with intrathecal therapy

- -Active ALL in the CNS (confirmed by CSF analysis) or testes (no clinical sign thereof)
- -Current autoimmune disease or history of autoimmune disease with potential CNS involvement
- -Allogeneic HSCT within 12 weeks prior to start of blinatumomab
- -Any active acute Graft-versus-Host Disease (GvHD) grade 2 to grade 4 according to the Glucksberg criteria or active chronic GvHD requiring systemic treatment
- -Cancer chemotherapy within 2 weeks prior to start of blinatumomab (exceptions: prior TKI therapy is  allowed  but  must  be  completed  prior  to  start  of  blinatumomab;  prophylactic  intrathecal chemotherapy and prophase dexamethasone are allowed until start of blinatumomab). In addition, any subject whose organ toxicity (excluding hematologic) from prior ALL treatment has not resolved to no more than CTCAE grade 1.
- -Immunotherapy (eg, rituximab) within 4 weeks prior to start of blinatumomab
- -Subject received prior anti-CD19 therapy
- -Eligibility for alloHSCT at the time of enrollment (as defined by disease status, performance status and availability of donor)
- -Abnormal screening laboratory values as defined below:
- o AST (SGOT) and/or ALT (SGPT) and/or alkaline phosphatase ≥ 5  x  upper limit of normal (ULN)
- o Total bilirubin ≥ 1.5 x ULN (unless related to Gilbert´s or Meulengracht disease)
- o Creatinine ≥ 1.5 ULN or creatinine clearance &lt; 60 mL/min (calculated)

- Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus (HBsAg positive) or hepatitis C virus (anti-HCV positive).

- Subject is pregnant or breast feeding, or might become pregnant within 3 months after the last dose of protocol-specified therapy.

## Treatments

A single cycle of blinatumomab was defined as 6 weeks in duration, which included 4 weeks of continuous intravenous (cIV) infusion of blinatumomab followed by a 2-week treatment-free interval.

A maximum of 5 cycles could be administered, in case of CR/CRh/Cri achieved within 2 induction cycles of treatment.

<div style=\"page-break-after: always\"></div>

In the first induction cycle, the initial dose of blinatumomab was 9 μg/day cIV infusion for the first 7 days of treatment which was increased (dose step) to 28 μg/day starting on day 8 (week 2) throug h day 29 (week 4). For all subsequent cycles (beginning with the second induction cycle through 3 consolidation cycles for applicable subjects), the administered dose was 28 μg/day throughout 4 weeks of continuous treatment.

## Prior and concomitant therapy

Premedication with dexamethasone was intended to prevent or reduce cytokine release syndrome (CRS) events associated with blinatumomab treatment and was recommended as prephase therapy.

## Within 1 week (+ 3 days) before initiation of blinatumomab treatment and after each

treatment cycle (after bone marrow aspiration on day 29), a mandatory central nervous system (CNS) prophylaxis consisting of an intrathecal regimen according to institutional or national guidelines was administered (e.g., methotrexate 12 to 15 mg, cytosine arabinoside 40 mg, and dexamethasone 4 mg or equivalent steroid dose). Central nervous system prophylaxis was omitted in case of anticipated safety risks caused by lumbar puncture during the treatment period of the study.

The following medication and therapies were prohibited after blinatumomab treatment started (i.e., all other necessary supportive therapies were allowed):

- -tyrosine kinase inhibitors
- -any antitumor therapy other than blinatumomab such as cytotoxic and/or cytostatic drugs, radiation therapy (except for palliative administration), immunotherapy
- -chronic  systemic  high-dose  corticosteroid  therapy  (except  for  dexamethasone  as  given  as comedication)
- -any other immunosuppressive therapies (except for transient use of corticosteroids)
- -any other investigational medicinal product.

## Objectives

## Primary Objective

The primary objective was to evaluate the rate of CR/complete remission with partial haematological recovery (CRh*) in adult subjects with relapsed/refractory Ph-positive B-precursor ALL.

## Secondary Objectives

The secondary objectives were as follows:

- -to  evaluate  the  rate  of  MRD  remission  in  adult  subjects  with  relapsed/refractory  Ph-positive  Bprecursor ALL
- -to evaluate other measures of efficacy of blinatumomab in adult subjects with relapsed/refractory Ph-positive B-precursor ALL
- -to estimate the safety of blinatumomab in adult subjects with relapsed/refractory Ph-positive Bprecursor ALL
- -to evaluate pharmacokinetics (PK) of blinatumomab in adult subjects with relapsed/refractory Phpositive B-precursor ALL

## Exploratory Objective

<div style=\"page-break-after: always\"></div>

The  exploratory  objective  was  to  evaluate  the  efficacy  of  blinatumomab  against  specific  bcr-abl mutations.

## Outcomes/endpoints

The primary efficacy endpoint was the proportion of subjects who achieved CR/CRh*.

CR was defined as less than or equal to 5% blasts in the bone marrow, no evidence of disease and full recovery of peripheral blood counts: platelets &gt; 100,000/μl, and ANC &gt; 1000/μl

CRh was defined as less than or equal to 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets &gt; 50,000/μl, and ANC &gt; 500/μl.

The secondary efficacy endpoints were indicated as follows:

- -rate of MRD remission within 2 cycles of treatment with blinatumomab
- -duration of CR or CRh*
- -CR rate and CRh* rate within 2 cycles of treatment with blinatumomab
- -CR + CRh* + CRi rate within 2 cycles of treatment with blinatumomab
- -overall survival, from the date of the first dose of blinatumomab to the event/censor date
- -allogeneic HSCT and 100-day mortality after allogeneic HSCT
- -incidence of adverse events and antibody formation
- -PK parameters including quantification of serum blinatumomab concentrations

The exploratory endpoint was to evaluate the efficacy of blinatumomab in subjects with specific bcr-abl mutations.

Subjects were evaluated for response/progression at the end of each cycle, and subsequently at least every 3 months. This is in line with the current clinical practice and overall acceptable. Bone marrow leukemic blast count was performed centrally, while peripheral blood blasts were evaluated locally. This is  acceptable,  yet  centralised  BM  evaluations  are  considered  of  primary  relevance  for  regulatory purposes.  MRD  evaluations  were  also  centralised,  and  the  selected  1x10 -4   threshold  to  define  MRD response  is  in  accord  with  current  guidelines  (see  e.g.  Bruggermann  M  et  al,  Leukemia  2010)  and considered acceptable.

## Sample size

Sample size estimation was based on the primary efficacy endpoint proportion of subjects who achieved a CR or CRh* within 2 cycles of treatment with blinatumomab.

Simon mini-max 2-stage design (Simon, 1989) was used with a sample size (23 subjects in stage 1, 41 evaluable subjects total) based on a 1-sided type 1 error of 0.025 and a power of 90% to detect the effective response rate assumption of ≥ 30% over an ineffective treatment rate of ≤ 10%. The study was planned to be stopped at stage 1 if fewer than 3 of 23 subjects were observed with CR or

<div style=\"page-break-after: always\"></div>

CRh* in stage 1. If at least 9 or more out of 41 subjects showed a CR or CRh* within 2 cycles of treatment with blinatumomab at the end of stage 2, the study's assumption of ineffective treatment was rejected.

## Randomisation/Blinding

Not Applicable as this is an open label, non-comparative study.

## Statistical methods

The  safety  and  efficacy  analyses  were  performed  on  the  full  analysis  set  (FAS),  which  included  all subjects who received an infusion of blinatumomab. Sensitivity analyses were performed on subjects who met the definition of a prospectively defined per protocol set (PPS) who did not have any major relevant protocol violations that affected the efficacy evaluation of the subject.

Table 9: Summary of Efficacy Analyses

<!-- image -->

The primary efficacy endpoint of this study was the proportion of subjects who achieved CR/CRh* within the first 2 cycles. The response assessments were performed at the end of each cycle. The best response within the first 2 cycles determined the primary efficacy endpoint.

<div style=\"page-break-after: always\"></div>

A hypothesized null true response rate of 10% was tested against an alternative response rate of 30%. The planned sample size yielded a 1-sided type I error rate of 0.025 and power of 90% when the true response rate was at least 30%.

## Results

## Participant flow

A total of 61 subjects were screened and 45 subjects were enrolled in the study. All enrolled subjects received blinatumomab.

A total of 39 subjects (86.7%) discontinued treatment with blinatumomab and the most common reason for  treatment  discontinuation  was  protocol-specified  criteria  (25  subjects  [55.6%]).  Eight  subjects (17.8%) completed the study and 37 subjects (82.2%) discontinued the study, all due to death.

Table 10: Study Disposition (Full Analysis Set)

|                                                                                               | Blinatumomab (N= 45) n(%%)   |
|-----------------------------------------------------------------------------------------------|------------------------------|
| Subjects enrolled                                                                             | 45 (100.0)                   |
| Investigational product accounting                                                            |                              |
| Subjects who never received investigational product                                           | 0 (0.0)                      |
| Subjects who received investigational product                                                 | 45 (100.0)                   |
| Subjects continuing investigational product                                                   | 0 (0.0)                      |
| Subjects who discontinued investigational product                                             | 39 (86.7)                    |
| Adverse event                                                                                 | 3 (6.7)                      |
| Death                                                                                         | 3 (6.7)                      |
| Protocol-specified criteria                                                                   | 25 (55.6)                    |
| Hematological or extramedullary relapse subsequent to CR/CRh'ICRi on protocol treatment       | 3(6.7)                       |
| Premature end to induction phase due to diseaselclinical progression without prior CR/CRhICRi | 12 (26.7)                    |
| Failure to achieve CR/CRh'ICRi within 2 treatment cycles                                      | 4 (8.9)                      |
| Intention to receive allogeneic HSCT                                                          | 6 (13.3)                     |
| Requirement for altemative therapy                                                            | 7 (15.6)                     |
| Other                                                                                         | 1 (2.2)                      |
| Lack ofresponse                                                                               | 1 (2.2)                      |
| Subjects who reached end of consolidation period                                              | 6 (13.3)                     |
| Study completion accounting                                                                   |                              |
| Subjects who completed study                                                                  | 8 (17.8)                     |
| Subjects continuing study                                                                     | 0 (0.0)                      |
| Subjects who discontinued study                                                               | 37 (82.2)                    |
| Death                                                                                         | 37 (82.2)                    |

HSCT · hematopoletlc stem cell transplantatlon.

Number of subjecis screened: 61

Flrst subject enrolled: 03 January 2014

Source: Modlifled from Table 14-1.1.

<div style=\"page-break-after: always\"></div>

## Allocation

## Analysis

<!-- image -->

Discontinued investigational product (n=39)

- Haematological or extramedullary relapse n=3
- Disease progression without prior CR/CRh*/CRi n=12
- Lack of efficacy (i.e. no CR/CRh*/CRi) within 2 cycles n=4
- Death n=3
- AE n=3
- Intention to receive HSCT n=6
- Required alternative therapy n=7
- Other n=1

Reached end of consolidation period (n=6)

End of study status

- Completed (end of follow-up period) n=8
- Ongoing n=0
- Death n=37

FAS population (n=45)

PPS population (n=40)

- received an excluded concomitant treatment n=2
- entered study even though entry criteria not satisfied n=4

SAS population (n=45)

FAS= Full Analysis Set, all subjects who received any infusion of blinatumomab

SAS= Safety Analysis Set, subjects who received any infusion of blinatumomab

PPS= Per Protocol Set, subjects from the FAS who did not have any major protocol deviation

<div style=\"page-break-after: always\"></div>

## Recruitment

Study start date: 03 January 2014 (first subject enrolled)

Study Completion Date: 06 January 2017 (last subject end of study)

Final analysis: 26 May 2017

This study was conducted at 19 centres in France, Germany, Italy, the United Kingdom, and the United States.

## Conduct of the study

## Study amendments

Table 11: Protocol Amendment Summary Table

<!-- image -->

CNS -central nervous system

At time of amendment 2.0, the evaluation of the duration of the MRD response was removed from exploratory  endpoints.  Sensitivity  analyses  on  subjects  who  undergo  an  alloHSCT  based  on  MRD remission status prior to alloHSCT was also removed. The maximum duration for 5 cycles was added.

Version 2.0 (dated 10 October 2014) of the SAP incorporated the changes from Protocol Amendment 2 (dated 15 September 2014) to remove the exploratory endpoint of duration of MRD response, and to further clarify the analysis details. No specific changes were made to the protocol-specified analyses.

## Protocol deviations

Thirteen subjects (28.9%) had at least 1 important protocol deviation and 5 subjects had more than 1 deviation:  received  the  wrong  treatment  or  incorrect  dose  (7  subjects  [15.6%]),  entry  criteria  not satisfied  (4  subjects  [8.9%]),  received  an  excluded  concomitant treatment (2 subjects [4.4%]), re-

<div style=\"page-break-after: always\"></div>

consent not performed for level 1-2 risk (1 subject [2.2%]), and predose dexamethasone not given (1 subject [2.2%]).

Table 12: Summary of Important Protocol Deviations (Full Analysis Set)

| Important Protocol Deviation Criterion                                  | Blinatumomab (N =45) n (%%)   |
|-------------------------------------------------------------------------|-------------------------------|
| Number of subjects with at least one important protocol deviation       | 13 (28.9)                     |
| Entered Study Even Though Entry Criteria Was Not Satisfied              | 4 (8.9)                       |
| Chemotherapy <2 wks or unresolved >G3 toxicity from prior ALL treatment | 3 (6.7)                       |
| Philadelphia chromosome-positive ALL with Prior 2nd Gen. TKI            | 1 (2.2)                       |
| Other Deviations                                                        | 1 (2.2)                       |
| Reconsent not perfomed for Level 1-2 risk                               | 1(2.2)                        |
| Other Treatment Compliance                                              | 1 (2.2)                       |
| Pre-dose dexamethasone not given                                        | 1 (2.2)                       |
| Received An Excluded Concomitant Treatment                              | 2 (4.4)                       |
| Received excluded medication/treatment                                  | 2 (4.4)                       |
| Received The Wrong Treatment Or Incorrect Dose                          | 7 (15.6)                      |
| IP dose not reduced after G3 CNS event                                  | 1 (2.2)                       |
| IP not withheld                                                         | 1 (2.2)                       |
| Use of compromised IP                                                   | 5 (11.1)                      |

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 13: Demographic and baseline characteristics (FAS)

|                                                             | Blinatumomab (N= 45)   |
|-------------------------------------------------------------|------------------------|
| Sex -n (%)                                                  |                        |
| Male                                                        | 24 (53.3)              |
| Female                                                      | 21 (46.7)              |
| Ethnicity - n (%)                                           |                        |
| Hispanic/Latino                                             | 2 (4.4)                |
| Not Hispanic/Latino                                         | 43 (95.6)              |
| Race - n (%)                                                |                        |
| White                                                       | 39 (86.7)              |
| Asian                                                       | 1 (2.2)                |
| Black (or African American)                                 | 3 (6.7)                |
| Other                                                       | 2 (4.4)                |
| Age (years)                                                 |                        |
| n                                                           | 45                     |
| Mean                                                        | 52.8                   |
| SD                                                          | 15.0                   |
| Minimum, maximum                                            | 23,78                  |
| Eastern Cooperative Oncology Group perfomance status -n (%) |                        |
|                                                             | 16 (35.6)              |
|                                                             | 20 (44.4)              |
| 2                                                           | 9 (20.0)               |
| Prior tyrosine kinase inhibitor treatment -- n (%)          |                        |
| 1                                                           | 7 (15.8)               |
| 2                                                           | 21 (46.7)              |
|                                                             | 13 (28.9)              |
| 4                                                           | 4 (8.9)                |
| Number of prior relapses - n (%)                            |                        |
| D                                                           | 3 (6.7)                |
| 1                                                           | 25 (55.6)              |
|                                                             | 13 (28.9)              |
| 23                                                          | 4 (8.9)                |

<div style=\"page-break-after: always\"></div>

ALT - alanlne amlnotransferase; AST = aspartate amlnotransferase; HScT - hematopoletlc stem cell Tewou jo jwll eddn - Nin 'g allenb - go :l aluenb - Lo :uoejuedsue Source: Modlfledfrom Table 14-2.1 and Table 14-2.2

<!-- image -->

Page 2of 2

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 14: Summary of Analysis Set

|                                                            | Blinatumomab (N = 45) n (%)   |
|------------------------------------------------------------|-------------------------------|
| Subjects in Full Analysis Set                              | 45 (100.0)                    |
| Subjects in Safety Analysis Set                            | 45 (100.0)                    |
| Subjects in Per Protocol Analysis Set                      | 40 (88.9)                     |
| Subjects excluded from Per Protocol Analysis Set           | 5 (11.1)                      |
| Receivedanexcluded concomitanttreatment                    | 2 (4.4)                       |
| Entered study even though eniry criteria was not satisfied | 4 (8.9)                       |
| Subjects in Pharmacokinetic Analysis Set                   | 42 (93.3)                     |
| Subjects excluded from Pharmacokinetic Analysis Set        | 3 (6.7)                       |
| Did not have atleast one PK sample                         | 3(6.7)                        |

Full analyslsset: all subjecis who recelved any Infuslon of bllnatumomab.

Note: Reasons for excluslon from an analysls set are not mutually excluslve.

Source:Modifled from Table 14-2.3

## Outcomes and estimation

## Primary Efficacy Endpoint - Best Response Within First 2 Cycles

In the FAS, 35.6% subjects (95% CI: 21.9%, 51.2%) achieved a CR/CRh* within the first 2 cycles of blinatumomab treatment. The 95% CI of the CR/CRh* rate excludes the ineffective treatment rate of 10% that was the basis of the null hypothesis.

The study treatment period of blinatumomab included 2 induction cycles and up to 3 consolidation cycles. Seventeen  subjects  (37.8%  FAS;  41.5%  PPS)  achieved  a  CR/CRh*  during  the  treatment  period;  1 additional achieved a CR/CRh* after the first 2 cycles. Two additional subjects converted to CR during subsequent cycles of blinatumomab: 1 subject with a CRh* and 1 subject with a CRi after 2 cycles.

<div style=\"page-break-after: always\"></div>

Table 15: Best Response during the First 2 Cycles of Blinatumomab Treatment (FAS and PP)

|                                                                                                                     | FAS (N= 45)   | PPS (N=40)                          |
|---------------------------------------------------------------------------------------------------------------------|---------------|-------------------------------------|
| Number of subjects with best overall response of CR/CRh* - n (%) (95%, CI)                                          | 16 (35.6)     | 16 (40.0) (21.9, 51.2) (24.9, 56.7) |
| Subject status                                                                                                      |               |                                     |
| CR -n(%)                                                                                                            | 14 (31.1)     | 14 (35.0)                           |
| (95% CI)                                                                                                            |               | (18.2, 46.6) (20.6, 51.7)           |
| CRh* -n (%-)                                                                                                        | 2 (4.4)       | 2 (5.0)                             |
| (95% CI)                                                                                                            | (0.5, 15.1)   | (0.6, 16.9)                         |
| CRi (without CRh') - n (%)                                                                                          | 2(4.4)        | 1 (2.5)                             |
| (95% CI)                                                                                                            | (0.5, 15.1)   | (0.1. 13.2)                         |
| Blast free hypoplastic or aplastic bone marrow (without CRi) - n (%)                                                | 3 (6.7)       | 3(7.5)                              |
| (95% CI)                                                                                                            | (1.4, 18.3)   | (1.6, 20.4)                         |
| Partial remission - n (%)                                                                                           | 2 (4.4)       | 2 (5.0)                             |
| (95% CI)                                                                                                            | (0.5, 15.1)   | (0.6, 16.9)                         |
| No response - n (%)                                                                                                 | 12 (26.7)     | 10 (25.0)                           |
| Progressive disease -n (%)                                                                                          | 4 (8.9)       | 4 (10.0)                            |
| Assessment not evaluable -n (%6)                                                                                    | 2(4.4)        | 1 (2.5)                             |
| No response data -n (%)                                                                                             | 4 (8.9)       | 3(7.5)                              |
| Number of subjects with best overallresponse of CR/CRh*/CRi-- n (%) (95%, 01)                                       | 18 (40.0)     | 17 (42.5) (25.7, 55.7) (27.0, 59.1) |
| Number of subjects with best overall response of CR/CRh'/CRilblast free hypoplastic or aplastic bone marrow - n (%) | 21 (46.7)     | 20 (50.0)                           |
| (10%.98)                                                                                                            |               | (31.7, 62.1) (33.8, 66.2)           |

remlsslon wlth Incomplete hematologlcal recovery; FAs = full analysls set; PPS = per protocol set. basellne levels.

Source: Modifled from Table 14-4.1.1 and Table 14-4.1.3

Table 16: Best Response by Cycle - Study 20120216 (Full Analysis Set)

| Cycle      | CR n (%)   | CRh\" n (%)   | CRi n (%)   |
|------------|------------|--------------|-------------|
| 1 (N=45)   | 10 (22.2%) | 2 (4.4)      | 1 (2.2)     |
| 2 (N =28)  | 13 (46.4)  | 1 (3.6)      | 1 (3.6)     |
| 3(IN = 12) | 8 (66.7)   | 1 (8.3)      | D           |
| 4 (N=9)    | 7 (77.8)   | 1 (11.1)     | D           |
| 5 (N= 7)²  | 4 (57.1)   | 1 (14.3)     | 口           |

CR= complete remission; CRh'= complete remission with partial hematological recovery: CRi= complete remissionwith incompletehematologicalrecovery:N=thenumber ofsubjectsin thecycle.

The denominator varies by cycle and is defined as the subjects who were treated in that cycle. Source:Modified from Table 14-4.3.1of Study 20120216 Primary AnalysisCSR

Subgroups  analysis  were  performed  for  primary  and  secondary  endpoints  based  on  baseline characteristics, including Bcr-abl mutations, number of previous TKI therapy, previous HSCT and number of relapses without prior HSCT.

<div style=\"page-break-after: always\"></div>

Figure 3: Response of CR/CRh* in the First 2 Cycles by Subgroups - Study 20120216 (Full Analysis Set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Secondary efficacy endpoints

- o Minimal Residual Disease Response During the First 2 Cycles

An MRD response was observed in 18 subjects (40%) in the FAS and all of them were complete responses (undetectable disease at an assay sensitivity level of at least 10 -4 ).

Of the 16 subjects with a best response of CR/CRh* after 2 cycles, 14 subjects (87.5%; 95% CI: 61.7%, 98.4%) achieved a complete MRD response: 12 subjects with a CR (85.7%, 12/14) and 2 subjects with a CRh*(100.0%, 2/2).

Four (4) additional subjects achieved complete MRD responses: 1 subject with a CRi and 3 subjects with blast-free hypoplastic or aplastic bone marrow.

## o Relapse-free Survival

Of the 16 subjects with a best response of CR/CRh* after 2 cycles of blinatumomab treatment, 5 subjects (31.3%) were relapse free at the time of last response evaluation.

The Kaplan-Meier (KM) estimate of median relapse-free survival was 6.8 months (95% CI: 4.4, not estimable [NE]).

<div style=\"page-break-after: always\"></div>

Table 17: Relapse-free Survival for Subjects who Achieved a Best Response of CR/CRh* in the First 2 Cycles (Full Analysis Set)

|                                         | Blinatumomab (N = 45)   |
|-----------------------------------------|-------------------------|
| Relapse-free Survival                   |                         |
| Subject status                          |                         |
| Number of subjects                      | 16                      |
| Events - n (%)                          | 11 (68.8)               |
| Relapse                                 | 10 (62.5)               |
| Death from any cause other than relapse | 1 (6.3)                 |
| Censored - n (%)                        | 5 (31.3)                |
| Alive w/o relapse                       | 5 (31.3)                |
| Time to event (KM) (months)a            |                         |
| 1st quartile (Q1)                       | 4.4                     |
| (95% CI)                                | (3.6, 6.7)              |
| Median                                  | 6.8                     |
| (95% CI)                                | (4.4, NE)               |
| 3rd quartile (Q3)                       | NE                      |
| (95% CI)                                | (6.7, NE)               |
| Min, Max                                | 3.6, 22.6               |
| Time to censoring (KM) (months)a.b      |                         |
| Median (95% CI)                         | 16.1 (10.6, 22.6)       |
| Q1, Q3                                  | 12.9, 18.2              |
| Min, Max                                | 3.6, 22.6               |

KM = Kaplan-Meier; NE = not estimable

a Months were calculated as days from first response date to event/censor date, divided by 30.5

Source: Modified from Table 14-4.6.1

b Time to censoring measures follow-up time by reversing the KM event indicator to be for censoring.

<div style=\"page-break-after: always\"></div>

The MAH specified that median relapse-free survival was similar for the PPS and when censoring at the time of HSCT in the FAS and PPS (Table below).

Table 18 : Median Relapse Free Survival Time for Subjects who Achieved CR/CRh* in the First Two Cycles by Subgroups (Full Analysis Set) - Extracted from CSR

| Subgroup                          | Level of Subgroup    | N   | Events    | Censored   | Median time (months)   | 95% C1      |
|-----------------------------------|----------------------|-----|-----------|------------|------------------------|-------------|
| Ber-abl mutations                 | Yes                  | 6   | 4 (66.7)  | 2 (33.3)   | 10.1                   | (3.7, NE)   |
|                                   | T315l mutation - Yes | 4   | 2 (50.0)  | 2 (50.0)   | NE                     | (4.4, NE)   |
|                                   | Other                | 2   | 2 (100.0) | 0 (0.0)    | 6.7                    | (3.7.9.7)   |
|                                   | No                   | 7   | 5 (71.4)  | 2 (28.6)   | 5.5                    | (3.6, NE)   |
| Ber-abl isofom (baseline lab)a    | P190                 | 10  | 7 (70.0)  | 3 (30.0)   | 6.8                    | (3.7, NE)   |
|                                   | P210                 | 5   | 3 (60.0)  | 2 (40.0)   | 10.5                   | (3.6, NE)   |
| Number of previous TKI therapies  |                      | 1   | 1 (100.0) | 0 (0.0)    | 5.5                    | (NE, NE)    |
|                                   | 2                    | 7   | 4 (57.1)  | 3 (42.9)   | 10.5                   | (3.8, NE)   |
|                                   | =3                   | 8   | 6 (75.0)  | 2 (25.0)   | 6.8                    | (3.6, NE)   |
| Prior alloHSCT                    | Yes                  | 5   | 3 (60.0)  | 2 (40.0)   | 5.5                    | (3.7, NE)   |
|                                   | No                   | 11  | 8 (72.7)  | 3 (27.3)   | 6.8                    | (3.8, NE)   |
| Relapse without prior HSCT        | Yes                  |     | 5 (62.5)  | 3 (37.5)   | 10.1                   | (3.8, NE)   |
|                                   | No                   | 8   | 6 (75.0)  | 2 (25.0)   | 5.4                    | (3.6, NE)   |
| Central bone marrow blasts        | <50%                 | 7   | 7 (100.0) | 0 (0.0)    | 4.4                    | (3.6, 9.7)  |
|                                   | 2 50%                | 9   | 4 (44.4)  | 5 (55.6)   | NE                     | (4.5, NE)   |
| Absolute Neutrophil Count (10°/L) | 5.0                  | 15  | 10 (66.7) | 5 (33.3)   | 6.8                    | (4.4, NE)   |
|                                   | ≥5.0-≤10.0           | 1   | 1 (100.0) | 0 (0.0)    | 3.7                    | (NE, NE)    |
|                                   | 2 10.0               | D   | 0 (0.0)   | 0 (0.0)    | NE                     | (NE, NE)    |
| White Blood Cell Count (10%/L)    | ≤3.0                 | 10  | 5 (50.0)  | 5 (50.0)   | NE                     | (3.8, NE)   |
|                                   | 23.0                 | 6   | 6 (100.0) | 0 (0.0)    | 5.5                    | (3.6, 10.5) |
| Relapse without prior HSCT        | Yes                  | 8   | 5 (62.5)  | 3 (37.5)   | 10.1                   | (3.8, NE)   |
|                                   | No                   | 8   | 6 (75.0)  | 2 (25.0)   | 5.4                    | (3.6, NE)   |

Months=Days/30.5.

Cl=confidenceinterval,NE=not estimable.

*The isofom is determined by MRD status at baseline. P190 was encoded yes if ela2&gt;10*, P210 was encoded yes if either b2a2 or b3a2 &gt;10*. Subjects with both P190 and P210 were counted in the P210 group.

Program:/userdata/stat/amg103/onc/20120216/analysis/fina/tables/program/t-ef-subgrp.sas

- o Time to Haematological Relapse (Duration of Response): Subjects With CR/CRh*

The KM estimate of median time to haematological relapse (duration of response) for the 16 subjects with CR/CRh* was 6.8 months (95% CI: 4.5, NE). The median time to haematological relapse was the same (6.8 months [95% CI: 3.8, NE]) in subjects with CR/CRh*/CRi. The KM plot for duration of response is provided in the figure below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

CR/CRh* = complete remissionlcomplete remission with partial hematological recovery:

HSCT = hematopoietic stem cell transplantation.

Source: Modified from Figure 14-4.1.2

Figure 4: Time from Response to Relapse for Subjects who Achieved a Best Response of CR/CRh* in the First 2 Cycles - Primary Analysis and Censoring at Time of HSCT (Full Analysis Set)

- o Overall Survival

At the time of the last follow-up date, 8 of 45 subjects (17.8%) were alive. The KM estimate of median OS was 9.0 months (95% CI: 5.7, 13.5), the KM median follow-up time was 25.1 months

Table 19: Summary of Overall Survival with and Without Censoring at the Time of HSCT (Full Analysis Set)

<!-- image -->

|                                                   | Blinatumomab (N = 45)   |
|---------------------------------------------------|-------------------------|
| Overall Survival                                  |                         |
| Number of subjects                                | 45                      |
| Events -n (%)                                     | 37 (82.2)               |
| Death from any cause                              | 37 (82.2)               |
| Censored - n (%)                                  | 8 (17.8)                |
| Alive                                             | 8 (17.8)                |
| Median (95% Cl) time to event (KM) (months)       | 9.0 (5.7.13.5)          |
| Median (95% Cl) time to censoring (KM) (months).b | 25.1 (20.8, 25.9)       |
| Overall Survival censored at time of HSCT         |                         |
| Number of subjects                                | 45                      |
| Events -n (%)                                     | 30 (66.7)               |
| Death from any cause                              | 30 (66.7)               |
| Censored -n (%)                                   | 15 (33.3)               |
| Alive                                             | 6 (13.3)                |
| HSCT                                              | 9 (20.0)                |
| Median (95% Cl) time to event (KM) (months)*      | 9.0 (5.7, 13.5)         |
| Median (95% Cl) time to censoring (KM) (months)ob | 24.8 (10.9, 25.9)       |

KM = Kaplan-Meier; HSCT = hematopoietic stem cell transplant; NE = not estimable

divided by 30.5.

*Months are calculated as days from the date of the first dose of blinatumomab to the event/censor date,

bTime to censoring measures follow-up time by reversing the KM event indicator to be for censoring.

Source: Modified from Table 14-4.10.1 and Table 14-4.11.1

<div style=\"page-break-after: always\"></div>

<!-- image -->

Censor indicated byverticalbar..

Figure 5: Overall Survival - Primary Analysis and Censoring at Time of HSCT (Full Analysis Set)

Table 20: Median Overall Survival Time by Subgroups (Full Analysis Set)

| Subgroup                         | Level of Subgroup    | N   | Events    | Censored   |   Median time (months) | 95% C1      |
|----------------------------------|----------------------|-----|-----------|------------|------------------------|-------------|
| Sex                              | Male                 | 忆   | 20 (83.3) | 4 (16.7)   |                   12.3 | (5.7, 16.0) |
|                                  | Female               | 21  | 17 (81.0) | 4 (19.0)   |                    6.2 | (4.7,11.5)  |
| Age at baseline                  | 2 18 -c35 years      | 5   | 5 (100.0) | 0 (0.0)    |                    6   | (1.6, 11.8) |
|                                  | 235-<55 years        | 17  | 13 (76.5) | 4 (23.5)   |                   12.6 | (4.7, 23.0) |
|                                  | 2 55- c65 years      | 11  | 9 (81.8)  | 2 (18.2)   |                   14.8 | (4.2, 20.6) |
|                                  | ≥ 65 years           | 12  | 10 (83.3) | 2 (16.7)   |                    7.8 | (2.2,13.5)  |
| Region                           | US                   | 11  | 10 (90.9) | 1 (9.1)    |                    3.4 | (1.0, 13.8) |
|                                  | Europe               |     | 27 (79.4) | 7 (20.6)   |                   11.7 | (6.2, 15.6) |
| ECOG performance status          | 0                    | 16  | 13 (81.3) | 3 (18.8)   |                   10.4 | (5.7, 13.8) |
|                                  | 1                    | 20  | 17 (85.0) | 3 (15.0)   |                    6.8 | (3.4, 18.1) |
|                                  | 2                    | 9   | 7 (77.8)  | 2 (22.2)   |                    9   | (0.8, NE)   |
| Bcr-abl mutations                | Yes                  | 17  | 14 (82.4) | 3 (17.6)   |                    6.5 | (4.2, 15.6) |
|                                  | T315l mutation - Yes | 10  | 8 (80.0)  | 2 (20.0)   |                   12.7 | (4.2, 18.1) |
|                                  | Other                | 7   | 6 (85.7)  | 1 (14.3)   |                    5.6 | (0.8, 12.1) |
|                                  | No                   | 20  | 17 (85.0) | 3 (15.0)   |                   10.4 | (4.7, 19.8) |
| Bcr-ablisofom (baseline lab)     | P190                 | 26  | 20 (76.9) | 6 (23.1)   |                   10.4 | (5.3, 15.6) |
|                                  | P210                 | 16  | 14 (87.5) | 2 (12.5)   |                    6.3 | (2.9, 14.8) |
| Number of previous TKI therapies |                      | 7   | 7 (100.0) | 0 (0.0)    |                    5   | (0.8, 16.0) |
|                                  | 2                    | 21  | 18 (85.7) | 3 (14.3)   |                    9   | (5.7, 13.5) |
|                                  | >=3                  | 17  | 12 (70.6) | 5 (29.4)   |                   12.6 | (4.2, 20.6) |
| Prior alloHSCT                   | Yes                  | 20  | 18 (90.0) | 2 (10.0)   |                    6.8 | (4.7, 13.8) |
|                                  | No                   | 25  | 19 (76.0) | 6 (24.0)   |                    9.2 | (5.3, 18.1) |

<div style=\"page-break-after: always\"></div>

| Relapse without prior HSCT                    | Yes                                            | 20    | 15 (75.0)          | 5 (25.0)          | 10.4     | (5.0, 18.1)             |
|-----------------------------------------------|------------------------------------------------|-------|--------------------|-------------------|----------|-------------------------|
| Central bone marrow blasts                    | No <50%                                        | 25 11 | 22 (88.0) 9 (81.8) | 3 (12.0) 2 (18.2) | 6.4 11.5 | (5.1, 13.8) (4.7, 19.8) |
|                                               | 250%                                           | 34    | 28 (82.4)          | 6 (17.6)          | 6.8      | (5.1, 13.8)             |
| Absolute Neutrophil Count (10%/L)             | 5.0                                            | 39    | 31 (79.5)          | 8 (20.5)          | 9.0      | (5.6, 15.6)             |
|                                               | 25.0-10.0                                      | 4     | 4 (100.0)          | 0 (0.0)           | 9.6      | (1.6, 13.8)             |
|                                               | 2 10.0                                         | 1     | 1 (100.0)          | 0 (0.0)           | 13.5     | (NE, NE)                |
| White Blood Cell Count (10*lL)                | ≤3.0                                           | 23    | 17 (73.9)          | 6 (26.1)          | 11.8     | (5.7, 20.6)             |
|                                               | ≥3.0                                           | 22    | 20 (90.9)          | 2 (9.1)           | 6.8      | (2.9, 13.5)             |
| Platelets(10%L)                               | 50                                             | 25    | 18 (72.0)          | 7 (28.0)          | 12.6     | (6.0, 20.6)             |
|                                               | ≥50-<100                                       | 11    | 11 (100.0)         | 0 (0.0)           | 7.1      | (3.4, 15.6)             |
|                                               | ≥100                                           |       | 8 (88.9)           | 1 (11.1)          | 5.3      | (0.8, 13.8)             |
| Renal impaiment (Creatinine clearance mL/min) | Nomal funclion (≥ 90 mL/min)                   | 31    | 26 (83.9)          | 5 (16.1)          | 7.1      | (5.0, 13.8)             |
|                                               | Mild impaiment (≥ 60 - 90 mL/min)              | 8     | 6 (75.0)           | 2 (25.0)          | 5.9      | (1.0, NE)               |
|                                               | Moderate impaiment (2≥ 30 - 60 mL/min) 1.5XULN |       | 5 (83.3)           | 1 (16.7)          | 13.1     | (5.6, NE)               |
| Hepatic impaiment                             | AST or ALT > 3 X ULN or total bilirubin >      | 3     | 3 (100.0)          | 0 (0.0)           | 3.4      | (1.0, 6.1)              |
|                                               | ≤1.5 XULN                                      | 42    | 34 (81.0)          |                   | 10.4     | (6.0, 13.8)             |
|                                               | AST and ALTs 3 X ULN and total bilinubin       |       |                    | 8 (19.0)          |          |                         |

Months=Days/30.5.

The isofomm is determined by MRD status at baseline. P190 was encoded yes if ela2&gt;10-4, P210 was encoded yes if either b2a2 or b3a2 &gt;10-. Subjects with both P190 and P210 were counted in the P2 10 group.

Cl=confidence interval, NE=not estimable.

- o Allogeneic  Hematopoietic  Stem  Cell  Transplantation  (HSCT)  and  100-day  Mortality  After Allogeneic HSCT

Nine  subjects  (9/45,  20.0%)  had  an  allogeneic  HSCT  during  the  study,  including  7  who  achieved CR/CRh* in the first 2 cycles (7/16 subjects, 43.8%).

Page4 of4

<div style=\"page-break-after: always\"></div>

Table 21: Proportion of Subjects with Allogeneic HSCT after Treatment by Best Response During the First Two Cycles (Full Analysis Set)

|                                                                                                              | Blinatumomab (N = 45)   |
|--------------------------------------------------------------------------------------------------------------|-------------------------|
| Subjects with CR/ CRh*- n(%)                                                                                 | 16 (100.0)              |
| HSCT after CR or CRh* - n(%)*                                                                                | 7 (43.8)                |
| (95% C1)                                                                                                     | (19.8, 70.1)            |
| Subjects with CR - n(%)                                                                                      | 14 (100.0)              |
| HSCT after CR - n(%)                                                                                         | 5 (35.7)                |
| (95% C1)                                                                                                     | (12.8, 64.9)            |
| Subjects with CRh*- n(%)                                                                                     | 2 (100.0)               |
| HSCT after CRh* - n(%)*                                                                                      | 2 (100.0)               |
| (95% C1)                                                                                                     | (15.8. 100.0)           |
| Subjects with HSCT - n(%)b                                                                                   | 9 (20.0)                |
| In remission after CR/CRh* within the first two cycles and no anti-leukemic medication after blinatumomabc   | 4 (8.9)                 |
| In remission after CR/CRh* within the first two cycles and with anti-leukemic medication after blinatumomabc | 1 (2.2)                 |
| Not in remission after CR/CRh* within the first two cycles                                                   | 2 (4.4)                 |
| Not having reached CR/CRh\" within the first two cycles                                                       | 2 (4.4)                 |
| Achieved CRi                                                                                                 | 0 (0.0)                 |
| Achieved Blast free hypoplastic or aplastic bone marrow (without CRi)                                        | 1 (2.2)                 |

Four  patients  with  allogeneic  HSCT  did  not  receive  any  additional  antileukemic  medication  after blinatumomab,  excluding  conditioning  regimen.  This  subset  of  subjects  was  evaluated  for  100-day mortality. The 100-day mortality rate based on these 4 patients was 25.0% (95% CI: 3.9%, 87.2%). The KM estimate of median survival after HSCT was 15.9 months (95% CI: 2.1, 16.9).

<!-- image -->

HSCT =hematopoietic stem cell transplant.

Source: Figure 14-4.4.1

Figure 6: 100-day Mortality After Receiving Allogeneic HSCT While in Remission (Full Analysis Set)

- o Anti-blinatumomab Antibody Assays

Page 1 of 1

<div style=\"page-break-after: always\"></div>

Anti-blinatumomab-binding antibody was evaluated with a validated blinatumomab anti-drug antibody assay with the electrochemiluminescence detection technology. Paired samples from pre- and post-dose were available for 31 subjects. All the samples were classified as negative for the presence of antiblinatumomab antibodies.

## Historical control study 20160462

Study 20160462 was a retrospective cohort study of salvage treatment outcomes among adult patients with relapsed or refractory philadelphia-chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL).

## Methods

This was a retrospective cohort study of historical data from adult patients with Ph+ R/R B-precursor ALL  who  received  current  standard  of  care  treatment  and  had  failed/intolerant  or  R/R  to  second generation TKI for ALL.

The  retrospective  cohort  of  patients  was  identified  and  developed  from  existing  clinical  databases collected  for  3  ALL  study  groups;  1  in  Spain  and  2  in  Italy  (University  of  Milan;  Institut  Català d'Oncologia; and University of Bologna, S. Orsola University Hospital).

The period of eligibility for the diagnosis and eligibility of patients into the study was from 2000 through end of data collection in 2017.

The baseline period started from the initial diagnosis of ALL and ended at the start of the first qualifying salvage therapy. Data on patients were collected starting with the diagnosis of ALL until the date of death  or  last  follow-up  as  of  the  date  of  data  collection.  For  time-to-event  analyses,  patients  were followed to the event or censored at the time they were lost to follow-up or were alive at the end of study.

Figure 7: Data analysis schema

<!-- image -->

<div style=\"page-break-after: always\"></div>

## · Study participants

## Key inclusion criteria

- -Patients with Ph+ B-precursor ALL who received their initial treatment after 01 January 2000 and had a qualifying salvage therapy defined as treatment after being:
- o R/R to at least 1 second generation TKI (dasatinib, nilotinib, bosutinib, ponatinib),
- o OR intolerant to a second generation TKI and failed/intolerant to imatinib mesylate
- -Patients with &gt; 5% blasts in the bone marrow at the qualifying salvage therapy
- -Patients ≥ 18 years at the time of qualifying salvage therapy

## Key Exclusion Criteria

- -Patients with a history of malignancy other than ALL within 5 years before the start of qualifying salvage therapy
- -Patients with a central nervous system or an isolated extramedullary disease
- -Patients treated with blinatumomab

## · Treatments

Qualifying salvage therapy was defined as the salvage therapy after meeting the inclusion criteria of failure/intolerant or R/R to a second generation TKI.

## · Objectives

## Primary Objective:

- -To estimate the proportion of adult patients with R/R Ph+ B-precursor ALL who achieve a CR (eg, CR,  CR  with  partial  haematological  recovery  [CRh*],  or  complete  response  with  incomplete haematological recovery [CRi]) after salvage therapy.

## Secondary Objectives

- -To estimate OS after salvage therapy in adult patients with R/R Ph+ B-precursor ALL
- -To estimate relapse-free survival (RFS) after salvage therapy in adult patients with R/R Ph+ Bprecursor ALL
- -To estimate the proportion of adult patients with R/R Ph+ B-precursor ALL who achieve minimal residual disease (MRD) response after salvage therapy
- -To estimate the proportion of adult patients with R/R Ph+ B-precursor ALL who receive allogeneic HSCT after salvage therapy
- -To describe treatment patterns for patients with R/R Ph+ ALL (eg, first or second generation TKIs, both, neither, conventional cytotoxic chemotherapy at each line of therapy)
- -To describe outcomes by baseline characteristics (eg, previous HSCT, previous TKI use)

<div style=\"page-break-after: always\"></div>

## · Endpoints

Primary Endpoints:

- -CR was defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts (platelets &gt; 100 000/µL and absolute neutrophil count [ANC] &gt; 1000/µL)
- -CRh* defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and partial recovery of peripheral blood counts (platelets &gt; 50 000/µL and ANC &gt; 500/µL)
- -CRi defined as ≤ 5% blasts in the bone marrow, no evidence of disease, and incomplete recovery of peripheral blood counts (platelets &lt; 100 000/µL or ANC &lt; 1000/µL)
- -CR + CRh*
- -CR + CRh*+ CRi

Secondary Endpoints:

- -OS defined as the time from the start of the qualifying salvage therapy to death
- -RFS defined as the time from the start of the qualifying salvage therapy to relapse or Death
- -MRD response defined as MRD &lt; 10 -4  measured by BCR-ABL quantitative polymerase chain reaction (or flow cytometry) (yes response), MRD &gt; 10 -4  (no response)
- -allogeneic HSCT after salvage therapy
- -treatment patterns (use of first or second generation TKI, both, or neither, or conventional cytotoxic chemotherapy in each line of therapy)

## · Sample size

Assuming the formula 1.96 × 0.5/(sample size)½ represents a reasonable approximation for the halfwidth of a 95% CI, the expected precision of the CR proportion estimate is +/- 13.9% for 50 patients and +/- 9.8% for 100 patients. Approximately 50 to 100 patients from Italy and Spain were identified to be available for this study.

## · Statistical methods

For the primary objective, the proportion of patients with a CR (CR, CRh*, CRi, and combinations of these) was estimated along with the asymptotic variance and 95% CI.

For the secondary objectives, KM OS rates at selected times after salvage therapy (6 months, 1 year, and 2 years) and the median OS was estimated. For KM rates, the variance and 95% CI was estimated using Greenwood's formula. For the median OS, the variance and 95% CI was estimated using the method described in Collett, 1994.

The RFS was estimated using the same methods as those for OS. The proportion of patients achieving an MRD response and receiving HSCT was estimated along with the asymptotic variance and 95% CI.

Overall  estimates  of  the  study  outcomes  were  described  for  the  unadjusted  study  population,  and weighted to match key patient and disease characteristics (eg, disease status, previous treatments) in the ALCANTARA (20120216) clinical study. The proportions across strata based on the key patient and disease characteristics were pooled into a combined estimate with each stratum weight matching the

<div style=\"page-break-after: always\"></div>

percentage  of  patients  observed  in  that  stratum  from  the  20120216  clinical  study.  A  95%  CI  was estimated for the combined estimate with variance based on the sum of the variances of the weighted stratum proportions. Propensity score modelling will be conducted to estimate the association between receipt of blinatumomab (versus the qualifying salvage therapy) and CR and OS outcomes, by adjusting with inverse probability of treatment weighting.

No stratified analyses were planned for this study.

Sensitivity  analysis  for  residual  confounding  and  bias:  A  sensitivity  analysis  compared  certain characteristics of this study population such as age at relapse, sex, and previous treatments with the patients  in  the  ALCANTARA  study  to  assess  potential  bias  and  residual  confounding.  Relationships between important clinical and other characteristics and study endpoints were examined to understand their potential as confounders in this study population, and controlled for when necessary.

## Results

## · Participant flow

A total of 55 patients was included.

Approximately 75.0% of patients with data available were from the 2 sites in Italy; 25,5% of patients were from the third site, in spain.

## · Conduct of the study

Start of data collection: 01 August 2017

End of data collection: 31 December 2017

Final report of study results: 12 April 2018

One amendment was implement, on 22 June 2017. The purpose of this amendment was to update the study end date to clarify that the observation period is prior to the date of inclusion of patients in the study and that no additional prospective data will be collected from the sites after the date of data collection.

## · Baseline characteristics

The study had an equal distribution of men (51%) and women (49%).

The median (min, max) age at diagnosis was 50.0 (19.0, 81.0) years and the median (min, max) age at last qualifying salvage therapy was 53.0 (20.0, 82.0) years. Approximately 40.0% patients were 55 years or older at diagnosis or at treatment.

Baseline disease characteristics are summarized in the table below.

<div style=\"page-break-after: always\"></div>

Table 22: Baseline Disease Characteristics

|                                                                                  | (N = 55) n (%)   |
|----------------------------------------------------------------------------------|------------------|
| Qualifying disease status - n (%)                                                |                  |
| R/R to at least 1 second generation TKI                                          | 52 (94.5)        |
| Intolerant to a second-generation TKl and failed/intolerant to imatinib mesylate | 1 (1.8)          |
| Both                                                                             | 2 (3.6)          |
| Lines of previous treatment - n (%)                                              |                  |
| In first salvage                                                                 | 7 (12.7)         |
| In second salvage                                                                | 31 (56.4)        |
| In third or higher salvage                                                       | 17 (30.9)        |
| Refractory to any previous treatment - n (%)                                     |                  |
| Yes                                                                              | 21 (38.2)        |
| No                                                                               | 34 (61.8)        |
| Not available for patient                                                        | (0'0) 0          |
| Refractory to the primary treatment - n (%)                                      |                  |
| Yes                                                                              | 3 (5.5)          |
| No                                                                               | 52 (94.5)        |
| Not available for patient                                                        | (0°0) 0          |
| Refractory to last treatment - n (%)                                             |                  |
| Yes                                                                              | 15 (27.3)        |
| No                                                                               | 17 (30.9)        |
| Not available for patient                                                        | 23 (41.8)        |
| Previous alloHSCT - n (%)                                                        |                  |
| Yes                                                                              | 18 (32.7)        |
| No                                                                               | 37 (67.3)        |
| Not available for patient                                                        | 0 (0.0)          |
| Year of diagnosis -n (%)                                                         |                  |
| 2001-2004                                                                        | 6 (10.9)         |
| 2005-2009                                                                        | 21 (38.2)        |
| 2010+                                                                            | 28 (50.9)        |
| Year of last qualifying salvage - n (%)                                          |                  |
| 2001-2004                                                                        | 0 (0.0)          |
| 2005-2009                                                                        | 15 (27.3)        |
| 2010 -2014                                                                       | 30 (54.5)        |
| 2015+                                                                            | 10 (18.2)        |
| Bone marrow blasts at diagnosis - n (%)                                          |                  |
| > 5% to 50%                                                                      | 3 (5.5)          |
| 50% or higher                                                                    | 38 (69.1)        |
| Not available for patient                                                        | 14 (25.5)        |
| Types of TKls before qualifying salvage - n (%)                                  |                  |
| Imatinib                                                                         | (0°0) 0          |
| Dasatinib                                                                        | 33 (60.0)        |
| Ponatinib                                                                        | 5 (9.1)          |
| Nilotinib                                                                        | 1(1.8)           |
| Multiple TKI                                                                     | 8 (14.5)         |
| None                                                                             | 8 (14.5)         |

alloHSCT = allogeneic hematopoietic stem cell transplantation; N = number of patients enrolled; R/R = relapsed/ refractory: TKI = tyrosine kinase inhibitor Program:/userdata/cfor/projects/p17\\_onc\\_174/pr\\_tfl\\_pgms/t03\\_base\\_disease.sas Output: t03\\_base\\_disease\\_01.rtf (Date Generated: 06MAR18:19:14:51) Source Data: datapool

<div style=\"page-break-after: always\"></div>

Table 23: ALL Salvage Treatment

<!-- image -->

|                                               | (N = 55) n (%)   |
|-----------------------------------------------|------------------|
| alloHSCT after last qualifying salvage -n (%) |                  |
| Yes                                           | 8 (14.55)        |
| No                                            | 47 (85.45)       |
| Type of salvage treatment - n (%)             |                  |
| Chemotherapyonly                              | 10 (18.18)       |
| Chemotherapy +Tkl                             | 14 (25.45)       |
| TKI only                                      | 16 (29.09)       |
| Other                                         | 15 (27.27)       |

N = number of patients enrolled; TKl = tyrosine kinase inhibitor Program:/userdatalcfor/projects/p17\\_onc\\_174/pr\\_tfl\\_pgmslt05\\_all\\_salvage.sas Output: t05\\_all\\_salvage\\_01.rtf (Date Generated: 07MAR18:14:10:07) Source Data: datapool

## · Numbers analysed

Of the 55 patients in the study evaluated for response:

- -16 provided data on CR (including CR, CRh*, and CRi)
- -51 provided data on OS
- -12 provided data on RFS.

## · Outcomes and estimations

## Primary Endpoints

Primary endpoints were CR, CRh and Cri, as summarized in the table below.

Table 24: Response to Treatment

|                                                                 | (N = 55) n (%)   | Excluding Unknown (N1 = 45) n (%)   |
|-----------------------------------------------------------------|------------------|-------------------------------------|
| Response to treatment -n (%)                                    |                  |                                     |
| Overall complete remission (CR + CRh)                           | 15 (27.27)       | 15 (33.33)                          |
| Complete remission (CR)                                         | 14 (25.45)       | 14 (31.11)                          |
| Complete remission with partial hematological recovery (CRh*)   | 1 (1.82)         | 1 (2.22)                            |
| Complete remission with incomplete hematological recovery (CRi) | 1 (1.82)         | 1 (2.22)                            |
| Refractory/SD                                                   | 15 (27.27)       | 15 (33.33)                          |
| Partial response (PR)                                           | 1 (1.82)         | 1 (2.22)                            |
| Progressive diseaselinfection deaih                             | 13 (23.64)       | 13 (28.88)                          |
| Unknown/missing                                                 | 10 (18.18)       | NA                                  |

N = number of patients enrolled; N1 = number of patients excluding those with an unknown or missing response; n = number of patients with a response; NA = not applicable; SD = stable disease Program:/userdata/cfor/projects/p17\\_onc\\_174/pr\\_tfl\\_pgms/t06\\_study\\_group\\_cr.sas Output: t06\\_study\\_group\\_cr\\_01.rtf (Date Generated: 07MAR18:14:10:41) Source Data:datapool

<div style=\"page-break-after: always\"></div>

Table 25: Time to Complete Remission

|                                    | (N = 15)    |
|------------------------------------|-------------|
| Time to remission (weeks)          |             |
| n                                  | 12          |
| Mean (SD)                          | 7.60 (5.31) |
| Median                             | 6.43        |
| 01.03                              | 4.64,7.93   |
| Min, Max                           | 3.4.23.1    |
| Time to remission category - n (%) |             |
| < 1 week                           | (0) 0       |
| 1-2weeks                           | (0) 0       |
| 3-4 weeks                          | 2(13)       |
| 5 -6 weeks                         | 3 (20)      |
| 7-8 weeks                          | 4(27)       |
| 29 weeks                           | 3 (20)      |
| Missing                            | 3 (20)      |

N = number of CR or CRh*: n = number of patients with a CR or CRh\" with timing of data available Primary approach used CR or CRh* data after the last salvage therapy for patients with outcome data following multiple lines of salvage therapy.

Program: /userdata/cfor/projects/p17\\_onc\\_174/pr\\_tfl\\_pgms/t07\\_time\\_to\\_cr.sas

Output: t07\\_time\\_to\\_cr\\_01.rtf (Date Generated: 30MAR18:10:31:35)

Source Data: datapool

## Secondary efficacy endpoints

- o OS

Of the 51 patients for whom the OS data were available, the median OS was 6.0 (95% CI: 4.4, 9.2) months where OS data after the last salvage therapy was used when outcome data after multiple lines of salvage therapy were available.

<!-- image -->

## Censor indicated by vertical bar I.

Programr TFLShellExamplelt ff\\_km\\_os.sas Ouput /ueardss/dorprgjecep17\\_one\\_174/oupuwt71\\_km\\_0e\\_01.r(Date Genarstad:01MARi8 18:28) SourceData:dstpool

## Footnotes.

Primay approach uses OSdaafollowinglast sdvagefor patients with outcome datafollowingmultiplelins of salvagetheapy

N = number of patients with an OS data available; OS = overall sunvival

Figure 8 : Kaplan-Meier Curve of Overall Survival

<div style=\"page-break-after: always\"></div>

Strata-specific (unweighted) estimates of median OS ranged from 4.4 to 7.6 months depending on the age at relapse and line of salvage therapy.

Table 26: Strata and Combined Estimate of Median Overall Survival

| Stratumx   | Agex   | Prior·lines-of Treatmentx   | Nx   | Nna   | Median·(95%·CI)·OS. in·monthsx   | Stratum· %. Observed. in-Study. 20120216.)   |
|------------|--------|-----------------------------|------|-------|----------------------------------|----------------------------------------------|
| 1x         | <55x   | alloHSCTμ                   | 15x  | 1x    | 4.4-(-2.1,..·NE)x                | 36.0%x                                       |
| 2x         | <55x   | In-all·salvagex             | 13x  | 2x    | 5.4.(-3.6,..9.6)x                | 14.0%x                                       |
| 3x         | >=55x  | alloHSCTx                   | 2x   | 0x    | 7.6-(NE,...·NE)x                 | 29.0%x                                       |
| 4x         | >=55x  | In-all-salvagex             | 21x  | 1x    | 6.0.(-3.1,..9.3)x                | 22.0%x                                       |
| Combinedbx | X      | X                           | X    | X     | 5.9.(-2.3,..9.5)x                | X                                            |

alloHSCT = allogeneic hematopoietic stem cell transplantation; N = number of patients with an OS data available; NE = not estimable; Nns = number of patients with an OS data not available; OS = overall survival

Without an alloHSCT.

b The combined OS median estimate was pooled across strata with each stratum weight matching the percentage of patients observed in that stratum from Study 20120216. The 95% Cl for the combined estimate was estimated by bootstrapping.

Primary approach used OS data after the last salvage therapy for patients with outcome data after multiple lines of salvage therapy.

Output: t08\\_est\\_mos\\_01.rtf (Date generated: 06MAR2018:14:23)

Program: /userdata/cfor/projects/p17\\_onc\\_174/pr\\_tfl\\_pgms/t08\\_est\\_mos.sas

Source data: datapool.sas7bdat

Table 27: Strata and Combined Estimate of 6-Month Overall Survival (OS) (Primary Approach, PhPrimary Analysis Set)

| Stratum    | Age        | Prior lines of Treatment   | N          | N na       | 6-Month OS Kaplan- Meier Rate (95% CI)   | Stratum % Observed in Study 20120216   |
|------------|------------|----------------------------|------------|------------|------------------------------------------|----------------------------------------|
| 1          | <55        | alloHSCT                   | 15         | 1          | 0.47 (0.21, 0.69)                        | 36.0%                                  |
| 2          | <55        | In all salvage a           | 13         | 2          | 0.48 (0.18, 0.73)                        | 14.0%                                  |
| 3          | >=55       | alloHSCT                   | 2          | 0          |                                          | 29.0%                                  |
| 4          | >=55       | In all salvage a           | 21         | 1          | 0.49 (0.26, 0.69)                        | 22.0%                                  |
| Combined b | Combined b | Combined b                 | Combined b | Combined b | Combined b                               | Combined b                             |

Page 1 of 1

## Footnotes:

Primary approach uses OS data following last salvage for patients with outcome data following multiple lines of salvage therapy.

N = Number of patients with OS data available.

Nna = Number of patients with OS data not available in study groups who provided OS data on other patients alloHSCT = allogeneic hematopoietic stem cell transplantation.

a Without an alloHSCT .

b The combined OS Kaplan-Meier rate estimate is pooled across strata with each stratum weight matching the percentage of subjects observed in that stratum from Study 20120216.   The 95% CI for the combined estimate was estimated by bootstrapping

Program: /userdata/cfor/projects/p17\\_onc\\_174/pr\\_tfl\\_pgms/t09\\_est\\_6\\_os.sas

Output: t09\\_est\\_6\\_os\\_01.rtf (Date generated: 20NOV2019:10:28) Source data: datapool.sas7bdat

<div style=\"page-break-after: always\"></div>

A total of 33 patients (63.5%) died (censored at HSCT) (Table 28). The KM-estimated median time to hematological OS events (censored at HSCT) was 5.5 (95% CI: 4.4, 7.6) months. The KM-estimated hematological OS at 18 months (censored at HSCT) was 14.0% (95% CI: 2.0%, 26.0%).

Table 28 : Hematological Overall Survival Analysis

|                            | Uncensored at HSCT (N= 52)   | Censored at HSCT (N= 52)   |
|----------------------------|------------------------------|----------------------------|
| Subject status             |                              |                            |
| Events -n (%)              | 37 (71.15)                   | 33 (63.48)                 |
| Death in CR                | 6 (11.5)                     | 4 (7.69)                   |
| Censored-n (%)             | 15 (28.8)                    | 19 (36.5)                  |
| Time to event (months)     |                              |                            |
| KM Median (95% Cl)         | 6.0 (4.4, 9.2)               | 5.5 (4.4, 7.6)             |
| KM Q1, 03                  | 3.4, 13.0                    | 3.1, 9.3                   |
| Min, Max                   | 0.1, 19.8                    | 0.1, 18.7                  |
| Time to censoring (months) |                              |                            |
| KM Median (95% Cl)         | 28.9 (8.9, 34.4)             | 27.6 (5.3, 57.1)           |
| KM Q1,03                   | 6.3, 34.4                    | 4.0, 32.1                  |
| Min, Max                   | 1.7. 57.1                    | 0.0, 57.1                  |
| KM proportion (95% Cl)     |                              |                            |
| Month 3                    | 0.81 (0.70, 0.91)            | 0.79 (0.67, 0.91)          |
| Month 6                    | 0.49 (0.35, 0.64)            | 0.47 (0.31, 0.63)          |
| Month 9                    | 0.36 (0.22, 0.51)            | 0.31 (0.16,0.47)           |
| Month 12                   | 0.28 (0.14, 0.42)            | 0.24 (0.10, 0.39)          |
| Month 18                   | 0.20 (0.07, 0.32)            | 0.14 (0.02, 0.26)          |
| Month 24                   | 0.14 (0.03, 0.25)            | 0.10 (0.00, 0.21)          |
| Month 30                   | 0.14 (0.03, 0.25)            | 0.10 (0.00, 0.21)          |
| Month 36                   | 0.14 (0.03, 0.25)            | 0.10 (0.00, 0.21)          |

of patients with OS data available; OS = overall survival

CR = complete remission; HSCT =hematopoietic stem cell transplantation; KM =Kaplan-Meier; N = number

Program:luserdatalcfor/projects/p17\\_onc\\_174/pr\\_tl\\_pgms/t12\\_os\\_survival\\_analysis.sas

Output: t12\\_os\\_survival\\_analysis\\_01.rf (Date generated: 4APR2018:20:24)

Source data: ADTTE

The hazard ratio (HR) (patients who received allogeneic HSCT after salvage therapy versus patients who did not receive allogeneic HSCT after salvage therapy) for OS adjusted for age, WBC count at diagnosis, and year of diagnosis including CR + CRh* status after salvage therapy was 0.32 (95% CI: 0.06, 1.67) (Table below).

Table 29: Hazard Ratio for OS and Duration of CR of Transplanted Versus Nontransplanted Patients as Assessed Through Time-dependent Cox Model

|                         | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N = 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N = 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N = 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N = 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N = 55)   |
|-------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                         | N                                                             | n Excluded for Missing Data                                   | Transplanted                                                  | HR (95%)                                                      | p value                                                       |
| Overall Survival        |                                                               |                                                               |                                                               |                                                               |                                                               |
| Unadjusted              | 51                                                            | 3                                                             | 8                                                             | 0.41 (0.14, 1.17)                                             | 0.0960                                                        |
| Adjusted                | 44                                                            | 10                                                            | 7                                                             | 0.16 (0.04, 0.67)                                             | 0.0128                                                        |
| Adjusted including CR.  | 44                                                            | 10                                                            | 7                                                             | 0.32 (0.06, 1.67)                                             | 0.176                                                         |
| Response                |                                                               |                                                               |                                                               |                                                               |                                                               |
| Overall CR (CR + CRh\")  | 13                                                            | 41                                                            | 6                                                             | 0.69 (0.09, 5.14)                                             | 0.72                                                          |
| All CR (CR + CRh\"+ CRi) | 14                                                            | 40                                                            | 9                                                             | 0.82 (0.11, 6.23)                                             | 0.85                                                          |
| No CR                   | 37                                                            | 17                                                            | 2                                                             | 0.98 (0.23, 4.16)                                             | 0.98                                                          |

CR = complete remission; CRh* = CR with partial hematological recovery: CRi = complete response with incomplete hematological recovery: HR = hazard ratio; N = number of patients enrolled; OS = overall sunvival; WBC = white blood cell

OS adjusted for age, WBC at diagnosis, and year of diagnosis.

Program: /userdata/cfor/projects/p17\\_onc\\_174/pr\\_til\\_pgms/t19\\_HR\\_HSCT\\_RFS\\_OS.sas

Output: t19\\_HR\\_HSCT\\_RFS\\_0S\\_01.rtf (Date generated: 03APR2018:08:53)

Source data: datapool. sas7bdat

<div style=\"page-break-after: always\"></div>

## o Relapse-free Survival

Strata-specific (unweighted) estimates of median RFS were not estimable because of limited number of events that occurred by the last follow-up (n = 2). The combined KM-estimated 6-month RFS rate could not be weighted to the population in Study 20120216. The KM plot for RFS is shown in the figure below.

## o Other analysis

## OS subgroup analysis:

Subgroup analysis of OS was provided for each baseline characteristics. This analysis suggested that the KM-estimated 6-month (59.0%) and 12-month (45.0%) OS was higher in patients who received previous allogeneic HSCT compared with patients who received salvage therapy without previous allogeneic HSCT (44.0% and 18.0%, respectively).

Patients who were not refractory to any previous treatment appeared to have longer OS than patients who were refractory to any previous treatment. Younger age at treatment suggested a trend of lower OS. Chemotherapy plus TKI as last salvage therapy suggested longer OS.

The hazard ratio (HR) (patients who received allogeneic HSCT after salvage therapy versus patients who did not receive allogeneic HSCT after salvage therapy) for OS adjusted for age, WBC count at diagnosis, and year of diagnosis including CR + CRh* status after salvage therapy was 0.32 (95% CI: 0.06, 1.67)

Table 30: Hazard Ratio for OS and Duration of CR of Transplanted Versus Nontransplanted Patients as Assessed Through Time-dependent Cox Model

|                        | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N= 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N= 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N= 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N= 55)   | Hazard Ratio (95% Cl) Transplanted/Nontransplanted (N= 55)   |
|------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                        | N                                                            | n Excluded for Missing Data                                  | Transplanted                                                 | HR (95%)                                                     | p value                                                      |
| Overall Survival       |                                                              |                                                              |                                                              |                                                              |                                                              |
| Unadjusted             | 51                                                           | 3                                                            | 8                                                            | 0.41 (0.14, 1.17)                                            | 0.0960                                                       |
| Adjusted\"              | 44                                                           | 10                                                           | 7                                                            | 0.16 (0.04, 0.67)                                            | 0.0128                                                       |
| Adjusted including CR  | 44                                                           | 10                                                           | 7                                                            | 0.32 (0.06, 1.67)                                            | 0.176                                                        |
| Response               |                                                              |                                                              |                                                              |                                                              |                                                              |
| Overall CR (CR + CRh²) | 13                                                           | 41                                                           | 6                                                            | 0.69 (0.09, 5.14)                                            | 0.72                                                         |
| All CR (CR+CRh\"+ CRi)  | 14                                                           | 40                                                           | 9                                                            | 0.82 (0.11, 6.23)                                            | 0.85                                                         |
| No CR.                 | 37                                                           | 17                                                           | 2                                                            | 0.98 (0.23, 4.16)                                            | 0.98                                                         |

CR = complete remission; CRh* = CR with partial hematological recovery: CRi = complete response with incompletehematological recovery:HR=hazardratio;N=numberofpatients enrolled;OS=overall survival; WBC =whitebloodcell

Program: /userdata/cfor/projects/p17\\_onc\\_174/pr\\_tf\\_pgms/t19\\_HR\\_HSCT\\_RFS\\_0S.sas

OS adjusted for age, WBC at diagnosis, and year of diagnosis.

Output: t19\\_HR\\_HSCT\\_RFS\\_OS\\_01.rtf (Date generated: 03APR2018:08:53)

Source data: datapool.sas7bdat

Hematological Overall Survival Analysis:

A  total  of  33  patients  (63.5%)  died  (censored  at  HSCT).  The  KM-estimated  median  time  to haematological OS events (censored at HSCT) was 5.5 (95% CI: 4.4, 7.6) months. The KM-estimated haematological OS at 18 months (censored at HSCT) was 14.0% (95% CI: 2.0%, 26.0%).

Hematological Relapse-free Survival Analysis: One patient (8.3%) had haematological relapse (censored at HSCT) after achieving a CR. The KM-estimated median time to haematological RFS events was not reached. The KM-estimated haematological RFS at 18 months (censored at HSCT) was 83.0% (95% CI: 54.0%, 100%).

<div style=\"page-break-after: always\"></div>

## Ancillary analyses

## Propensity Score Analysis

A Propensity Score Analysis was performed to estimate the association between receipt of blinatumomab (versus the qualifying salvage therapy) and OS and CR/CRh* outcomes among patients with Philadelphia-positive relapsed or refractory ALL, with a comparison to historical cohort 20160462.

In an attempt to create a balance between the 2 groups of data with respect to key prognostic factors, a propensity score analysis was completed.

Primary objective of the Propensity Score Analysis was:

- -Evaluate the effect of blinatumomab, with OS comparison between adult subjects with Phi + RR ALL from Study 20120216 receiving blinatumomab and patients from Study 20160462 receiving standard of  care  treatment;  comparison  was  performed  after  OS  adjustments  for  each  study  patient's propensity score.

Secondary objective of the Propensity Score Analysis was:

- -To evaluate the effect of blinatumomab with respect to CR/CRh* rate after making adjustments for each study patient's propensity score.

Overall  survival  was  aligned  between  Study  20120216  and  Study  20160462  while  CR/CRh*  was determined  with  the  first  2  cycles  of  blinatumomab  treatment  for  Study  21020216  while  in  Study 20160462 the time to response was not specified in the protocol (mean of 133 days with standard error of 41 and a median of 48 days).

In  order  to  meet  these  objectives,  adequate  balance  had  to  be  achieved  between  this  historical comparator population and the Study 20120216 clinical trial population.

## Methods

The propensity score analysis included subjects from the Full Analysis sets for Studies 20120216 and 20160462, and only included patients from 20160462 which met the primary entry criteria for 20120216.

Balance between 20120216 population and 20160462 was obtained by applying inverse probability of treatment weights (IPTW) calculated from a propensity score model.

Four common approaches for making propensity score adjustments include 1) stratification, 2) covariate adjustment, 3) matching, and 4) inverse probability of treatment weighting (IPTW). With time-to-event endpoints, stratification  and  covariate  adjustment  have  been  shown  to  produce  biased  estimates  of marginal and conditional hazard ratios (Austin, 2013; Austin et al, 2007). Therefore, given that OS has been designated as the primary endpoint, only matching and IPTW could be considered for this analysis. However, a limitation of matching is that it can require large sample sizes if the degree of propensity score overlap is limited and many patients need to be dropped from the analysis due to an inability to find  a  proper  match  within  the  pre-specified  caliper  bounds.  Given  the  limited  sample  size  of  the blinatumomab treatment group, matching was not considered viable for propensity score adjustments. Therefore, IPTW was used for propensity score adjustments in this analysis.

Due to the low sample size a limited number of covariates were selected for the propensity score model (number of salvage therapies and no prior salvage). Moreover, because of the relatively small sample size (combined N=100) and low power for identifying influential covariates, p&lt;0.30 was used as the threshold for entering and keeping covariates in the model.

<div style=\"page-break-after: always\"></div>

Although 100% of the propensity scores for the historical comparator were contained within the 95% range  of  the  propensity  scores  for  blinatumomab,  the  historical  comparator  data  was  not  evenly distributed over the range of scores for blinatumomab. Balance was assessed based on overlap of the propensity score values and standardized differences of the individual baseline covariates before and after IPTW adjustment.

Upon deriving propensity scores for each patient, balance between the two treatment groups with respect to their PS was assessed via box plots. The overall balance was to be considered sufficient if at least 25% of the control data overlapped with the inner 95th percentile of the blinatumomab data, as prespecified in the SSAP.

Given the relative small sample size of Study 20160462 and Study 20120216, and reasonable estimates of the blinatumomab treatment effect the comparisons of OS and CR/CRh* were not sufficiently powered (&lt; 80%). To account for this, a Bayesian augmentation approach was applied to the endpoint analyses in which prior distributions for the comparison parameters (ie, the hazard ratio, and odds ratio) were specified and parameterized using key efficacy outcomes from the randomized trial in adult Philadelphianegative relapsed/refractory subjects, Study 00103311. The variance of the priors determine the amount of 'borrowing' that occurred from the prior models and were selected to provide 80% power for the comparisons. Potential bias from this 'borrowing' was assessed using sensitivity analyses at lower power levels and were provided in addition to the analysis without Bayesian augmentation.

With and without the Bayesian augmentation, the effect of treatment on OS was modelled using Cox Proportional Hazards model and CR/CRh* was modelled using a Logistic generalized linear model. Robust variance estimates with their respective CIs were provided for non-Bayesian analyses. For Bayesian models, point estimates and 95% CI were estimated using summary statistics and the relative highest posterior density interval of the posterior distributions and for model parameters of interest.

Table 31: Covariant Balance for Unadjusted and Adjusted Factors - Propensity Score Analysis Subjects and Patients

<!-- image -->

|                                                                            | Unadjusted                | Unadjusted                | Unadjusted          | Unadjusted          | Unadjusted                             | Unadjusted   | Adjusted with IPTW (ATE)    | Adjusted with IPTW (ATE)    | Adjusted with IPTW (ATE)   | Adjusted with IPTW (ATE)   | Adjusted with IPTW (ATE)              | Adjusted with IPTW (ATE)   |
|----------------------------------------------------------------------------|---------------------------|---------------------------|---------------------|---------------------|----------------------------------------|--------------|-----------------------------|-----------------------------|----------------------------|----------------------------|---------------------------------------|----------------------------|
| Factor                                                                     | Hlstorleal Control (N=55) | Hlstorleal Control (N=55) | Bllnatumomab (N=45) | Bllnatumomab (N=45) | Slandard-lzed Dlference (Control-Blln) | p-value      | Hlstorlcal Control (N-99.4) | Hlstorlcal Control (N-99.4) | Bllnatumomab (N-100.2)     | Bllnatumomab (N-100.2)     | Standard-zed Diference (Control-BlIn) | p-value                    |
|                                                                            | suml mean                 | SD/%                      | sum/ mean           | SD/%                | Slandard-lzed Dlference (Control-Blln) | p-value      | suml mean                   | SDI%                        | sum/ mean                  | SDI%                       | Standard-zed Diference (Control-BlIn) | p-value                    |
| Female (%%)                                                                | 27                        | 49.1%                     | 21                  | 46.7%               | 0.05                                   | 0.809        | 46.9                        | 47.2%6                      | 38.7                       | 38.7%                      | 0.17                                  | 0.420                      |
| Age at tlme ot trealment - years (mean [sD])                               | 52.0                      | 16.7                      | 52.8                | 15                  | -0.08                                  | 0.790        | 51.3                        | 21.8                        | 53.0                       | 22.5                       | -0.08                                 | 0.619                      |
| Age at primary dlagnosls - years (mean [so])                               | 49.7                      | 16.7                      | 50.6                | 15                  | -0.06                                  | 0.773        | 48.9                        | 22.1                        | 50.8                       | 22.4                       | -0.09                                 | 0.577                      |
| Prlor HSCT (%)                                                             | 18                        | 32.7%                     | 22                  | 48.9%               | -0.33                                  | 0.103        | 35.3                        | 35.6%6                      | 46.6                       | 46.6%                      | -0.23                                 | 0.303                      |
| Tlme from dlagnosls tomost recent treatment (basellne) -months (mean [SD]] | 27.8                      | 19.4                      | 27.3                | 26.1                | 0.02                                   | 0.916        | 28.4                        | 26.4                        | 26.3                       | 36.1                       | 0.07                                  | 0.662                      |
| Number of Prlor Salvages-n (%)                                             | 1.2                       | 0.8                       | 1.4                 | 1.4                 | -0.16                                  | 0.396        | 1.3                         | 1.4                         | 1.3                        | 1.7                        | -0.02                                 | 0.889                      |
| No Pror Salvages -n (%6)                                                   | 7                         | 12.7%                     | 14                  | 31.1%               | -0.46                                  | 0.029        | 21                          | 21.1%                       | 21                         | 21.0%                      | 0.00                                  | 0.985                      |

Source: Table 11-2 of the Propenslly Score Analysls, Module 5.3.5.4.

The primary null hypothesis tested for this analysis was that blinatumomab has no effect on OS as compared to historical controls.

<div style=\"page-break-after: always\"></div>

Overall  survival  was  calculated  relative  to  the  start  date  of  blinatumomab  infusion/standard  of  care treatment in the first treatment cycle. All deaths were counted as events on the date of death. Patients alive were censored on the last known date that they were alive. The PS-weighted OS analysis was performed  using  a  Cox  proportional  hazards  model  with  each  patient's  treatment  status  as  an independent factor.

## Results

## · Primary Endpoint: OS

The Bayes-augmented IPTW adjusted hazard ratio comparing blinatumomab to historical comparator was 0.77 (95% CI: 0.61, 0.96) representing 23% reduction in the hazard of death for the blinatumomab treatment group compared to the historical control group. For comparison, the non-Bayes IPTW adjusted hazard ratio was 0.81 (95% CI: 0.57, 1.15).

Due to  the  inclusion  of  prior  HSCT  in  the  endpoint  model,  survival  curves  and  point  estimates  are calculated given the proportion of prior HSCT: 0.327 for historical control and 0.4 for blinatumomab. The Bayesian-augmented survival for blinatumomab subjects at 3-, 6-, 9-, and 12-months is provided in the table below. Nine-month survival curves are shown in the figure below.

Table 32: Summary of Overall Survival Analyses Adjusted by Propensity Score Method (Full Analysis Set, ATE Weight)

| Endpoint               | Historical Control   | Blinatumomab                                                                                                 | Ratio*            |
|------------------------|----------------------|--------------------------------------------------------------------------------------------------------------|-------------------|
| No Prior               |                      |                                                                                                              | 0.81 (0.57. 1.14) |
| at 3-month -r (%)      | 0.79                 | 0.83 (0.74,0.93) 0.59 (0.47, 0.74) 0.47 (0.35,0.64) 0.40 (0.28, 0.57) 0.83 (0.82,0.85) 0.60 (0.57,0.63) 0.48 |                   |
| 95%% C1                | (0.70, 0.89)         |                                                                                                              |                   |
| at 6-month             | 0.52                 |                                                                                                              |                   |
| 95% C1                 | (0.40, 0.68)         |                                                                                                              |                   |
| at 9-month             | 0.39                 |                                                                                                              |                   |
| 95% C1                 | (0.27. 0.57)         |                                                                                                              |                   |
| at 12-month            | 0.32                 |                                                                                                              |                   |
| 95% C1                 | (0.20, 0.50)         |                                                                                                              |                   |
| Nommal Prior-80%.Power |                      |                                                                                                              | 0.77 (0.61, 0.96) |
| at 3-month -r (%)      | 0.79                 |                                                                                                              |                   |
| 95% C1                 | (0.77. 0.81)         |                                                                                                              |                   |
| at 6-month             | 0.51                 |                                                                                                              |                   |
| 95% C1                 | (0.47, 0.55)         |                                                                                                              |                   |
| at 9-month             | 0.39                 |                                                                                                              |                   |
| 95% C1                 | (0.34, 0.43)         | (0.44,0.52)                                                                                                  |                   |
| at 12-month            | 0.31                 | 0.41                                                                                                         |                   |
| 95% C1                 | (0.26, 0.35)         | (0.37,0.44)                                                                                                  |                   |

ATE ·average trealment etlect.

Note: Analysls utllzes the IPT welghts.

Hazard ratlofor overall survlval

Survlval estlmates are calculated glven proporllon ot prdor HscT: 0.327 for Control and 0.4 tor qewowmeug

Source: Modfled trom Table 11-3 of the Propenslty Score Analysls.

<div style=\"page-break-after: always\"></div>

Figure 9: Overall Survival Cox Model Estimates by Study, Adjusted With IPTW (ATE)

<!-- image -->

## · Secondary Endpoints: CR/CRh*

The Bayes-augmented odds ratio estimate was 1.70 (95% CI: 0.94, 2.94). Complimentary response rate estimates with 95% CIs for blinatumomab and the historical comparator were 0.36 (95% CI: 0.28, 0.46) and 0.25 (95% CI: 0.17, 0.34) respectively.

The  non-Bayes  odds  ratio  estimate  was  1.54  (95%  CI:  0.61,  3.89).  Complimentary  response  rate estimates for blinatumomab and historical comparator were 0.36 (95% CI: 0.22, 0.52) and 0.26 (95% CI: 0.16, 0.40) respectively.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

| Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study).   | Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study).   | Title: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study).                        |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                          | 20120216                                                                                                                                                                                                                                  | 20120216                                                                                                                                                                                                                                                       |
| Design                                                                                                                                                                                                                                    | Phase II, open-label, multicenter, single-arm study                                                                                                                                                                                       | Phase II, open-label, multicenter, single-arm study                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                           | Duration of main phase: Study Initiation Date: Study Completion Date:                                                                                                                                                                     | 26 months: 3 week screening-prephase, two 6-weeks cycles of induction phase, up to three 6-weeks cycles of consolidation phase, FU visit 30 days later, and 18 months FU. 03 January 2014 (first subject enrolled) 06 January 2017 (last subject end of study) |

<div style=\"page-break-after: always\"></div>

| Hypothesis                         | The best response within the first 2 cycles determined the primary efficacy endpoint. A hypothesized null true response rate of 10% was tested against an alternative response rate of 30%. The planned sample size yielded a 1- sided type I error rate of 0.025 and power of 90% when the true response rate   | The best response within the first 2 cycles determined the primary efficacy endpoint. A hypothesized null true response rate of 10% was tested against an alternative response rate of 30%. The planned sample size yielded a 1- sided type I error rate of 0.025 and power of 90% when the true response rate   | The best response within the first 2 cycles determined the primary efficacy endpoint. A hypothesized null true response rate of 10% was tested against an alternative response rate of 30%. The planned sample size yielded a 1- sided type I error rate of 0.025 and power of 90% when the true response rate   | The best response within the first 2 cycles determined the primary efficacy endpoint. A hypothesized null true response rate of 10% was tested against an alternative response rate of 30%. The planned sample size yielded a 1- sided type I error rate of 0.025 and power of 90% when the true response rate            |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatments groups                  | Blincyto                                                                                                                                                                                                                                                                                                         | Blincyto                                                                                                                                                                                                                                                                                                         | Blincyto                                                                                                                                                                                                                                                                                                         | A single cycle of blinatumomab was defined as 6 weeks in duration, which included 4 weeks of continuous intravenous (cIV) infusion of blinatumomab followed by a 2-week treatment-free interval. A maximum of 5 cycles could be administered, in case of CR/CRh/Cri achieved within 2 induction cycles of treatment. N=45 |
| Endpoints and definitions          | primary efficacy                                                                                                                                                                                                                                                                                                 | primary efficacy                                                                                                                                                                                                                                                                                                 | CR/CRh                                                                                                                                                                                                                                                                                                           | proportion of subjects who achieved CR/CRh within 2 cycles of blinatumomab                                                                                                                                                                                                                                                |
|                                    | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | MRD rate                                                                                                                                                                                                                                                                                                         | rate of MRD remission within 2 cycles of treatment with blinatumomab                                                                                                                                                                                                                                                      |
|                                    | secondary efficacy                                                                                                                                                                                                                                                                                               | secondary efficacy                                                                                                                                                                                                                                                                                               | RFS                                                                                                                                                                                                                                                                                                              | <free text>                                                                                                                                                                                                                                                                                                               |
|                                    | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | CR, CRh, and CR+CRh+CRi rates                                                                                                                                                                                                                                                                                    | CR rate and CRh* rate within 2 cycles of treatment with blinatumomab CR + CRh* + CRi rate within 2 cycles of treatment with blinatumomab                                                                                                                                                                                  |
|                                    | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | OS                                                                                                                                                                                                                                                                                                               | overall survival                                                                                                                                                                                                                                                                                                          |
|                                    | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | allogeneic HSCT and 100-day mortality                                                                                                                                                                                                                                                                            | allogeneic HSCT and 100-day mortality after allogeneic HSCT                                                                                                                                                                                                                                                               |
|                                    | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | AEs and antibodies                                                                                                                                                                                                                                                                                               | incidence of adverse events and antibody formation                                                                                                                                                                                                                                                                        |
|                                    | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | secondary efficacy endpoints                                                                                                                                                                                                                                                                                     | PK parameters                                                                                                                                                                                                                                                                                                    | PK parameters including quantification of serum blinatumomab concentrations                                                                                                                                                                                                                                               |
|                                    | exploratory endpoint                                                                                                                                                                                                                                                                                             | exploratory endpoint                                                                                                                                                                                                                                                                                             | specific bcr- abl mutations                                                                                                                                                                                                                                                                                      | evaluate the efficacy of blinatumomab in subjects with specific bcr-abl mutations.                                                                                                                                                                                                                                        |
| Database lock                      | Final analysis: 26 May 2017                                                                                                                                                                                                                                                                                      | Final analysis: 26 May 2017                                                                                                                                                                                                                                                                                      | Final analysis: 26 May 2017                                                                                                                                                                                                                                                                                      | Final analysis: 26 May 2017                                                                                                                                                                                                                                                                                               |
| Results and Analysis               | Results and Analysis                                                                                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                                      |
| Analysis                           | Analysis                                                                                                                                                                                                                                                                                                         | Primary Analysis                                                                                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                          |
| Analysis population and time point | Analysis population and time point                                                                                                                                                                                                                                                                               | Full Analysis Set: n=45 Final analysis: 26 May 2017                                                                                                                                                                                                                                                              | Full Analysis Set: n=45 Final analysis: 26 May 2017                                                                                                                                                                                                                                                              | Full Analysis Set: n=45 Final analysis: 26 May 2017                                                                                                                                                                                                                                                                       |
| description Descriptive statistics | description Descriptive statistics                                                                                                                                                                                                                                                                               | Treatment group                                                                                                                                                                                                                                                                                                  | Treatment group                                                                                                                                                                                                                                                                                                  | Blincyto                                                                                                                                                                                                                                                                                                                  |
| and estimate variability           | and estimate variability                                                                                                                                                                                                                                                                                         | Number of subject                                                                                                                                                                                                                                                                                                | Number of subject                                                                                                                                                                                                                                                                                                | 45                                                                                                                                                                                                                                                                                                                        |
|                                    |                                                                                                                                                                                                                                                                                                                  | CR/CRh                                                                                                                                                                                                                                                                                                           | CR/CRh                                                                                                                                                                                                                                                                                                           | 35.6%                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                         | CI                                                                                                                                                                                                      | CI                                                                                                                                                                                                      | [21.9%, 51.2%]                                                                                                                                                                                                            |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                         | MRD                                                                                                                                                                                                     | MRD                                                                                                                                                                                                     | 40%                                                                                                                                                                                                                       |
|                                                                                                                                                                                                         | RFS (n=16) median CI                                                                                                                                                                                    | RFS (n=16) median CI                                                                                                                                                                                    | 31.3% 6.8 months [4.4, NE]                                                                                                                                                                                                |
|                                                                                                                                                                                                         | Time to Hematological Relapse, median                                                                                                                                                                   | Time to Hematological Relapse, median                                                                                                                                                                   | 6.8 months 4.5, NE                                                                                                                                                                                                        |
|                                                                                                                                                                                                         | CI OS, median CI                                                                                                                                                                                        | CI OS, median CI                                                                                                                                                                                        | 9.0 months 5.7, 13.5                                                                                                                                                                                                      |
|                                                                                                                                                                                                         | HSCT (n=45) 100-day mortality rate                                                                                                                                                                      | HSCT (n=45) 100-day mortality rate                                                                                                                                                                      | 20.0% 25.0% ( 95% CI: 3.9%, 87.2%)                                                                                                                                                                                        |
|                                                                                                                                                                                                         | (n=4)                                                                                                                                                                                                   | (n=4)                                                                                                                                                                                                   |                                                                                                                                                                                                                           |
|                                                                                                                                                                                                         | median survival after                                                                                                                                                                                   | median survival after                                                                                                                                                                                   | 15.9 months (95% CI: 2.1, 16.9)                                                                                                                                                                                           |
| Title: Retrospective cohort study of salvage treatment outcomes among adult patients with relapsed or refractory philadelphia-chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL). | Title: Retrospective cohort study of salvage treatment outcomes among adult patients with relapsed or refractory philadelphia-chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL). | Title: Retrospective cohort study of salvage treatment outcomes among adult patients with relapsed or refractory philadelphia-chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL). | Title: Retrospective cohort study of salvage treatment outcomes among adult patients with relapsed or refractory philadelphia-chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL).                   |
| Study identifier                                                                                                                                                                                        | 20160462                                                                                                                                                                                                | 20160462                                                                                                                                                                                                | 20160462                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                  | Retrospective cohort study                                                                                                                                                                              | Retrospective cohort study                                                                                                                                                                              | Retrospective cohort study                                                                                                                                                                                                |
|                                                                                                                                                                                                         | Duration of main phase:                                                                                                                                                                                 | Duration of main phase:                                                                                                                                                                                 | Period of eligibility for the diagnosis: from 2000 through end of data collection in 2017. Start of data collection: 01 August 2017 End of data collection: 31 December 2017 Final report of study results: 12 April 2018 |
| Treatments groups                                                                                                                                                                                       | current standard of care treatment                                                                                                                                                                      | current standard of care treatment                                                                                                                                                                      |                                                                                                                                                                                                                           |
| Endpoints and definitions                                                                                                                                                                               | primary efficacy endpoints                                                                                                                                                                              | CR/CRh/CRi                                                                                                                                                                                              | proportion of subjects who achieved CR/CRh/Cri after salvage therapy                                                                                                                                                      |
| Endpoints and definitions                                                                                                                                                                               | secondary efficacy endpoints                                                                                                                                                                            | OS                                                                                                                                                                                                      | overall survival, time from the start of the qualifying salvage therapy to death                                                                                                                                          |
| Endpoints and definitions                                                                                                                                                                               | secondary efficacy endpoints                                                                                                                                                                            | RFS                                                                                                                                                                                                     | Time from the start of the qualifying salvage therapy to relapse or Death                                                                                                                                                 |
| Endpoints and definitions                                                                                                                                                                               | secondary efficacy endpoints                                                                                                                                                                            | MRD rate                                                                                                                                                                                                | MRD response defined as MRD < 10 -4 measured by BCR-ABL quantitative polymerase chain reaction (or flow cytometry)                                                                                                        |
| Results and Analysis                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                      |
| Analysis description                                                                                                                                                                                    | Primary Analysis                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                          |
| Analysis population                                                                                                                                                                                     | Full Analysis Set: n=55                                                                                                                                                                                 | Full Analysis Set: n=55                                                                                                                                                                                 | Full Analysis Set: n=55                                                                                                                                                                                                   |
| Descriptive statistics and estimate variability                                                                                                                                                         | Treatment group                                                                                                                                                                                         | Treatment group                                                                                                                                                                                         | standard of care treatment                                                                                                                                                                                                |
| Descriptive statistics and estimate variability                                                                                                                                                         | CR/CRh                                                                                                                                                                                                  | CR/CRh                                                                                                                                                                                                  | 15 (27.27%)                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                             | OS, median (n=51) CI                                                                                                                                                                                                                        | OS, median (n=51) CI                                                                                                                                                                                                                        | 6.0 months 4.4, 9.2                                                                                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                             | RFS                                                                                                                                                                                                                                         | RFS                                                                                                                                                                                                                                         | NE                                                                                                                                                                                                                                          |
| Tittle: Propensity Score Analysis of Overall Survival and the Rate of Complete Remission or Complete Remission With Partial Hematological Recovery Among Adult Patients With Philadelphia-positive B-precursor Acute Lymphoblastic Leukemia | Tittle: Propensity Score Analysis of Overall Survival and the Rate of Complete Remission or Complete Remission With Partial Hematological Recovery Among Adult Patients With Philadelphia-positive B-precursor Acute Lymphoblastic Leukemia | Tittle: Propensity Score Analysis of Overall Survival and the Rate of Complete Remission or Complete Remission With Partial Hematological Recovery Among Adult Patients With Philadelphia-positive B-precursor Acute Lymphoblastic Leukemia | Tittle: Propensity Score Analysis of Overall Survival and the Rate of Complete Remission or Complete Remission With Partial Hematological Recovery Among Adult Patients With Philadelphia-positive B-precursor Acute Lymphoblastic Leukemia |
| Study identifier                                                                                                                                                                                                                            |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                             |
| Design                                                                                                                                                                                                                                      | Propensity Score Analysis                                                                                                                                                                                                                   | Propensity Score Analysis                                                                                                                                                                                                                   | Propensity Score Analysis                                                                                                                                                                                                                   |
| Treatments groups                                                                                                                                                                                                                           | Study 20120216:                                                                                                                                                                                                                             | Study 20120216:                                                                                                                                                                                                                             | Blincyto                                                                                                                                                                                                                                    |
| Treatments groups                                                                                                                                                                                                                           | Study 20160462:                                                                                                                                                                                                                             | Study 20160462:                                                                                                                                                                                                                             | Standard of care treatment                                                                                                                                                                                                                  |
| Endpoints and definitions                                                                                                                                                                                                                   | primary efficacy endpoints                                                                                                                                                                                                                  | OS                                                                                                                                                                                                                                          | OS comparison between Study 20120216 and Study 20160462                                                                                                                                                                                     |
| Endpoints and definitions                                                                                                                                                                                                                   | secondary efficacy endpoints                                                                                                                                                                                                                | CR/CRh*                                                                                                                                                                                                                                     | CR/CRh* comparison between Study 20120216 and Study 20160462                                                                                                                                                                                |
| Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        | Results and Analysis                                                                                                                                                                                                                        |
| Analysis description                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            | Primary Analysis                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                             | HR for OS (95% CI), non-Bayes IPTW                                                                                                                                                                                                          | 0.81 (95% CI: 0.57, 1.15).                                                                                                                                                                                                                  | 0.81 (95% CI: 0.57, 1.15).                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                             | HR for OS (95% CI), Bayes augmented                                                                                                                                                                                                         | 0.77 (95% CI: 0.61, 0.96).                                                                                                                                                                                                                  | 0.77 (95% CI: 0.61, 0.96).                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                             | HR for CR/CRh* (95% CI), non-Bayes IPTW                                                                                                                                                                                                     | 1.54 (95% CI: 0.61, 3.89).                                                                                                                                                                                                                  | 1.54 (95% CI: 0.61, 3.89).                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                             | HR for CR/CRh* (95% CI), Bayes augmented                                                                                                                                                                                                    | 1.70 (95% CI: 0.94, 2.94).                                                                                                                                                                                                                  | 1.70 (95% CI: 0.94, 2.94).                                                                                                                                                                                                                  |

## B. The treatment of paediatric patients with Philadelphia-positive relapsed/refractory ALL who have failed treatment with at least 2 TKIs and have no alternative treatment options.

Additionally, the MAH seeks approval for blinatumomab for paediatric patients with Philadelphia-positive relapsed/refractory ALL. Efficacy data are provided for 3 paediatric subjects with Philadelphia-positive relapsed/refractory ALL from Study MT103 205.

Title of Study: ' A Single-Arm Multicenter Phase II Study preceded by Dose Evaluation to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab (MT103) in Paediatric and Adolescent Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukaemia (ALL)'

## Methods

## · Study design

This was a first paediatric phase 1/2, open-label, single arm study to investigate the PK, safety and clinical activity of blinatumomab in paediatric patients within different age groups (&lt;2 years, 2-6 years,

<div style=\"page-break-after: always\"></div>

- 7-17 years) with B-precursor ALL in second or later bone marrow relapse, in any marrow relapse after alloHSCT, or refractory to other treatments.

<!-- image -->

ALL=acutelymphoblasticleukemia;BM=bonemarrow;DSMB=DrugSafetyMonitoringBoard.

- *Doses (5 μg/m2/day; 15 μg/m2/day; 30 μg/m2/day; 60 μg/m2/day planned) were to be evaluated consecutively; alternative dose groups could be evaluated.
- **Three age groups (7-17 years; 2-6 years; &lt;2 years) were to be enrolled; age group &lt;2 years would be enrolled only after 6 patients in each of the older age groups had been treated with the recommendedphase2dose.

Figure 10: Schema for study MT103-205

## · Study participants

## Key inclusion criteria

1. Morphologic and immunophenotypic evidence of B-precursor ALL (pro B-, pre B-, common ALL) with &gt; 25% blasts in bone marrow (M3) at study enrolment.
2. Age &lt; 18 years at enrolment
3. Relapsed/refractory disease:
- Second or later bone marrow relapse,
- Any marrow relapse after allogeneic HSCT, or
- Refractory to other treatments:
-  Patients  in  first  relapse  must  have  failed  to  achieve  a  CR  following  full  standard  reinduction chemotherapy regimen of at least 4 weeks duration
- Patients who have not achieved a first remission must have failed a full standard induction regimen
4. Karnofsky performance status ≥ 50% for patients ≥ 16 years and Lansky Performance Status (LPS) of ≥ 50% for patients &lt; 16 years
5. Organ function requirements: Patients must have:
- a. Creatinine clearance ≥ 70 mL/min/1.73 m2 or a normal serum creatinine based on age/gender prior to day 1
- b. Adequate liver function defined as:
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age OR direct bilirubin ≤ 1.5 mg/DL prior to day 1

<div style=\"page-break-after: always\"></div>

## - ALT (SGPT) ≤ 135 IU/L at least once during screening

## Key exclusion criteria

1. Active acute or extensive chronic GvHD
2. Immunosuppressive agents to prevent or treat GvHD within 2 weeks prior to blinatumomab treatment

3.  Evidence  for  current  CNS  involvement  by  ALL  (CNS  2,  CNS  3)  or  testicular  involvement  by  ALL [patients with CNS relapse at the time of M3 relapse are not eligible for the Phase I part but are eligible for the Phase II part of the study, if CNS is successfully treated prior to enrollment]. Two successive CSF evaluations at least one week apart following completion of CNS therapy that are CNS1 are required

4.  History  of  relevant  CNS  pathology  or  current  relevant  CNS  pathology  (seizure,  paresis,  aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder)

5. History of autoimmune disease with potential CNS involvement or current autoimmune disease

6. Any HSCT within 3 months prior to blinatumomab treatment

7.  Cancer  chemotherapy  within  2  weeks  prior  to  blinatumomab  treatment  (except  for  intrathecal chemotherapy  and/or  low  dose  maintenance  therapy  such  as  vinca  alkaloids,  mercaptopurine, methotrexate, glucocorticoids)

8. Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled  chronic  infection,  any  other  concurrent  disease  or  medical  condition  that  could  be exacerbated by the treatment or would seriously complicate compliance with the protocol

## · Treatments

Patients  received  blinatumomab,  ciV  at  a  constant  daily  flow  rate.  Doses  ranged  between  3.75-60 μg/m2/day in phase I.

A treatment cycle was defined as 4 weeks of blinatumomab cIV infusion followed by a treatment free interval of 2 weeks. Patients who experienced adverse events, which required interruption of treatment, may be restarted on modified doses.

Patients who achieved a CR within the first 2 cycles of treatment, had the option to receive up to 3 additional consolidation cycles of blinatumomab.

Patients with hematological relapse during their follow-up period may receive up to three additional cycles  of  blinatumomab  at  the  investigator´s  discretion.  Re-treatment  would  be  performed  at  the recommended dose.

## · Objectives

## Primary objective

Phase 1: To determine the recommended phase 2 dose of blinatumomab

Phase 2: To assess the efficacy of blinatumomab

Secondary objectives:

Phase 1:

<div style=\"page-break-after: always\"></div>

- -To  assess  safety,  PK  and  changes  in  pharmacodynamic  markers  of  different  dose  levels  of blinatumomab in different age groups
- -To assess the anti-leukaemia activity of blinatumomab
- -To assess the development of anti-drug antibodies (ADA) to blinatumomab

## Phase 2:

- -To assess the safety of blinatumomab
- -To assess the development of ADA to blinatumomab

## · Outcomes/endpoints

## Primary endpoints

Phase 1 Part: Maximal tolerable dose (MTD) defined by ≤ 1 of 6 patients experiencing dose limiting toxicity (DLT) or maximal administered dose (MAD). A DLT was defined as any blinatumomab related TEAE with CTCAE grade 3 or above in general, occurred during the cycle 1/28 days.

Phase 2 Part: Rate of CR within the first 2 cycles.

## Secondary endpoints

Phase 1 part:

- Overall incidence and severity of adverse events
- Quantification and characterization of pharmacokinetic parameters over time
- Rate of CR within the first 2 cycles
- Time to haematological relapse.
- CR duration (time to haematological relapse)
- Overall survival
- Relapse free survival
- Proportion of patients who develop anti-drug antibodies at any time
- Quantification and characterization of cytokine serum concentrations

## Phase 2 part:

- Overall incidence and severity of AEs
- Proportion of patients who undergo alloHSCT after treatment with blinatumomab
- Time to haematological relapse
- CR duration
- Overall survival
- Relapse free survival
- Proportion of patients who develop anti-drug antibodies (ADA) at any time

<div style=\"page-break-after: always\"></div>

## Exploratory endpoints

- Rate of MRD response
- Rate of complete MRD response.
- Time to all 3 subcategories of CR and time to CRc, CR*, CR3.
- 100-day mortality after allogeneic HSCT

## · Duration of Patient Participation/Duration of the Study

Each patient participated for up to 34 weeks in the core study including:

- A screening period of up to 2 weeks
- A treatment period of up to 30 weeks consisting of up to 5 consecutive cycles of 6 weeks each
- An End of Core Study visit 30 days after last dose of study medication.

Following the last treatment cycle all patients were followed for efficacy and survival at 3, 6, 9, 12, 18 and 24 months after treatment start. Patients who discontinued treatment prior to completion of 5 cycles of blinatumomab entered immediately the follow-up study period.

The core study lasted for up to 44 months including the recruitment for the Phase I part of the study (24 months) and recruitment for the Phase II part of the study (12 months). The primary endpoint was assessed approximately 3 months after enrolment of the last patient. The end of the trial was defined as the last protocol mandated evaluation for the last patient in the study.

## Results

Data and discussion are focussed on Phi + patients from study MT103 205.

Efficacy data are provided for 3 paediatric subjects with Philadelphia-positive relapsed/refractory ALL from Study MT103 205.

All 3 subjects were heavily pre-treated and received an allogeneic HSCT from an unrelated donor. Two subjects received the registrational dose of 515 μg/m2/day blinatumomab, and 1 subject received 15 μg/m2/day blinatumom ab. Two of the 3 paediatric subjects achieved a best response of CR with full recovery of peripheral blood counts, while 1 subject had no response to treatment.

## C. Adult patients in first or second hematologic CR with Philadelphiapositive MRD-positive ALL

Data in adult subjects in hematologic CR with Philadelphia-positive MRD-positive ALL are retrieved from the MRD-positive ALL studies MT103-203 and MT103-202.

Study MT103-203 is an open-label, multicenter, single-arm, phase 2 study in subjects ≥ 18 years of age whose MRD-positive B-cell precursor ALL was in CR as defined by less than 5% blasts in the bone marrow after at least 3 intense chemotherapy blocks (N = 116).

Study  MT103-202  was  an  exploratory,  open-label,  multicenter,  single-arm,  phase  2  study  in  adult subjects with MRD-positive B-cell precursor ALL. Subjects were ≥ 18 years of age and were in complete

<div style=\"page-break-after: always\"></div>

hematologic remission with molecular failure or molecular relapse starting any time after consolidation I of front-line therapy (after at least 3 intense chemotherapy blocks) with GMALL standards or any time outside GMALL standards (N = 21).

MRD response was the primary endpoint in both the MT103-202 and MT103-203 studies. Complete MRD response rate was chosen as the primary endpoint to describe the efficacy of blinatumomab in subjects with MRD-positive B-cell precursor ALL.

The numbers of Philadelphia-positive subjects in both studies was small: a total of 10 subjects (MT103202, n = 5; MT103-203, n = 5). In Study MT103-203, subjects with Philadelphia-positive ALL were excluded from the study if they were eligible for treatment with TKIs (ie, Philadelphia-positive subjects with no documented treatment failure of or intolerance/contraindication to at least 2 TKIs). In Study MT103-202,  TKIs  registered  for  treatment  of  bcr-abl-positive  B-lineage  ALL  were  permitted  as concomitant treatment.

Subpopulation  analyses  for  the  combined  data  from  Studies  MT103-202  and  MT103-203  had  been provided in this prior variation. These analysis, extracted from this prior variation, are summarized in tables below.

The majority of subjects had an MRD complete response regardless of Philadelphia chromosome status: 87% (107 of 123) of Philadelphia-negative subjects and 70.0% (7 of 10) of Philadelphiapositive subjects.

Median RFS (95% CI) was 6.2 months (0.7 to NE) for subjects who were Philadelphia-positive compared with 22.3 months (15.4 to 50.8) for subjects who were Philadelphia-negative; Kaplan-Meier estimates (95%  CI)  at  18  months  were  40%  (95%  CI:  12%  to  67%)  and  57%  (95%  CI:  48%  to  66%), respectively).

Duration of hematologic remission was 44.3 months (2.1 to NE) and NE (25.1 to NE), respectively; Kaplan-Meier estimates (95% CI) at 18 months were 56% (20% to 80%) and 68% (59% to 76%), respectively.

<div style=\"page-break-after: always\"></div>

Table 33: MRD Response Rates in Cycle 1 for Subpopulations: Study MT103-202 &amp; Study MT103-203 (Prim EP FAS) - extracted from SCE, variation EMEA/H/C/003731/II/00011

| Number of Subjecls          | Study MT103-202 n n (76) Confidence Interval   | Study MT103-203 n n(%6) Confidence Interval     | [el0l. n n(76) ConfidenceInterval   |
|-----------------------------|------------------------------------------------|-------------------------------------------------|-------------------------------------|
|                             | MRD Response Rate (MRD Level ≤ 10*             | MRD Response Rate (MRD Level ≤ 10*              | MRD Response Rate (MRD Level ≤ 10*  |
|                             | N= 20                                          | N= 113                                          | N= 133                              |
| Age in years                |                                                |                                                 |                                     |
| 2 18 to<35                  | n=6 5 (83.3) (35.9 to 99.6)                    | n=36 33 (91.7) (77.5 to 98.2)                   | n=42 38 (90.5)                      |
| Median (95%. Cl) 235 to c55 | n=4 3 (75.0)                                   | n=38 31 (81.6)                                  | (77.4 to 97.3) n=42 34 (81.0)       |
| 2.55 to 65                  | n=4 3 (75.0) (19.4 to 99.4)                    | 忆=u 20 (83.3) (62.6 to 95.3)                    | n=28 23 (82.1) (63.1 to 983.9)      |
| 265 Sex Male                | n=6 5 (83.3)                                   | n=15 14 (93.3)                                  | n=21 19 (90.5)                      |
| Female                      | (35.9 to 99.6)                                 | (68.1 to 99.8)                                  | n=75                                |
|                             | n=8 6 (75.0) (34.9 to 96.8)                    | n=67 57 (85.1) (74.3 to 92.6)                   | 63 (84.0)                           |
| Positive status             |                                                |                                                 | (69.6 to 98.8)                      |
|                             | n=12 10 (83.3) (51.6 to 97.9)                  | (76.4 to 96.4)                                  | (73.7 to 91.4) n=58 51 (87.9)       |
|                             | n=5                                            | n=5                                             | (76.7 to @5.0) n=10                 |
|                             | 3 (60.0)                                       | n=46 41 (89.1) 4 (80.0)                         | 7 (70.0)                            |
| Philadelphia chromosome     | n= 19 15 (78.9)                                | n = 108 94 (87.0) (79.2 to 92.7) n=73 65 (89.0) | (34.8 to 93.3)                      |
|                             | (54.4 to (93.9)                                | (79.5 to 95.1)                                  | n=123 107 (87.0) (79.0 to 92.4)     |
| Remission status CR1        |                                                |                                                 | n=92 80 (87.0)                      |
|                             | 13 (96.7) (59.5 to (98.3)                      |                                                 |                                     |
|                             | (14.7 to 94.7)                                 | (28.4 to 99.5)                                  |                                     |
| Negative status             |                                                |                                                 |                                     |
|                             | n=15                                           |                                                 |                                     |
|                             |                                                |                                                 | (78.3 to 93.1)                      |
| CR2 ormore                  | n=1                                            | n=40 33 (82.5)                                  | n=41                                |
|                             | 1 (97.5)                                       |                                                 | 34 (82.9)                           |
|                             | (2.5 to 100.0)                                 | (67.2 to 92.7)                                  |                                     |
|                             |                                                |                                                 | (67.9 to 92.48)                     |

CR1 = complete remission 1 (no prior relapse); CR2 = complete remission 2 (afier first relapse): MRD = minimal residual disease; PCR = polymerase chain reaction; Prim EP FAS = primary endpoint full analysis set

Note: Subjects in the primary endpoint full analysis set received at least 1 infusion of blinatumomab and excluded subjects in Study MT103-202 who lacked an MRD assessment in the follow-up period. Subjects Were included in Study MT103-203 who had 1 infusion of blinatumomab with an MRD assay via PCR techniques with a minimum sensitivity 1 x 10*'. Subjects in the target disease population set excluded subjecis in the primary endpoint full analysis set who had blast counts &gt; 5% at baseline, or baseline PCR MRD assay with sensitivity &gt; 1 x 10* or MRD level &lt; 1 x 10 as per central laboratory testing at screening. MRD response is defined as an MRD level that is not detectable or c 10 with central laboratory assay with (MT103-203).

Source: SCE Table 4.10.3.1, SCE Table 4.10.4.1, SCE Table 4.10.7.1, and SCE Table 4.10.8.1.

<div style=\"page-break-after: always\"></div>

Table 34: Summary of RFS for Subpopulations: Study MT103-202 &amp; Study MT103-203 (Primary Endpoint Full Analysis Set) - extracted from SCE, variation EMEA/H/C/003731/II/00011

| Number of Subjects              | Study MT103-202   | Study MT103-203   | Total             |
|---------------------------------|-------------------|-------------------|-------------------|
|                                 | N = 20            | N= 113            | N= 133            |
| Age in years                    |                   |                   |                   |
| 2 18 to c35                     | n=6               | n=36              | n=42              |
| Events -n (%)                   | 2 (33.3)          | 19 (52.8)         | 21 (50.0)         |
| Median time in months (95% CI)  | NE (50.8. NE)     | NE (24.6, NE)     | NE (50.8. NE)     |
| 235 to c55                      | n=4               | n=38              | n =42             |
| Events -n (%)                   | 2 (50.0)          | 21 (56.3)         | 23 (54.8)         |
| Median time in months (95% Cl)  | 31.0 (19.1, NE)   | 5.9 (2.8. 11.0)   | 119.1(7.9, NE)    |
| 2 55 to 65                      | n=4               | n=24              | n=28              |
| Events -n (%)                   | 2 (50.0)          | 17 (70.8)         | 19 (67.9)         |
| Median time in months (95% Cl)  | NE (3.2, NE)      | 15.1 (6.0, 22.3)  | 15.1 (6.5, 35.2)  |
| 2 65                            | n=6               | n=15              | n =21             |
| Events -n (%)                   | 3 (50.0)          | 7 (46.7)          | 10 (47.6)         |
| Median time in months (95% Cl)  | NE (4.2, NE)      | NE (2.8. NE)      | 44.3 (5.1. NE)    |
| Sex                             |                   |                   |                   |
| Male                            | n=8               | n=67              | n=75              |
| Events -n (%)                   | 5 (62.5)          | 37 (55.2)         | 42 (56.0)         |
| Median time in months (95% Cl)  | 47.6 (6.5, NE)    | 19.1 (12.0, NE)   | 22 3 (12.4, 50.8) |
| Female                          | n = 12            | n=46              | n =58             |
| Events -n (%)                   | 4 (33.3)          | 27 (58.7)         | 31 (53.4)         |
| Median time in months (959% C1) | NE (4.2. NE)      | 18.7 (7.1, NE)    | 19.2 (9.1, NE)    |
| Philadelphia chromosome         |                   |                   |                   |
| Positive status                 | n=5               | n=5               | n = 10            |
| Events -n (%)                   | 3 (60.0)          | 4 (80.0)          | 7 (70.0)          |
| Median time in months (95% Cl)  | 44.3 (4.2. NE)    | 5.1 (0.7. NE)     | 6.2 (0.7, NE)     |
| Negative status                 | n = 15            | n=108             | n=123             |
| Events -n (%)                   | 6 (40.0)          | 60 (55.8)         | 66 (53.7)         |
| Median time in months (95% Cl)  | NE (12.4, NE)     | 19.1 (14.3, 35.2) | 22.2 (15.4, 50.8) |
| Remission status                |                   |                   |                   |
| CR1                             | n = 19            | n=73              | Z6 = u            |
| Events -n (%)                   | 8 (42.1)          | 34 (46.6)         | 42 (45.7)         |
| Median time in months (95% Cl)  | NE (12.4, NE)     | 35.2(18.9, NE)    | 44.3 (22.3. NE)   |
| CR2or more                      | n=1               | n =40             | n=41              |
| Events -n (%)                   | 1 (100.0)         | 30 (75.0)         | 31 (75.6)         |
| Median time in months (95% Cl)  | 19.1 (NE, NE)     | 9.8 (5.1. 15.0)   | 10.4 (5.1, 15.4)  |

MRD = minimal residual disease: NE = not estimable; PCR =polymerase chain reaction; RFS =relapse-free survival

CR1 = complete remission 1 (no prior relapse): CR2 = complete remission 2 (after firstrelapse):

RFS was measured from the first infusion of blinatumomab.

Note: Subjects in the primary endpoint full analysis set received at least 1 infusion of blinatumomab and were included in Study MT103-203 who had 1 infusion of blinatumomab with an MRD ass3y via PCR techniques with a minimum sensitivity 1 x 10*. Subjects in the target disease population set excuded subjecis in the primary endpoint full analysis set who had blast counts &gt; 5% at baseline, or baseline PCR MRD assay with sensitivity &gt; 1 x 10* or MRD level &lt; 1 x 10° as per central laboratory testing at screening. Source: SCE Table 4.11.1.1, SCE Table 4.11.2.1, SCE Table 4.11.5.1, and SCE Table 4.11.6.1.

<div style=\"page-break-after: always\"></div>

Table 35: Duration of Hematologic Remission for Subpopulations: Study MT103-202 &amp; Study MT103-203 (Primary Endpoint Full Analysis Set) - extracted from SCE, variation EMEA/H/C/003731/II/00011

| Number of Subjects              | Study MT103-202                   | Study MT103-203                   | Total                             |
|---------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                 | Duration of Hematologic: Response | Duration of Hematologic: Response | Duration of Hematologic: Response |
|                                 | N=20                              | N= 113                            | N= 133                            |
| Age in years                    |                                   |                                   |                                   |
| 218 to <35                      | n=6                               | n=36                              | n =42                             |
| Events -n (%)                   | 2 (33.3)                          | 15 (41.7)                         | 17 (40.5)                         |
| Median time in months (95% Cl)  | NE (12.4, NE)                     | NE (10.4. NE)                     | NE (50.8. NE)                     |
| 2 35 to <55                     | n=4                               | n=38                              | n=42                              |
| Events -n (%)                   | 1 (25.0)                          | 12 (31.6)                         | 13 (31.0)                         |
| Median time in months (95% Cl)  | NE (31.0, NE)                     | NE (18.7. NE)                     | NE (25.1. NE)                     |
| 2 55 to ≤65                     | n=4                               | n=24                              | n=28                              |
| Events -n (%)                   | 2 (50.0)                          | 9 (37.5)                          | 11 (39.3)                         |
| Median time in months (95% Cl)  | NE (3.2. NE)                      | NE (9.3, NE)                      | NE (9.3, NE)                      |
| 265                             | n=6                               | n=15                              | n=21                              |
| Events -n (%)                   | 3 (50.0)                          | 5 (33.3)                          | 8 (38.1)                          |
| Median time in months (95%6 Cl) | NE (5.1. NE)                      | NE (NE, NE)                       | NE (44.3. NE)                     |
| Sex                             |                                   |                                   |                                   |
| Male                            | n=8                               | n=67                              | n=75                              |
| Events -n (%)                   | 4 (50.0)                          | 26 (38.8)                         | 30 (40.0)                         |
| Median time in months (95% Cl)  | 50.8 (6.5, NE)                    | NE (19.1, NE)                     | NE (44.3, NE)                     |
| Female                          | n =12                             | n=46                              | n=58                              |
| Events -n (96)                  | 4 (33.3)                          | 15 (32.6)                         | 19 (32.8)                         |
| Median time in months (95% Cl)  | NE (4.2, NE)                      | NE (18.7. NE)                     | NE (25.1, NE)                     |
| Philadelphia chromosome         |                                   |                                   |                                   |
| Positive status                 | n=5                               | n=5                               | n = 10                            |
| Events -n (%6)                  | 3 (60.0)                          | 2 (40.0)                          | 5 (50.0)                          |
| Median time in months (95% Cl)  | 44.3 (4.2, NE)                    | NE (2.1, NE)                      | 44.3 (2.1, NE)                    |
| Negative status                 | n =15                             | n=108                             | n =123                            |
| Events -n (%)                   | 5 (33.3)                          | 39 (36.1)                         | 44 (35.8)                         |
| Median time in months (95% Cl)  | NE (12.4, NE)                     | NE (24.3, NE)                     | NE (25.1, NE)                     |
| Remission status                |                                   |                                   |                                   |
| CR                              | n = 19                            | n=73                              | n=92                              |
| Events -n (%6)                  | 8 (42.1)                          | 19 (26.0)                         | 27 (29.3)                         |
| Median time in months (95% C1)  | NE (12.4, NE)                     | NE (NE, NE)                       | NE (44.3, NE)                     |
| CR2ormore                       | n=1                               | n=40                              | n=41                              |
| Events -n (%)                   | 0                                 | 22 (55.0)                         | 22 (53.7)                         |
| Median time in months (95% Cl)  | NE (NE, NE)                       | 12.0 (5.7, NE)                    | 12.0 (7.1, NE)                    |

MRD = minimal residual disease; PCR = polymerase chain reaction

CR1 = first complete remission (no prior relapse); CR2 = second complete remission (after first relapse):

The duration of MRD response was calculated as the time from onset of MRD response until MRD or hematologic relapse or date of last confimation of negative MRD status.

Note: Subjects in the primary endpoint full analysis set received at least 1 infusion of blinatumomab and were includedin Study MT103-203who had 1 infusion of blinatumomabwithan MRD assay viaPCR techniques with a minimum sensitivity 1 x 10*. Subjects in the target disease population set excluded subjecis in the primary endpoint full analysis set who had blast counts &gt; 5% at baseline, or baseline PCR MRD assay with sensitivity &gt; 1 x 10 or MRD level &lt; 1 x 10° as per central laboratory testing at screening. Source: SCE Table 4.12.1.1, SCE Table 4.12 2.1, SCE Table 4.12.5.1, and SCE Table 4.12.6.1.

## 2.4.3. Discussion on clinical efficacy

Discussion on clinical efficacy is presented for each of the claimed indications

- The treatment as monotherapy of adult patients with Philadelphia chromosomepositive relapsed/refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

<div style=\"page-break-after: always\"></div>

This extension is based on the results of a complete phase 2, single-arm study (Study 20120216). A historical control study (Study 20160462) and a propensity score analysis were conducted to estimate the effects of blinatumomab compared with standard of care ALL therapy for treatment of Philadelphiapositive relapsed/refractory ALL.

## Design and conduct of clinical studies

The main pivotal study 20120216 is a Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive Bprecursor Acute Lymphoblastic Leukemia (Alcantara Study).

Eligible adult subjects for this study should have Phi + B-precursor ALL, relapsed or refractory after second generation (G2) TKI, or intolerant to G2 TKI and refractory to G1 TKI. Patients should not be eligible for alloHSCT at the time of enrollment. The target indication specifies that patients should have 'no alternative treatment option'. One could consider that illegibility to alloHSCT should be accurately specified in the indication. However, this is covered by the proposed indication, as part of alternative treatment options. Further, it is noted that the population targeted by the claimed indication is stricter than the studied population, which also includes subjects who had failed one single second generation TKI: the inclusion of less pre-treated patients in study 20120216 questions the generalizability of the results  to  the  targeted  later  line  of  therapy.  Further,  resistance  to  TKIs  is  mainly  driven  by  point mutations within the ABL kinase domain. and the choice of TKI is then usually guided by mutational analysis, with the aim of maximizing responses. In this regard, no mutational analysis was required to assess  eligibility  to  study  20120216,  so  it  is  unclear  whether  patients  in  study  20120216  can  be considered representative of a population with no alternative options, as per the claimed indication. Eligibility for allogeneic HSCT was also considered an exclusion criteria, yet.

## Efficacy data and additional analyses, study 20120216:

A total of 45 patients were included (FAS). Only 6 of them could complete the end of the consolidation phase  (13.3%),  and  8  patients  completed  the  study  (17.8%).  Most  of  patients  (n=37;  82.2%) discontinued study, all due to death. However, only 3 patients discontinued the treatment due to death. Most of treatment discontinuations were due to progression without prior CR/CRh/Cri (n=12), followed by requirement for alternative therapy (n=7) and intention to receive HSCT (n=6).

The study included patients with chromosome Phi detected (100%), by cytogenetics, FISK and/or PCR. To be noted, 35.6% of patients had Phi only, while 48.9% had Phi and other cytogenetics abnormalities. Study population was almost balanced between men and women (53.5% vs 46.5%), with a mean age of 52.8 years. Most of subjects were ECOG 1 (35.6%) or 2 (44.4%).

As per inclusion criteria, all patients had received prior TKI, and most of patients had received at least 2 or more prior TKI (46.7% with 2 TKIs). However, it should be noted that 7 patients (15.6%) had only received 1 prior TKI, which is earlier than the target indication limited to at least 2 prior TKIs. Most of included patients were in first (55.6%) or 2 nd  relapse (28.9%). However, 3 patients had no prior relapse. A higher proportion of patients had no prior HSCT (55.5%). Thus, as per ESMO guidelines, subjects meet high risk factors such as age, ECOG 2 (44.4%), pro B Phi + (100%) and BCR ABL1 (25%).

## Historical control study, Study 20160462

Study 20160462 was a retrospective cohort study of salvage treatment outcomes among adult patients with relapsed or refractory philadelphia-chromosome positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL). The objective was to estimate the proportion of adult patients with R/R Ph+ B-precursor

<div style=\"page-break-after: always\"></div>

ALL who achieve a CR (eg, CR, CR with partial haematological recovery [CRh*], or complete response with incomplete haematological recovery [CRi]) after salvage therapy. Study 20160462 only included patients  who  meet  the  inclusion  and  exclusion  criteria  for  study  20120216  so  that  the  key  study endpoints could be summarized to provide a historical context to the blinatumomab efficacy results from the 20120216 study. However, the inclusion and exclusion criteria did not automatically create a balance between the 2 groups of data with respect to key prognostic factors.

A Propensity Score Analysis was performed to estimate the association between receipt of blinatumomab in study 20120216 (versus the qualifying salvage therapy in study 20160462) and OS and CR/CRh* outcomes among patients with Philadelphia-positive relapsed or refractory ALL

During the initial  assessment limitations  due  to  non-comparative  study  design  and  limited  historical cohort were highlighted. Moreover, the absence of improvement of OS while HSCT is not censored was of concern. To be noted, all 4 patients who received HSCT without additional treatment had died at 17 months. The clinical relevance of efficacy results obtained with blinatumomab in the target indication were further discussed during the assessment rounds.

The following limitations should be highlighted:

- Non-comparative design of the pivotal study;
- Despite attempts to implement a comparative historical cohort, samples were too limited to allow a robust propensity score analysis, and non-negligible deviations and missing data were observed;
- Covariates for the propensity analysis were limited to number of salvage therapies, no prior salvage and prior HSCT
- Additional  extrapolation  was  necessary,  with  a  Bayesian  augmentation  approach,  due  to  limited available data; The Bayesian approach was based on a previous study (00103311), in a different population (Phi neg patients), with the hypothesis that data from this study 00103311 could be extrapolated to studies 20120216 and 20160462.

The pivotal study 20120216, carried out on 45 patients, evidenced a CR/CRh rate of 35.6%; [21.9%, 51.2%]) within the first 2 cycles of blinatumomab treatment, a median RFS of 6.8 months (95% CI: 4.4, NE) and a median OS of 9.0 months (95% CI: 5.7, 13.5). However, no difference in OS results in the pivotal study was observed with or without censoring at time of HSCT. The absence of improvement of OS while HSCT is not censored, and the risk of detrimental long term effect of blinatumomab treatment on OS after HSCT remain an uncertainty. Moreover, it should be noted that all 4 patients who received HSCT without additional treatment, had died at 17 months. It should be noted that in the historical control  cohort,  a  total  of  8  patients  received  alloHSCT  after  qualifying  salvage  therapy.  Median  OS, uncensored at HSCT, was 6.0 months (4.4; 9.2), and median OS, censored at HSCT, was similar (5.5 months [4.4; 7.6]). Adjusted HR (with or without alloHSCT after qualifying salvage therapy) for OS was 0.32 (95% CI: 0.06, 1.67).

The propensity score analysis showed a trend in increasing OS with blinatumomab treatment in RR Phi + ALL patients, when compared to historical cohort study, with a Bayes-augmented adjusted hazard ratio of  0.77 (95% CI: 0.61, 0.96). No significant difference in CR/CRh was evidenced.

The  MAH  provided  a  discussion  on  limitations  of  the  propensity  score  analysis  and  Bayesian augmentation.

One can only consider in the propensity score model covariates that are measured adequately in each study. Therefore, unlike with randomized studies, the analysis does not have the ability to create a balance between treatment groups with respect to all covariates (including unmeasured and unknown covariates). For example, potentially important baseline covariates such as bone marrow blast counts and peripheral blood counts were not available in the external data. However unless these covariates

<div style=\"page-break-after: always\"></div>

are extremely strong prognostic factors, they should not influence the overall results and conclusions of this analysis.

An underlying assumption of the propensity score analysis is that the overall treatment management of relapsed/refractory Philadelphia-positive ALL (after failure of at least one second generation TKI) during the timeframe of the external data is represented by the 55 standard of care subjects available for this analysis. In this analysis, the distribution of baseline dates for control patients overlaps with that for the blinatumomab subjects. Treatments have not dramatically changed during the external control study period. Chemotherapy with or without TKIs and HSCT remained the primary treatment options available. Currently,  the  only  new  therapies  for  Philadelphia-positive  ALL  are  inotuzumab  and  tisagenlecleucel which were not available at the time this trial was conducted.

Due to the limited sample sizes in each of the datasets there may be insufficient power to detect clinically meaningful  differences  between  the  treatment  groups  even  with  Bayesian  augmentation.  With  the Bayesian augmentation, statistically significant results were observed for OS. This significance was not present without this augmentation in OS, and not present even with augmentation for CR/CRh*. However point  estimates  for  the  effects  of  both  OS  and  CR/CRh*  were  fairly  consistent  across  all  sensitivity analyses. Even with augmentation, this analysis assumes that the limited dataset is representative of the overall treatment populations.

The completeness and quality of the historical data is unlikely to be as good as that of the clinical trial data.

One of the most important assumptions for conducting the Bayesian analysis to borrow information is the exchangeability between Study 00103311 population and the combined 020120216 and 20160462 study  population.  If  this  assumption  does  not  hold,  the  results  can  be  misleading.  However,  the assumption of  exchangeability  is  considered  to  hold  well  in  this  context.  Although  Study  00103311 evaluated  Philadelphia-negative  relapsed/refractory  ALL  subjects,  it  evaluated  subjects  who  already failed other available therapies for relapsed/refractory ALL, and who, from a clinical perspective, have a poor prognosis comparable to relapsed/refractory patients with Philadelphia-positive status. Also, both Philadelphia-negative and Philadelphia-positive leukemic cells express CD19 therefore blinatumomab's mechanism of action does not depend on a subject's Philadelphia chromosome status.

P-values  for  the  analysis  of  the  primary  and  secondary  endpoints  are  not  presented  because  the interpretation of those p-values would be difficult in light of the aforementioned limitations. Additionally, there are multiple analyses being conducted without adjustments for multiplicity. Rather, the 95% CIs are intended act as 'goal posts' for statistical significance as is the body of evidence among all analyses conducted (ie, overall and sensitivity analyses for the primary and secondary endpoints). Philadelphiapositive patients are a rare subset of refractory ALL. Both Philadelphia-positive and Philadelphia-negative patients treated with blinatumomab in these studies have failed other therapies and have poor prognosis and both are expected to respond similarly to treatment with blinatumomab.

The difficulty to conduct randomized comparative trials was acknowledged, as well as the acceptability of historical comparative cohort. The MAH provided a comparison of results between studies carried in Phi  +  and  Phi  -  patients.  Based  on  ESMO  guidelines,  Ph+  ALL  patients  are  considered  as  high  risk patients.  Despite  similar  clinical  manifestations,  considering  differences  in  prognosis  and  treatment, comparison between Phi + and Phi - ALL remained uncertain.

Despite methodological limitations of these data, clinical relevance of results obtained in Phi + RR ALL patients, after at least 2 TKI treatments, was endorsed in these patients without alternative treatment, with CR rate of 35.6% (16/45) [21.9% to 51.2%], including 14 MRD response.

<div style=\"page-break-after: always\"></div>

A durable response was obtained, with OS of 7.1 months 95% (CI: 5.6 months to NE). At time of the last follow-up date, 8 of 45 subjects (17.8%) were alive (including 5 from patients in CR).

Similar trends were observed when comparing results obtained in Phi - patients, but low comparability of these two populations should be kept in mind.

The above data are reflected in section 5.1 of the SmPC ….

## · The treatment as monotherapy of paediatric patients with Philadelphia-positive relapsed/refractory ALL who have failed treatment with at least 2 TKIs and have no alternative treatment options.

The MAH based the request for extension of indication to Phi + RR ALL paediatric patients, with a least 2 prior TKIs, on 3 paediatric subjects with Phi + RR ALL from Study MT103 205 on the basis of data from a previous submission ( EMEA/H/C/003731/II/0018 ). No dedicated subgroup analysis on Phi +  patients  was  available  in  CSR  for  study  MT103 205.  All  3  subjects  were  heavily  pre-treated  and received an allogeneic HSCT from an unrelated donor. Two subjects received the registrational dose of 515 μg/m2/day blinatumomab, and 1 subject received 15 μg/m2/day blinatumomab. Two of the 3 paediatric subjects achieved a best response of CR with full recovery of peripheral blood counts, while 1 subject had no response to treatment.

The MAH provided detailed individual case data regarding the 3 paediatric patients from study MT103205. These data were complemented with 3 paediatric cases from study 20130320 and 2 paediatric cases from study 20160441.  Globally, 3/8 paediatric subjects reached CR, all with MRD negative after 2 cycles, and 2/8 reached CR without complete hematologic remission. Four (4) out of these 8 patients went to aHSCT.

Three (3) patients died from ALL progression, 4 died from other reason (one each liver failure due to adenovirus infection post aHSCT, fatal septic shock, multi organ failure and pulmonary aspergillosis), and 1 remained alive at time of last FU.

However, it should be highlighted that among these 8 patients, only 2 fulfilled the target indication, with at least 2 prior TKIs, including one non responder and 1 patient in CR; Both patients were included in study MT103-205.

In support of the claimed extension of indication, the MAH attempted an extrapolation from Phi - to Phi + patients.  Despite  similar  presentation  in  Phi  +  and  Phi  -  ALL  patients,  poorer  prognosis  in  Phi  + patients remains and outcomes are not truly comparable. Thus this extrapolation is not fully supported.

Similar trends in CR rates would not fully support extrapolation from adult to pediatric populations (see also considerations under Clinical Pharmacology). As previously highlighted and acknowledged by the applicant, only 2 pediatric patients are covered by the target indication (after at least 2 prior TKIs); only one of them presented with a CR. Thus the CR rate results would be impossible to interpret  due to low numbers and thus imprecision and wide CI.

The applicant provided also a Bayesian extrapolation from adult to pediatric patients. This approach is interesting but not adequate for this situation. The model is based on adult patients and does not provide further certainties in the pediatric population. In the 3 tested models, the 8 pediatric patients were added to the adult population.

The applicant provided also additional data from isolated patients, outside of any clinical study (3 patients from an academic center in Italy, 6 pediatric patients in expanded access setting, and 2 literature cases, with data provided via personal communication with the treating physicians). Despite encouraging data in these patients in CR, no conclusion could be drawn.

The results observed in younger subjects treated in pivotal study 20120216 are not encouraging (none of the 5 patients aged ≥ 18 and &lt;35 years achieved CR with blinatumomab, with a median OS of just 6

<div style=\"page-break-after: always\"></div>

months). Despite no CR observed in these 5 patients, 2 patients achieved blast-free hypocellular bone marrow and complete MRD responses within the first 2 cycles of blinatumomab treatment.

As a conclusion, these results remain insufficient to justify this extension of indication in Phi + RR ALL pediatric patients. The MAH has agreed not to further pursue this indication.

.

## · The treatment of adult patients in first or second hematologic CR with Philadelphia-positive MRD-positive ALL.

The claimed indication is based on a very limited sample size of 10 patients, pooled from two different studies in MRD-positive ALL: studies MT103-203 (n=5) and MT103-202 (n=5).

The MAH provided a very limited discussion on efficacy of blinatumomab in adult patients in hematologic CR with Philadelphia-positive ALL who have MRD.

Data provided in this variation do not allow sufficient discussion or comparison between both studies to ensure comparability of pooled subjects in terms of baselines and study method (i.e. selection criteria, MRD thresholds …). Moreover, no discussion on the robustness of these data for the extrapolation to larger MRD+, Phi +, population was provided.

In Study MT103-203, MRD CR was achieved within the first cycle in 77.9% (95% CI: 69.1, 85.1) of subjects. In the subgroup of Phi + patients, MRD CR was reached in 60% of patients [14.7; 94.7].

In Study MT103-202, MRD CR was achieved within the first cycle in 80% (16/20; 95% CI: 56.3, 94.3) of subjects. In the subgroup of Phi + patients, MRD CR was reached in 80% of patients [28.4; 99.5].

Once studies MT103-203 and MT103-202 pooled, median RFS (95% CI) in Phi + subjects was clearly shorter for MRD Phi+ patients (6.2 months (0.7 to NE)) than for MRD Phi neg patients (22.3 months (15.4 to 50.8)).

The MAH concluded that in summary, the majority of subjects in the MRD-positive ALL studies had a complete MRD response regardless of Philadelphia chromosome status. Median RFS and duration of hematologic  remission  in  Studies  MT103-202  and  MT103-203  were  shorter  in  subjects  who  were Philadelphia-positive,  which  is  associated  with  a  worse  prognosis,  compared  with  those  who  were Philadelphia-negative; however, 95% CIs were overlapping even though the number of Philadelphiapositive subjects included in the studies was small.

Despite a similar trend in MRD CRs between Phi +/Phi neg MRD ALL subjects, these RFS results sharply shorter in MRD Phi + patients question on the duration of the effect in Phi + patients, even if studies were not powered for comparison. No further conclusion could be drawn from duration of hematologic remission. No discussion on HSCT after blinatumomab treatment in these 10 patients was provided in the variation.

Overall,  'extrapolation'  of  the  efficacy  observed  in  the  Ph-  setting  is  hardly  appropriate,  due  to differences in post-remission treatment standards, disease biology and observed extent of benefit (in particular with respect to the shorter median DoR in Ph+ ALL patients). Further, in study MT103-202 concomitant use of TKIs was allowed, and no data have been provided on how many subjects received combination (i.e. blinatumomab + TKI) therapy.

In order to complete results, the applicant provided CR/CRh duration in patients with MRD response in ALCANTARA  study  (20120216).  However,  these  results  do  not  reflect  the  targeted  indication.

<div style=\"page-break-after: always\"></div>

ALCANTARA study included adult RR Phi + ALL patients, while MRD extension in Phi + patients concerns adult Phi + ALL patients in CR with MRD. Thus the duration of response in RR patients who reached CR/CRh does not reflect the duration of MRD negativity in MRD patients, not yet in RR.

Based on previously authorized indication in Phi - MRD patients, the applicant kept the target indication unchanged, without specifying prior TKI treatment nor the absence of data in MRD patients without prior allo HSCT.

An  approach  to  further  support  an  extrapolation  of  the  indication  (from  Philadelphia  negative  to Philadelphia  positive)  in  the  adults  by  providing  additional  PK  data  was  proposed  by  the  applicant referring to the EMA reflection papers on the use of extrapolation (EMA, 2008 and 2018). However these documents (EMEA/CHMP/EWP/692702/2008 reflection paper on the extrapolation of results from clinical studies conducted outside the eu to the eu-population)  and (EMA/189724/2018 reflection paper of the use of extrapolation in the development of medicines for paediatrics) were deemed out of the scope here. Such an extrapolation of indication based on PK proposed by the applicant has not been described in any applicable guideline. Therefore, the extrapolation of indication based solely on PK can definitively not be supported.

As a conclusion, the medical need in adult relapse Phi + ALL patients is acknowledged, as well as the relapse risk associated with MRD. However, despite clarifications provided, efficacy data available remain minimal and not deemed sufficient to conclude on risk benefit balance in the targeted indication. The MAH has agreed not to further pursue this indication.

## 2.4.4. Conclusions on the clinical efficacy

Clinical  efficacy  in  ' the  treatment  as  monotherapy  of  adult  patients  with  Philadelphia  chromosomepositive relapsed/refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options' can be considered as established

This  extension  is  based  on  the  results  of  a  complete  phase  2,  non-comparative  single-arm  study 20120216.  A  historical  control  study  20160462  and  a  propensity  score  analysis  were  conducted  to estimate the effects of blinatumomab compared with standard of care ALL therapy for treatment of Phi+ RR ALL adult patients.

Despite methodological limitations of the submitted data, clinical relevance of results obtained in Phi + RR ALL patients, after at least 2 TKI treatments, was endorsed in these patients without alternative treatment, with a durable CR rate of 35.6% (16/45) [21.9% to 51.2%], including 14 MRD response and OS of 7.1 months 95% (CI: 5.6 months to NE). At time of the last follow-up date, 8 of 45 subjects (17.8%) were alive (including 5 from patients in CR).

During the procedure the MAH has agreed not to further pursue at this stage the following indications for

- The treatment as monotherapy of paediatric patients with Philadelphia-positive relapsed/refractory  ALL  who  have  failed  treatment  with  at  least  2  TKIs  and  have  no alternative treatment options.
- The treatment of adult patients in first or second hematologic CR with Philadelphia-positive MRD-positive ALL.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical safety

## 2.5.1. Introduction

Blinatumomab is currently approved in the European Union (EU) for the treatment of adults and children greater than 1 years old with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL  and  for  the  treatment  of  adults  in  first  or  second  hematologic  complete  remission  (CR)  with Philadelphia chromosome-negative minimal residual disease (MRD)-positive ALL.

## Known safety profile

The adverse reactions in these indications were identified in clinical studies of patients with B precursor ALL (N = 843). The most serious adverse reactions that may occur during blinatumomab treatment include:  infections  (24.8%),  neurologic  events  (13.8%),  neutropenia/febrile  neutropenia  (10.1%), cytokine release syndrome (3.3%), and tumour lysis syndrome (0.7%).

The most common adverse reactions were: pyrexia (69.2%), infusion-related reactions (43.4%), infections - pathogen unspecified (42.1%), headache (32.9%), anaemia (22.8%), thrombocytopenia (20.9%), febrile neutropenia (20.2%), oedema (20.0%), neutropenia (19.7%), rash (16.7%), increased liver hepatic enzymes (16.1%), bacterial infectious disorders (15.4%), tremor (15.2%), cough (15.1%), leukopenia (13.4%), back pain (13.3%), chills (13.0%), hypotension (12.8%), viral infectious disorders (12.7%), decreased immunoglobulins (12.5%), cytokine release syndrome (11.6%), tachycardia (11.3%), insomnia (10.7%), fungal infectious disorders (10.6%) and pain in extremity (10.2%).

## Extension of indication

The purpose of this variation application is to widen the indication to include:

- The treatment of adult patients with Philadelphia chromosome-positive relapsed/refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
- The treatment of paediatric patients with Philadelphia chromosome-positive relapsed/refractory ALL who have failed treatment with at least 2 TKIs and have no alternative treatment options.
- The treatment of adult patients in first or second hematologic CR with Philadelphia chromosome positive MRD-positive ALL.

## Source of safety data

Clinical studies contributing to safety in subjects with ALL are summarized in the Table 36. Safety data were collected and analysed for all 8 studies shown in this table.

This safety analysis provides safety data from Study 20120216, the phase 2, open-label, single-arm, multicenter study of blinatumomab in adult subjects with Philadelphia-positive relapsed/refractory ALL.

This  review  also  includes  safety  results  from  pooled  studies  of  adult  subjects  with  Philadelphia chromosome -negative relapsed/refractory ALL) (Studies 00103311, MT103-211, and MT103-206 [N = 528]).

Supportive safety data are also provided, as follows:

· Pediatric relapsed/refractory B-cell precursor ALL Analysis Set from Study MT103-205 (N = 93) and Study  20130320  (N  =  40).  Note,  3  subjects  from  Study  MT103-205  had  Philadelphia-positive relapsed/refractory ALL

<div style=\"page-break-after: always\"></div>

- Adult and pediatric relapsed/refractory B-cell precursor ALL pooled Analysis Set (N = 706) (Studies MT103-211, MT103-206, 00103311, MT103-205, 20130320, 20120216) (relapsed/refractory ALL pooled population). Note, 2 subjects in Study MT103-206 had Philadelphia-positive relapsed/refractory ALL.

·  Adult  MRD-positive B-cell precursor ALL Analysis Set from Study MT103-202 (N = 21) and Study MT103-203 (N = 116). Note, 10 subjects with Philadelphia-positive ALL were included in both studies (MT103-202, n = 5; MT103 203, n = 5).

Data from all 8 studies (above) are pooled (N = 843) and provided side-by-side to provide the overall safety profile for blinatumomab (ALL pooled population).

In this safety discussion, a focus on safety data from Study 20120216 and pooled safety data will be presented.

Safety profiles in paediatric population and in MRD-positive Phi + adult patients are discussed separately.

<div style=\"page-break-after: always\"></div>

## 2.5.2. Clinical safety in adult RR Phi + ALL patients

Table 36: Summary of Clinical Studies Contributing to the Safety Data of Blinatumomab for the Treatment of ALL

<!-- image -->

| Study Number                                                                    | Objective(s) of the Study                                                       | Study Design and Type of Control                                                | Number of Subjects TreatedlSafety Set                                                                                                                                                                            |
|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell precursor ALL | Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell precursor ALL | Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell precursor ALL | Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell precursor ALL                                                                                                                                  |
| 20120216                                                                        | Efficacy Safety PK                                                              | Phase 2  Single-arm Open-label Multicenter                                      | 45                                                                                                                                                                                                               |
| Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL | Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL | Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL | Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL                                                                                                                                  |
| 00103311                                                                        | Efficacy Safety                                                                 | Phase 3 Randomized Controlled  Open-label Multicenter                           | 405 randomized [271 blinatumomab; 134 standard of care chemotherapy) (safety analysis: 267 blinatumomab; 109 standard of care chemotherapy)                                                                      |
| MT103-211                                                                       | Efficacy Safety PKIPD                                                           | Phase 2  Single-arm · Open-label · Multicenter                                  | 238 (225 included in the safety analysis set for this variation application: 189 under protocol version 3.0; 36 under protocol version 4.0; an additional 13 subjects were treated in an open-enrollment cohort) |
| MT103-206                                                                       | Efficacy Safety QTc evaluation PKIPD                                            | Phase 2  Single-arm Open-label Multicenter Dose ranging                         | 36                                                                                                                                                                                                               |
| Pediatric Relapsed/Refractory B-cell Precursor ALL                              | Pediatric Relapsed/Refractory B-cell Precursor ALL                              | Pediatric Relapsed/Refractory B-cell Precursor ALL                              | Pediatric Relapsed/Refractory B-cell Precursor ALL                                                                                                                                                               |
| MT103-205                                                                       | Efficacy Safety PKIPD                                                           | Phase 1/2  Single-am Open-label Multicenter  Dose finding                       | 93 (49 in phase 1 and 44 in phase 2): 70 at the recommended dose (5-15 μg/m?/day)                                                                                                                                |
| 20130320                                                                        | Safety Efficacy                                                                 | Expanded access Single-arm - Open-label ·Multicenter                            | Approximately 100 planned (40 at the data cutoff date for this variation application; 1 additional subject was previously enrolled in Study MT103-205)                                                           |
| Adult MRD-positive B-cell precursor ALL                                         | Adult MRD-positive B-cell precursor ALL                                         | Adult MRD-positive B-cell precursor ALL                                         | Adult MRD-positive B-cell precursor ALL                                                                                                                                                                          |
| MT103-202                                                                       | Efficacy Safety PKIPD                                                           | Phase 2  Single-am Open-label - Multicenter                                     | 21                                                                                                                                                                                                               |
| MT103-203                                                                       | Efficacy Safety QTc Evaluation                                                  | Phase 2 - Single-am  Open-label -Multicenter                                    | 116                                                                                                                                                                                                              |

ALL = acute lymphoblastic leukemia; MRD = minimal residual disease; PD = pharmacodynamics; PKC = phammacokinetics; QTc = corrected QT interval Note: For the purposes of this submission, safety data for the adult Philadelphia-positive relapsed/refractory ALL bonulation (Shudv 20120216) will be compared with the adult Philadelohia-nedative relapsedlrefractory

## 2.5.2.1. Patient exposure

The protocol-defined dose and regimen for each of the 8 studies that comprise the safety database are shown in the table below.

In Study 20120216 primary analysis, a total of 45 subjects received at least 1 infusion of blinatumomab.

<div style=\"page-break-after: always\"></div>

Table 37: Blinatumomab Dose Regimen by Study

<!-- image -->

| Prolocol Number                                                                              | Planned Dose                                                                                     | Dose Regimen                                                                                                                                                                                                                                                                                                                                  | Maximum Number of Cycles                                                                                                                                                                          |
|----------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell Precursor ALL Analysis Set | Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell Precursor ALL Analysis Set     | Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell Precursor ALL Analysis Set                                                                                                                                                                                                                                                  | Adult Philadelphia Chromosome-positive Relapsed/Refractory B-cell Precursor ALL Analysis Set                                                                                                      |
| 20120216                                                                                     | 9/28 μg/day                                                                                      | Blinatumomab 9 μg/day clV (week 1, cycle 1)followed by 28 μg/day for remaining period. Responders: up to 3 additional cycles.                                                                                                                                                                                                                 | Up to 5 cycles [4 weeks treatment followed by 2 weeks treatment-free period)                                                                                                                      |
| Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL Analysis Set | Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL Analysis Set     | Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL Analysis Set                                                                                                                                                                                                                                                  | Adult Philadelphia Chromosome-negative Relapsed/Refractory B-cell precursor ALL Analysis Set                                                                                                      |
| 00103311                                                                                     | 9/28 μg/day                                                                                      | Blinatumomab 9 μg/day clV (week 1, cycle 1jfollowed by 28 μg/day for remaining period.                                                                                                                                                                                                                                                        | Up to 9 cycles\" [4 weeks treatment followed by 2 weeks treaiment-free period; for maintenance therapy. up to an additional 4 cycles [4 weeks treatment followed by 8-week treatment-free period]) |
| MT103-211                                                                                    | 9/28 μg/day                                                                                      | Blinatumomab 9 μg/day clV (week 1, cycle 1)followed by 28 μg/day for remaining period. Responders: up to 3 additional cycles.                                                                                                                                                                                                                 | Up to 5 cycles (4 weeks treatment followed by 2 weeks treatment-free period); Retreatment up to 3 additional cycles                                                                               |
|                                                                                              | 9 pg/day is generally equivalent to 5 μg/mlday 28 μg/day is generally equivalent to 15 pg/m*/day | 9 pg/day is generally equivalent to 5 μg/mlday 28 μg/day is generally equivalent to 15 pg/m*/day                                                                                                                                                                                                                                              | 9 pg/day is generally equivalent to 5 μg/mlday 28 μg/day is generally equivalent to 15 pg/m*/day                                                                                                  |
|                                                                                              | MT103-2065/15/30 μg/m?/day                                                                       | Blinatumomab 5 μg/m/day (week 1) followed by 15 μg/m7/day for remaining period. Responders: up to 3 additional cycles. A few subjects received a further dose escalation to 30 μg/m?/day and during dose evaluation, a few subjects received 15 pg/m?/day from day 1.                                                                         | Up to 5 cycles (4 weeks treatment followed by 2 weeks treatment-free period)j; Retreatment up to 3 additional cycles                                                                              |
| Pediatric Relapsed/Refractory B-cell Precursor ALL Analysis Set                              | Pediatric Relapsed/Refractory B-cell Precursor ALL Analysis Set                                  | Pediatric Relapsed/Refractory B-cell Precursor ALL Analysis Set                                                                                                                                                                                                                                                                               | Pediatric Relapsed/Refractory B-cell Precursor ALL Analysis Set                                                                                                                                   |
| MT103-205                                                                                    | 63.75 to 60 μg/m7/day                                                                            | Phase 1: Blinatumomab 3.75 to 60 μg/m2/day clV, 4 weeks on/2 weeks off Phase 2: Up to 5 cycles with recommended dose (from phase 1) of blinatumomab 5 μg/m*/day (week 1. cycle 1) followed by 15 μg/m?/day for remaining period. Responders: up to                                                                                            | Up to5 cycles(4weeks treatment followed by 2 weeks treatment-free period); Retreatment up to 3 additional cycles                                                                                  |
| 20130320                                                                                     | 5/15 μg/m/day                                                                                    | Blinatumomab 5 μg/m/day (week 1. cycle 1) followed by 15 μg/m/day for remaining period. Responders: up to 3 additional cycles.                                                                                                                                                                                                                | Up to 5 cycles (4 weeks treatment followed by 2 weeks treatment-free period)                                                                                                                      |
| Adult MRD-positive ALL Analysis Set                                                          | Adult MRD-positive ALL Analysis Set                                                              | Adult MRD-positive ALL Analysis Set                                                                                                                                                                                                                                                                                                           | Adult MRD-positive ALL Analysis Set                                                                                                                                                               |
| MT103-202                                                                                    | 15/30 μg/m*/day                                                                                  | Blinatumomab clV infusion over 4 weeks followed by 2-week treatment-free period (upup to 3 additional cycles to a max of 10 cycles). The blinatumomab dose is 15 μg/m?/day, an intrasubject dose escalation to 30 yg/m/day was pemmitted for subjects with stable disease who had not responded after 1 cycle at the 15 μg/m°/day dose level. | Up to 7 cycles;Retreaiment                                                                                                                                                                        |
| MT103-203                                                                                    | 15 μg/m7/day                                                                                     | Blinatumomab 15 μg/m/day clV infusion over 4 weeks followed by 2-week treatment-free period (up to a maximum of 4 cycles)                                                                                                                                                                                                                     | Up to 4 cycles;Retreaiment up to 3 additional cydles                                                                                                                                              |

ALL = acute lymphoblastic leukemia; clV = continuous intravenous; MRD = minimal residual disease includes 2 induction cycles, 3 consolidation cycles and 4 maintenance cycles.

Page 2 of 2

<div style=\"page-break-after: always\"></div>

Table 38 : Summary of Blinatumomab Exposure Among Acute Lymphoblastic Leukemia (ALL) Studies (Safety Analysis Set)

|                                                                                                                          | Adult R/R Ph+ ALL   | Adult R/R Ph-ALL                                        | Pediatric R/R ALL           | R/R ALL Pooled   | Adult MRD+ ALL               | ALL Pooled (Total)    |
|--------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------------------------------------------|-----------------------------|------------------|------------------------------|-----------------------|
|                                                                                                                          | 20120216 (N= 45)    | MT103-211 MT103-206 00103311 (Blinatumomab am) (N= 528) | MT103-205 20130320 (N= 133) | Total (N = 706)  | MT103-202 MT103-203 (N= 137) | All Studies (N = 843) |
| Core Study                                                                                                               |                     |                                                         |                             |                  |                              |                       |
| Treatment exposure (days)                                                                                                |                     |                                                         |                             |                  |                              |                       |
| n                                                                                                                        | 45                  | 528                                                     | 133                         | 706              | 137                          | 843                   |
| Mean                                                                                                                     | 59.88               | 56.98                                                   | 41.43                       | 54.24            | 57.52                        | 54.77                 |
| SD                                                                                                                       | 40.55               | 48.45                                                   | 31.41                       | 45.62            | 35.70                        | 44.15                 |
| Median                                                                                                                   | 53.90               | 47.95                                                   | 28.10                       | 39.90            | 55.50                        | 47.90                 |
| Q1.Q3                                                                                                                    | 28.00, 83.60        | 24.80, 79.60                                            | 25.90, 55.80                | 25.50, 67.30     | 28.00, 83.60                 | 27.00, 73.80          |
| Min, Max                                                                                                                 | 11.0, 141.1         | 0.4, 258.3                                              | 1.6, 146.4                  | 0.4,258.3        | 0.7, 195.7                   | 0.4,258.3             |
| Total exposure in patient years                                                                                          | 7.38                | 82.38                                                   | 15.09                       | 104.84           | 21.58                        | 126.42                |
| Number of started cycles                                                                                                 |                     |                                                         |                             |                  |                              |                       |
| n                                                                                                                        | 45                  | 528                                                     | 133                         | 706              | 137                          | 843                   |
| Mean                                                                                                                     | 2.3                 | 2.3                                                     | 1.8                         | 2.2              | 2.3                          | 2.2                   |
| SD                                                                                                                       | 1.5                 | 1.7                                                     | 1.1                         | 1.6              | 1.2                          | 1.5                   |
| Median                                                                                                                   | 2.0                 | 2.0                                                     | 1.0                         | 2.0              | 2.0                          | 2.0                   |
| Q1.Q3                                                                                                                    | 1.0, 3.0            | 1.0, 3.0                                                | 1.0, 2.0                    | 1.0, 3.0         | 1.0, 3.0                     | 1.0, 3.0              |
| Min, Max                                                                                                                 | 1.5                 | 1.9                                                     | 1.6                         | 1.9              | 1.7                          | 1.9                   |
| Number of completed cycles*                                                                                              |                     |                                                         |                             |                  |                              |                       |
| n                                                                                                                        | 45                  | 528                                                     | 133                         | 706              | 137                          | 843                   |
| Mean                                                                                                                     | 2.0                 | 1.8                                                     | 1.2                         | 1.7              | 1.7                          | 1.7                   |
| SD                                                                                                                       | 1.5                 | 1.8                                                     | 1.2                         | 1.7              | 1.3                          | 1.7                   |
| Median                                                                                                                   | 2.0                 | 1.0                                                     | 1.0                         | 1.0              | 1.0                          | 1.0                   |
| Q1.03                                                                                                                    | 1.0, 3.0            | 0.0, 2.0                                                | 0.0, 2.0                    | 0.0, 2.0         | 1.0, 2.0                     | 1.0, 2.0              |
| Min, Max                                                                                                                 | 0.5                 | 0. 9                                                    | 0.5                         | 0. 9             | 0. 7                         | 0. 9                  |
| Number of subjects with study drug intemuption due to treatment emergent                                                 | 16 (35.6)           | 175 (33.1)                                              | 24 (18.0)                   | 215 (30.5)       | 39 (28.5)                    | 254 (30.1)            |
| adverse events -n (%) Number of subjects with study drug discontinuation due to treatment emergent adverse events -n (%) | 3 (6.7)             | 83 (15.7)                                               | 13 (9.8)                    | 99 (14.0)        | 23 (16.8)                    | 122 (14.5)            |
| Number of subjects with prior interuption due to treatment emergent adverse events - n(%)                                | (0'0) 0             | 39 (7.4)                                                | 5 (3.8)                     | 44 (6.2)         | 11 (8.0)                     | 55 (6.5)              |

Page 2of 2

ALL = acute lymphoblastic leukemia; MRD+ = minimal residual disease-positive; n = number of subjects; Ph- = Philadelphia chromosome negative; Ph+ = Philadelphia chromosome-positive; R/R = relapsed/refractory

The number of cycles includes initial and re-started cycles.

Safety analysis set: All subjects who received at least 1 infusion of blinatumomab.

Source: Modified from Table iss-05.1

<div style=\"page-break-after: always\"></div>

## 2.5.2.2. Adverse events

## · Overview of safety profile

Adverse  events  were  defined  as  events  that  started  between  the  start  of  the  first  infusion  of blinatumomab (initial treatment or retreatment) and 30 days after the end of the last infusion during the study. Subjects continued to be followed every 3 months for 18 months to measure response duration and OS, after the adverse events collection period was over. Changes in the safety data from the final analysis (through to 06 January 2017) are also reported, as applicable.

Adverse events are presented in the following sections for the phase 2, randomized study in adults with Philadelphia-positive relapsed/refractory B-cell precursor ALL (Study 20120216) Safety Analysis Set (N = 45) and for the pooled adult Philadelphia-negative relapsed/refractory ALL population Safety Analysis Set  (N  =  528).  Any  differences  (ie, ≥ 10%  difference  in  subject  incidence)  between  the  2 relapsed/refractory populations are noted.

Per the protocol, disease progression of the primary tumour was not considered to be an adverse event. Signs and/or symptoms of disease progression (regardless of primary or secondary tumour) that were new or  worsened  from  baseline  signs  and/or  symptoms  as  well  as  new  primary  malignancies  were considered adverse events.

Table 39: Summary of Subject Incidence of Treatment-emergent Adverse Events (Full Analysis Set) - Study 20120216

|                                                             | Blinatumomab (N = 45)   |
|-------------------------------------------------------------|-------------------------|
| All treatment-emergent adverse events - n (%)               | 45 (100.0)              |
| Grade 23                                                    | 37 (82.2)*              |
| Grade 24                                                    | 18 (40.0)               |
| Serious adverse events                                      | 28 (62.2)               |
| Leading to discontinuation of investigational product       | 3 (6.7)                 |
| Serious                                                     | 2(4.4)                  |
| Leading to interruption of investigational product          | 16 (35.6)b              |
| Serious                                                     | 12 (26.7)b              |
| Fatal adverse events                                        | 5 (11.1)                |
| Treatment-related treatment-emergent adverse events - n (%) | 41 (91.1)               |
| Grade 2 3                                                   | 20 (44.4)               |
| Grade 2 4                                                   | 7 (15.6)                |
| Serious adverse events                                      | 12 (26.7)               |
| Leading to discontinuation of investigational product       | 2(4.4)                  |
| Serious                                                     | 1 (2.2)                 |
| Leading to interruption of investigational product          | 12 (26.7)               |
| Serious                                                     | 7 (15.6)                |
| Fatal adverse events                                        | 1 (2.2)                 |

b In Study 20120216 final analysis, there was 1 additional subject who experienced a serious adverse event leading to treatment intemuption.

In Study 20120216 final analysis, 38 subjects (84.4%) experienced a grade 2 3 adverse events.

Source: Table 14-6.1 of 20120216 Primary Analysis CSR and Table 14-6.1 of 20120216 Final Analysis CSR

<div style=\"page-break-after: always\"></div>

Table  40:  Summary  of  Treatment-emergent  Adverse  Events  Across  Blinatumomab  ALL  Studies  (Safety Analysis Set)

<!-- image -->

|                                                             | Adult R/R Ph+ ALL   | Adult R/R Ph-ALL                                          | Pediatric R/R ALL            | R/R ALL Pooled   | Adult MRD+ ALL                | ALL Pooled (Total)   |
|-------------------------------------------------------------|---------------------|-----------------------------------------------------------|------------------------------|------------------|-------------------------------|----------------------|
|                                                             | 20120216 (N = 45)   | MT103-211 MT103-206 00103311 (Blinatumomab arm) (N = 528) | MT103-205 20130320 (N = 133) | Total (N = 706)  | MT103-202 MT103-203 (N = 137) | All Studies (N= 843) |
| All treatment-emergent adverse events - n (%6)              | 45 (100.0)          | 523 (99.1)                                                | 132 (99.2)                   | 700 (99.2)       | 137 (100.0)                   | 837 (99.3)           |
| Grade ≥ 3                                                   | 37 (82.2)           | 443 (83.9)                                                | 110 (82.7)                   | 590 (83.6)       | 88 (64.2)                     | 678 (80.4)           |
| Grade 2 4                                                   | 18 (40.0)           | 251 (47.5)                                                | 70 (52.6)                    | 339 (48.0)       | 39 (28.5)                     | 378 (44.8)           |
| Serious                                                     | 28 (62.2)           | 335 (63.4)                                                | 71 (53.4)                    | 434 (61.5)       | 83 (60.6)                     | 517 (61.3)           |
| Fatal                                                       | 5 (11.1)            | 91 (17.2)                                                 | 15 (11.3)                    | 111 (15.7)       | 2 (1.5)                       | 113 (13.4)           |
| Leading to study drug discontinuation                       | 3 (6.7)             | 83 (15.7)                                                 | 13 (9.8)                     | 99 (14.0)        | 23 (16.8)                     | 122 (14.5)           |
| Grade 2 3                                                   | 3 (6.7)             | 77 (14.6)                                                 | 11 (8.3)                     | 91 (12.9)        | 18 (13.1)                     | 109 (12.9)           |
| Grade ≥ 4                                                   | 1 (2.2)             | 45 (8.5)                                                  | 7 (5.3)                      | 53 (7.5)         | 6 (4.4)                       | 59 (7.0)             |
| Serious                                                     | 2 (4.4)             | 71 (13.4)                                                 | 12 (9.0)                     | 85 (12.0)        | 17 (12.4)                     | 102 (12.1)           |
| Fatal                                                       | 0 (0.0)             | 26 (4.0)                                                  | 3 (2.3)                      | 29 (4.1)         | 2 (1.5)                       | 31 (3.7)             |
| Leading to study drug interruption                          | 16 (35.6)           | 175 (33.1)                                                | 24 (18.0)                    | 215 (30.5)       | 39 (28.5)                     | 254 (30.1)           |
| Grade ≥ 3                                                   | 12 (26.7)           | 119 (22.5)                                                | 14 (10.5)                    | 145 (20.5)       | 22 (16.1)                     | 167 (19.8)           |
| Grade 2 4                                                   | 1 (2.2)             | 34 (6.4)                                                  | 4 (3.0)                      | 39 (5.5)         | 8 (5.8)                       | 47 (5.6)             |
| Serious                                                     | 12 (26.7)           | 117 (22.2)                                                | 18 (13.5)                    | 147 (20.8)       | 29 (21.2)                     | 176 (20.9)           |
| Fatal                                                       | 0 (0.0)             | 9 (1.7)                                                   | 0 (0.0)                      | 9 (1.3)          | 0 (0.0)                       | 9 (1.1)              |
| Treatment related treatment-emergent adverse events - n (%) | 41 (91.1)           | 447 (84.7)                                                | 114 (85.7)                   | 602 (85.3)       | 133 (97.1)                    | 735 (87.2)           |
| Grade 2 3                                                   | 20 (44.4)           | 290 (54.9)                                                | 73 (54.9)                    | 383 (54.2)       | 73 (53.3)                     | 456 (54.1)           |
| Grade 2 4                                                   | 7 (15.6)            | 122 (23.1)                                                | 35 (26.3)                    | 164 (23.2)       | 32 (23.4)                     | 196 (23.3)           |
| Serious                                                     | 12 (26.7)           | 172 (32.6)                                                | 32 (24.1)                    | 216 (30.6)       | 69 (50.4)                     | 285 (33.8)           |
| Fatal                                                       | 1 (2.2)             | 13 (2.5)                                                  | 1 (0.8)                      | 15 (2.1)         | 1 (0.7)                       | 16 (1.9)             |
| Leading to study drug discontinuation                       | 2 (4.4)             | 45 (8.5)                                                  | 9 (6.8)                      | 56 (7.9)         | 16 (11.7)                     | 72 (8.5)             |
| Grade 2 3                                                   | 2 (4.4)             | 39 (7.4)                                                  | 7 (5.3)                      | 48 (6.8)         | 13 (9.5)                      | 61 (7.2)             |
| Grade2 4                                                    | 1 (2.2)             | 18 (3.4)                                                  | 5 (3.8)                      | 24 (3.4)         | 4 (2.9)                       | 28 (3.3)             |
| Serious                                                     | 1 (2.2)             | 37 (7.0)                                                  | 9 (6.8)                      | 47 (6.7)         | 13 (9.5)                      | 60 (7.1)             |
| Fatal                                                       | 0 (0.0)             | 6 (1.1)                                                   | 1 (0.8)                      | 7 (1.0)          | 1 (0.7)                       | 8 (0.9)              |
| Leading to study drug interruption                          | 12 (26.7)           | 121 (22.9)                                                | 16 (12.0)                    | 149 (21.1)       | 35 (25.5)                     | 184 (21.8)           |
| Grade 23                                                    | 8 (17.8)            | 82 (15.5)                                                 | 9 (6.8)                      | 99 (14.0)        | 20 (14.6)                     | 119 (14.1)           |
| Grade 2 4                                                   | 1 (2.2)             | 19 (3.6)                                                  | 1 (0.8)                      | 21 (3.0)         | 7 (5.1)                       | 28 (3.3)             |
| Serious                                                     | 7 (15.6)            | 75 (14.2)                                                 | 11 (8.3)                     | 93 (13.2)        | 26 (19.0)                     | 119 (14.1)           |
| Fatal                                                       | 0 (0.0)             | 3 (0.6)                                                   | (0'0) 0                      | 3 (0.4)          | 0 (0.0)                       | 3(0.4)               |

ALL = acute lymphoblastic leukemia; MRD+ = minimal residual disease-positive; Ph- = Philadelphia chromosome negative; Ph+ = Philadelphia chromosome-positive;

Safety analysis set: All subjects who received at least 1 infusion of blinatumomab.

R/R = relapsed/refractory

Severity graded using Common Teminology Criteria for Adverse Events (CTCAE) version 4.03.

:Table iss-06.1.0.0

Source:

Page 2 of 2

<div style=\"page-break-after: always\"></div>

## · Common Adverse Events

Table 41: Incidence of Treatment-emergent Adverse Events in ≥ 10% of Subjects in Any ALL Population by Preferred Term in Descending Frequency -Pooled Analyses (Safety Analysis Set)

|                                                 | Adult R/R Ph+ ALL   | Adult R/R Ph-ALL    | Pediatric R/R ALL   | RIR ALL Pooled    | Adult MRD+ ALL   | ALL Pooled (Total)   |
|-------------------------------------------------|---------------------|---------------------|---------------------|-------------------|------------------|----------------------|
|                                                 |                     | MT103-211 MT103-206 | MT103-205 20130320  |                   | MT103-202        | All Studies          |
|                                                 |                     | 00103311            |                     |                   |                  |                      |
|                                                 | 20120216            |                     |                     | Total             | MT103-203        |                      |
|                                                 | (N= 45)             | (Blinatumomab am)   | (N = 133)           | (N = 706)         | (N= 137)         | (N= 843)             |
| Preferred Term                                  | n (%)               | (N =528) n (%)      | n (%)               | n (%)             | n (%)            | n (%)                |
| Number of subjects reporting treatment-emergent | 45 (100.0)          | 523 (99.1)          | 132 (99.2)          | 700 (99.2)        | 137 (100.0)      | 837 (99.3)           |
| adverse events                                  |                     |                     |                     |                   |                  |                      |
| Pyrexia                                         | 26 (57.8)           | 324 (61.4)          | 106 (79.7)          | 456 (64.6)        | 124 (90.5)       | 580 (68.8)           |
| Headache                                        | 14 (31.1)*          | 172 (32.6)          | 37 (27.8)           | 223 (31.6)        | 54 (39.4)        | 277 (32.9)           |
| Nausea                                          | 7 (15.6)            | 114 (21.6)          | 33 (24.8)           | 154 (21.8)        | 32 (23.4)        | 186 (22.1)           |
| Anaemia                                         | 13 (28.9)           | 116 (22.0)          | 47 (35.3)           | 176 (24.9)        | 8 (5.8)          | 184 (21.8)           |
| Febrile neutropenia                             | 18 (40.0)           | 129 (24.4)          | 20 (15.0)           | 167 (23.7)        | 3 (2.2)          | 170 (20.2)           |
| Hypokalaemia                                    | 8 (17.8)            | 104 (19.7)          | 28 (21.1)           | 140 (19.8)        | 28 (20.4)        | 168 (19.9)           |
| Diarrhoea                                       | 9 (20.0)            | 111 (21.0)          | 16 (12.0)           | 136 (19.3)        | 28 (20.4)        | 164 (19.5)           |
| Fatigue                                         | 6 (13.3)            | 85 (16.1)           | 12 (9.0)            | 103 (14.6)        | 36 (26.3)        | 139 (16.5)           |
| Vomiting                                        | 6 (13.3)            | 68 (12.9)           | 32 (24.1)           | 106 (15.0)        | 29 (21.2)        | 135 (16.0)           |
| Oedema peripheral                               | 8 (17.8)            | 107 (20.3)          | 7 (5.3)             | 122 (17.3)        | 11 (8.0)         | 133 (15.8)           |
| Neutropenia                                     | 3 (6.7)             | 95 (18.0)           | 15 (11.3)           | 113 (16.0)        | 18 (13.1)        | 131 (15.5)           |
| Tremor                                          | 4 (8.9)             | 75 (14.2)           | 9 (6.8)             | 88 (12.5)         | 40 (29.2)        | 128 (15.2)           |
| Cough                                           | 5 (11.1)            | 85 (16.1)           | 19 (14.3)           | 109 (15.4)        | 18 (13.1)        | 127 (15.1)           |
| Thrombocytopenia                                | 10 (22.2)           | 81 (15.3)           | 24 (18.0)           | 115 (16.3)        | 12 (8.8)         | 127 (15.1)           |
| Constipation                                    | 7 (15.6)            | 84 (15.9)           | 12 (9.0)            | 103 (14.6)        | 17 (12.4)        | 120 (14.2)           |
| Back pain                                       | 4 (8.9)             | 70 (13.3)           | 22 (16.5)           | 96 (13.6)         | 16 (11.7)        | 112 (13.3)           |
| Chills                                          | 4 (8.9)             | 60 (11.4)           | 7 (5.3)             | 71 (10.1)         | 39 (28.5)        | 110 (13.0)           |
| Hypotension                                     | 6 (13.3)            | 65 (12.3)           | 17 (12.8)           | 88 (12.5)         | 19 (13.9)        | 107 (12.7)           |
| Cytokine release syndrome                       | 3 (6.7)             | 68 (12.9)           | 23 (17.3)           | 94 (13.3)         | 4 (2.9)          | 98 (11.6)            |
| Alanine aminotransferase increased              | 5 (11.1)*           | 56 (10.6)           | 20 (15.0)           | 81 (11.5)         | 11 (8.0)         | 92 (10.9)            |
| Insomnia                                        | 3 (6.7)             | 61 (11.6)           | 4 (3.0)             | 68 (9.6)          | 22 (16.1)        | 90 (10.7)            |
| Pain in extremity                               | 3 (6.7)             | 54 (10.2)           | 19 (14.3)           | 76 (10.8)         | 10 (7.3)         | 86 (10.2)            |
| Abdominal pain                                  | 3 (6.7)             | 56 (10.6)           | 21 (15.8)           | 80 (11.3)         | 5 (3.6)          | 85 (10.1)            |
| Bone pain                                       | 9 (20.0)            | 55 (10.4)           | 14 (10.5)           | 78 (11.0)         | 4 (2.9)          | 82 (9.7)             |
| Hypertension                                    | 4 (8.9)             | 40 (7.6)            | 27 (20.3)           | 71 (10.1)         | 9 (6.6)          | 80 (9.5)             |
| Rash                                            | 1 (2.2)             | 53 (10.0)           | 7 (5.3)             | 61 (8.6)          | 16 (11.7)        | 77 (9.1)             |
| Dizziness                                       | 4 (8.9)             | 52 (9.8)            | 6 (4.5)             | 62 (8.8)          | 14 (10.2)        | 76 (9.0)             |
| Aspartate aminotransferase increased            | 6 (13.3)*           | 47 (8.9)            | 16 (12.0)           | 69 (9.8)          | 6 (4.4)          | 75 (8.9)             |
| Hypomagnesaemia                                 | 2 (4.4)             | 57 (10.8)           | 8 (6.0)             | 67 (9.5)          | 6 (4.4)          | 73 (8.7)             |
| Weight increased                                | 1 (2.2)             | 40 (7.6)            | 16 (12.0)           | 57 (8.1)          | 14 (10.2)        | 71 (8.4)             |
| Arthralgia                                      | 4 (8.9)             | 41 (7.8)            | 7 (5.3)             | 52 (7.4)          | 17 (12.4)        | 69 (8.2)             |
| Leukopenia                                      | 2 (4.4)             | 37 (7.0)            | 14 (10.5)           | 53 (7.5)          | 16 (11.7)        | 69 (8.2)             |
| Epistaxis                                       | 5 (11.1)            | 39 (7.4)            | 15 (11.3)           | 59 (8.4)          | 1 (0.7)          | 60 (7.1)             |
| Pain                                            | 7 (15.6)*           | 32 (6.1)            | 17 (12.8)           | 56 (7.9)          | 2 (1.5)          | 58 (6.9)             |
| Dyspnoea                                        | 6 (13.3)            | 41 (7.8)            | 4 (3.0)             | 51 (7.2)          | 6 (4.4)          | 57 (6.8)             |
| Asthenia                                        | 6 (13.3)            | 44 (8.3)            | 2 (1.5)             | 52 (7.4)          | 5 (3.6)          | 57 (6.8)             |
| Platelet count decreased                        | 2 (4.4)             | 26 (4.9)            | 20 (15.0)           | 48 (6.8)          | 2 (1.5)          | 50 (5.9)             |
| C-reactive protein increased                    | 2 (4.4)             | 27 (5.1)            | 3 (2.3)             | 32 (4.5)          | 17 (12.4)        | 49 (5.8)             |
| Device related infection                        | 5 (11.1)            | 30 (5.7)            | 4 (3.0)             | 39 (5.5)          | 9 (6.6)          | 48 (5.7)             |
| Nasopharyngitis                                 | 3 (6.7)             | 25 (4.7)            | 2 (1.5)             | 30 (4.2)          | 15 (10.9)        | 45 (5.3)             |
| White blood cell count decreased                | 2 (4.4)             | 26 (4.9)            | 14 (10.5)           | 42 (5.9)          | 3 (2.2)          | 45 (5.3)             |
| Paraesthesia                                    | 6 (13.3)            | 28 (5.3)            | 3 (2.3)             | 37 (5.2)          | 7 (5.1)          | 44 (5.2)             |
| Confusional state                               | 5 (11.1)            | 27 (5.1)            | 3 (2.3)             | 35 (5.0)          | 7 (5.1)          | 42 (5.0)             |
| Chest pain                                      | 5 (11.1)            | 32 (6.1)            | 4 (3.0)             | 41 (5.8)          | 1 (0.7)          | 42 (5.0)             |
| Blood immunoglobulin G decreased                | 0 (0.0)             | 15 (2.8)            | 5 (3.8)             | 20 (2.8)          | 19 (13.9)        | 39 (4.6)             |
| Neutrophil count decreased                      | 0 (0.0)             | 21 (4.0)            | 15 (11.3)           | 36 (5.1)          | 2 (1.5)          | 38 (4.5)             |
| Aphasia                                         | 2 (4.4)             | 17 (3.2)            | 2 (1.5)             | 21 (3.0)          | 16 (11.7)        | 37 (4.4)             |
| Musculoskeletal pain Erythema                   | 5 (11.1)            | 21 (4.0)            | 4 (3.0)             | 30 (4.2) 28 (4.0) | 3 (2.2) 3 (2.2)  | 33 (3.9) 31 (3.7)    |
| Blood immunoglobulin A decreased                | 5 (11.1) 0 (0.0)    | 18 (3.4) 9 (1.7)    | 5 (3.8) 1 (0.8)     | 10 (1.4)          | 14 (10.2)        | 24 (2.8)             |

ALL = acute lymphoblastic leukemia; MRD+ = minimal residual disease-positive; Ph- = Philadelphia chromosome negative; Ph+ = Philadelphia chromosome-positive; R/R = relapsed/refractory

Adverse events coded using Medical Dictionary for Regulatory Activities (MedDRA) version 18.1.

Safety analysis set: All subjects who received at least 1 infusion of blinatumomab.

* Subject incidence of treatment-emergent adverse events by preferred term in Study 20120216 final analysis was updated: headache (15 [33.3%]). pain (8 [17.8%]). aspartate aminotransferase increased (7 [15.6%]). and alanine aminotransferase increased (6 [13.3%]].

Source: Modified from Table iss-06.2.1 and Table 14-6.2 of 20120216 Final Analysis CSR

Page 3 of 3

<div style=\"page-break-after: always\"></div>

In study 20120216, the incidence of adverse events per 100 weeks was lower for subjects who were treated at the 28μg/da y dose of blinatumomab (137.8 incidence per 100 weeks; 44 subjects/320.8 crude  exposure  weeks)  compared  with  subjects  who  were  treated  with  the  9μg/day  dose  of blinatumomab (381.6 incidence per 100 weeks; 45 subjects/64.2 crude exposure weeks).

## · Grade 3/ 4 TEAEs

In Study 20120216 primary analysis, the rates of grade ≥ 3  and  grade ≥ 4  events were 82.2% and 40.0%, respectively (Table 40). In the final analysis for this study, the incidence rate of grade ≥ 3 adverse events was 84.4%. The incidence of grade ≥ 4 adverse events remained unchanged (40.0%) in the final analysis.

Regardless of Philadelphia chromosome status, the types and frequencies of grade ≥ 3 and grade ≥ 4 adverse events were similar among the adult relapsed/refractory ALL subjects, with the exception of the incidence  of  treatment-related  grade ≥ 3  adverse  events,  which  had  a  higher  rate  in  subjects  with Philadelphia-negative  relapsed/refractory  ALL  (54.9%  versus  44.4%  in  subjects  with  Philadelphiapositive relapsed/refractory ALL).

<div style=\"page-break-after: always\"></div>

## · Treatment-related Adverse Events

In Study 20120216 primary analysis, the rate of treatment-related adverse events was 91.1%. The rate of grade ≥ 3 and grade ≥ 4 treatment-related adverse events was 44.4% and 15.6%, respectively. There was 1 (2.2%) fatal event considered by the investigator to be related to blinatumomab.

The highest rate of treatment-related adverse events by SOC in Study 20120216 was General Disorders and  Administration  Site  Conditions  (64.4%).  The  most  common  (subject  incidence  rate ≥ 10%) treatment-related adverse events in adult subjects with Philadelphia-positive relapsed/refractory ALL were pyrexia (46.7%), febrile neutropenia (24.4%), anaemia (13.3%), and ALT increased, AST and headache increased (11.1% each).

The  rate  of  treatment-related  grade ≥ 3  adverse  events  was  more  than  10%  lower  in  the  adult Philadelphia-positive  relapsed/refractory  ALL  population  compared  with  the  Philadelphia-negative population (44.4% versus 54.9%) (Table 40).

Regardless  of  Philadelphia  chromosome  status,  the  types  of  treatment-related  adverse  events  (by preferred term) were similar among the subjects in relapsed/refractory ALL studies (.

The highest rate of treatment-related adverse events by SOC in adult subjects with Philadelphia-negative relapsed/refractory ALL was General Disorders and Administration Site Conditions (51.1%). The most common (subject incidence rate ≥ 10%) treatment-related adverse events in the Philadelphia-negative relapsed/refractory  ALL  population  were  pyrexia  (43.0%),  headache  (14.2%),  febrile  neutropenia (12.7%), CRS (12.5%), and neutropenia and tremor (11.6% for each).

Apart from febrile neutropenia, which had a higher incidence rate in adult subjects with Philadelphiapositive relapsed/refractory ALL compared with adult subjects with Philadelphia-negative relapsed/refractory ALL (24.4% versus 12.7%), there were no other treatment-related adverse events reported with a subject incidence of ≥ 10% between the relapsed/refractory populations.

<div style=\"page-break-after: always\"></div>

## 2.5.2.3. Serious adverse event/deaths/other significant events

## · Deaths

Adverse events were defined per the iSAP as adverse events that occurred between the start of the first infusion of blinatumomab (initial treatment or re-treatment) and 30 days after the end of the last infusion during the study. Updated data on fatal adverse events that occurred after study completion through 22 February 2018 were also provided.

In the primary analysis for Study 20120216, 11.1% (5/45) of subjects had fatal adverse events (Table 42).One  fatal  adverse  event  (septic  shock)  was  reported  by  the  investigator  to  be  related  to blinatumomab treatment:

- A 33-year-old female subject with relapsed/refractory ALL, who was receiving multiple concomitant medications, had a medical history including hypersensitivity reaction due to vancomycin ('Red man syndrome'),  thrombocytopenia,  leukocytosis  and  catheter-related  infection.  Blinatumomab  was discontinued after approximately 3 months of treatment per protocol requirements. Ten days later, the subject was diagnosed with shingles and acyclovir was initiated. Two days later, the subject was admitted to the hospital unconscious, with hypotension, tachycardia, hypoxia, and fever. She was diagnosed  with  septic  shock,  pulmonary  hemorrhage,  pneumonia,  and  respiratory  failure.  She required intubation, intravenous fluids, and support; however, her condition worsened and she died 1 day after admission to hospital. The investigator reported that there was a reasonable possibility that the fatal event of septic shock was related to blinatumomab, but not to study conduct.

After Study 20120216 primary analysis cut-off date, there was 1 additional subject that died prior to study completion on 06 January 2017. The death was attributed to the adverse events of neoplasm malignant and pneumonia. The death occurred approximately 58 weeks after discontinuing blinatumomab and was not considered to be related to study treatment by the investigator.

Table 42: Fatal Treatment-emergent Events by System Organ Class and Preferred Term (Full Analysis Set) - Study 20120216 Primary Analysis

| System Organ Class Preferred Term                     | Blinatumomab (N = 45) n (%)   |
|-------------------------------------------------------|-------------------------------|
| Subjects with fatal treatment-emergent adverse events | 5 (11.1)                      |
| General disorders and administration site conditions  | 1 (2.2)                       |
| Multi-organ failure                                   | 1 (2.2)                       |
| Infections and infesiations                           | 2 (4.4)                       |
| Sepsis                                                | 1 (2.2)                       |
| Septic shock                                          | 1 (2.2)                       |
| Nernvous system disorders                             | 1 (2.2)                       |
| Cerebral haemomhage                                   | 1 (2.2)                       |
| Respiratory. thoracic and mediastinal disorders       | 1 (2.2)                       |
| Respiratory failure                                   | 1 (2.2)                       |

Adverse events were coded according to Medical Dictionary for Regulatory Activities version 18.0 and are in descending order of frequency of preferred terms within the system organ class.

Source: Table 14-6.11 of Study 20160216 Primary Analysis C5R

<div style=\"page-break-after: always\"></div>

Across the blinatumomab ALL studies, a total of 491 deaths were reported: 154 of 843 (18.3%) deaths occurred on-treatment or within 30 days from last infusion; 337 of 843 (40.0%) deaths occurred &gt; 30 days after the last infusion. Of the causes of death not reported as disease progression, aetiologies such as infections (eg, sepsis) were observed and would be expected in this population.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the rate of all fatal events and treatment-related fatal events were similar (11.1% versus 17.2% and 2.2% versus 2.5%, respectively).

The  SOC  with  the  highest  incidence  of  fatal  adverse  events  in  the  adult  Philadelphia-negative relapsed/refractory ALL population was Infections and Infestations (55/528; 10.4%) The most frequently reported fatal adverse events (reported in &gt;  2 subjects) in the adult Philadelphia-negative relapsed/refractory ALL population were sepsis (n = 14; 2.7%), septic shock (n = 8; 1.5%), pneumonia (n = 6; 1.1%), multi-organ failure (n = 4; 0.8%), and acute lymphocytic leukaemia (n = 3; 0.6%). Thirteen of the 91 deaths that occurred in the Philadelphia-negative relapsed/refractory ALL population were considered by the investigator as related to blinatumomab treatment. Of these 13 deaths, 10 deaths were the result of infections, 2 deaths were the result of respiratory failure (1 of these subjects developed bacteraemia approximately 1 week before the onset of respiratory failure), and 1 death was reported due to encephalopathy.

## · Other SAEs

In Study 20120216 primary analysis, serious adverse events were reported for 28 subjects (62.2%).

The highest rate of serious adverse events by SOC was in Infections and Infestations (20.0%; 9/45). There were 12 subjects (26.7%) with serious adverse events which were considered to be related to blinatumomab by the investigator.

After  Study  20120216  completion  through  22  February  2018,  2  subjects  experienced  other  serious adverse events (1 subject experienced otitis media and acute kidney injury, and 1 subject experienced TLS). None of the events were considered related to blinatumomab treatment by the investigator and both subjects recovered from the events.

Table 43: Treatment-emergent Serious Adverse Events by Preferred Term That Occurred in ≥ 2 Subjects (Full Analysis Set) -Study 20120216 Primary Analysis

| Preferred Term                                               | Blinatumomab (N=45) n (%)   |
|--------------------------------------------------------------|-----------------------------|
| Subjecis reporting treatment-emergent serious adverse events | 28 (62.2)                   |
| Febrile neutropenia                                          | 4 (8.9)                     |
| Devicerelated infection                                      | 3 (6.7)                     |
| Sepsis                                                       | 3 (6.7)                     |
|                                                              | 3 (6.7)                     |
| Leukocytosis                                                 | 2 (4.4)                     |
| Non-cardiac chest pain                                       | 2 (4.4)                     |
| Pyrexia                                                      | 2 (4.4)                     |
| Respiratory failure                                          | 2 (4.4)                     |

Coded using Medical Dictionary for Regulatory Activities version 18.0.

Source: Modified from Table 14-6.3 of 20120216 Primary Analysis CSR

<div style=\"page-break-after: always\"></div>

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the rate of serious adverse events were similar (62.2% versus 63.4%).

The highest rate of serious adverse events by SOC in the Philadelphia-negative population was also in Infections and Infestations (29.5% [156/528]) . The most frequently reported serious adverse events (subject incidence ≥ 2%) in this population were febrile neutropenia (8.5%), pyrexia (6.4%), sepsis and pneumonia (4.5% for each), device-related infection (2.8%), overdose (2.7%), encephalopathy (2.5%), CRS and neutropenia (2.3% for each), and septic shock (2.1%). There were no serious adverse events (by preferred term) reported with a ≥ 10% difference between the adult Philadelphia-positive and -negative relapsed/refractory populations.

Table 44: Serious Treatment-emergent Adverse Events by Preferred Term in ≥ 2% of Subjects (Where n &gt; 1) in Any ALL Population, in Descending Frequency for Blinatumomab ALL Studies (Safety Analysis Set)

| Preferred Tem                       | Adult R/R Ph+ ALL 20120216 (N= 45) n (%)   | Adult R/R Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab arm) (N = 528) n (%)   | Pediatic R/R ALL MT103-205 20130320 (N= 133) n (%)   | R/RALL Pooled Total (N = 706) n (%%)   | Adult MRD+ ALL MT103-202 MT103-203 (N = 137) n (%)   | ALL Pooled (Total) All Studies: (N = 843) n (%)   |
|-------------------------------------|--------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------|----------------------------------------|------------------------------------------------------|---------------------------------------------------|
| Number of subjectsreporting serious | 28 (62.2)                                  | 335 (63.4)                                                                          | 71 (53.4)                                            | 434 (61.5)                             | 83 (60.6)                                            | 517 (61.3)                                        |
| treatment-emergent adverse events   |                                            |                                                                                     |                                                      |                                        |                                                      |                                                   |
| Pyrexia                             | 2 (4.4)                                    | 34 (6.4)                                                                            | 15 (11.3)                                            | 51 (7.2)                               | 17 (12.4)                                            | 68 (8.1)                                          |
| Febrile neutropenia                 | 4 (8.9)                                    | 45 (8.5)                                                                            | 9 (6.8)                                              | 58 (8.2)                               | 2 (1.5)                                              | 60 (7.1)                                          |
| Sepsis                              | 3 (6.7)                                    | 24 (4.5)                                                                            | 6 (4.5)                                              | 33 (4.7)                               | 1 (0.7)                                              | 34 (4.0)                                          |
| Pneumonia                           | 1 (2.2)                                    | 24 (4.5)                                                                            | 3 (2.3)                                              | 28 (4.0)                               | 2 (1.5)                                              | 30 (3.6)                                          |
| Device related infection            | 3 (6.7)                                    | 15 (2.8)                                                                            | 3 (2.3)                                              | 21 (3.0)                               | 4 (2.9)                                              | 25 (3.0)                                          |
| Cytokine release syndrome           | 1 (2.2)                                    | 12 (2.3)                                                                            | 9 (6.8)                                              | 22 (3.1)                               | 2 (1.5)                                              | 24 (2.8)                                          |
| Overdose                            | 1 (2.2)                                    | 14 (2.7)                                                                            | 4 (3.0)                                              | 19 (2.7)                               | 5 (3.6)                                              | 24 (2.8)                                          |
| Tremor                              | 3 (6.7)                                    | 9 (1.7)                                                                             | (0:0) 0                                              | 12 (1.7)                               | 8 (5.8)                                              | 20 (2.4)                                          |
| Encephalopathy                      | 1 (2.2)                                    | 13 (2.5)                                                                            | 0 (0.0)                                              | 14 (2.0)                               | 6 (4.4)                                              | 20 (2.4)                                          |
| Neutropenia                         | 0 (0.0)                                    | 12 (2.3)                                                                            | 2 (1.5)                                              | 14 (2.0)                               | 5 (3.6)                                              | 19 (2.3)                                          |
| Aphasia                             | 1 (2.2)                                    | 7 (1.3)                                                                             | 1 (0.8)                                              | 9 (1.3)                                | 6 (4.4)                                              | 15 (1.8)                                          |
| Seizure                             | 0 (0.0)                                    | 7 (1.3)                                                                             | 3 (2.3)                                              | 10 (1.4)                               | 4 (2.9)                                              | 14 (1.7)                                          |
| Septic shock                        | 1 (2.2)                                    | 11 (2.1)                                                                            | 0 (0.0)                                              | 12 (1.7)                               | 0 (0.0)                                              | 12 (1.4)                                          |
| Respiratory failure                 | 2 (4.4)                                    | 4 (0.8)                                                                             | 6 (4.5)                                              | 12 (1.7)                               | 0 (0.0)                                              | 12 (1.4)                                          |
| Infection                           | 0 (0.0)                                    | 7 (1.3)                                                                             | 3 (2.3)                                              | 10 (1.4)                               | 0 (0.0)                                              | 10 (1.2)                                          |
| C-reactive protein increased        | 0(0.0)                                     | 4 (0.8)                                                                             | 1 (0.8)                                              | 5 (0.7)                                | 4 (2.9)                                              | 9 (1.1)                                           |
| Leukocytosis Lymphopenia            | 2 (4.4) 0 (0.0)                            | 6 (1.1) 1(0.2)                                                                      | (0:0) 0 (00) 0                                       | 8 (1.1) 1 (0.1)                        | 0 (0.0) 6 (4.4)                                      | 8 (0.9) 7 (0.8)                                   |
| Non-cardiac chest pain              |                                            |                                                                                     |                                                      |                                        |                                                      |                                                   |
|                                     | 2 (4.4)                                    | 0 (0.0)                                                                             | (00) 0                                               | 2 (0.3)                                | 0 (0.0)                                              | 2 (0.2)                                           |
| Staphylococcal infection            | (0'0) 0                                    | 4 (0.8)                                                                             | (0:0) 0                                              | 4 (0.6)                                | 3(2.2)                                               | 7 (0.8)                                           |
| Hypoxia                             | 0 (0.0)                                    | 1 (0.2)                                                                             | 3 (2.3)                                              | 4 (0.6)                                | 0 (0.0)                                              | 4 (0.5)                                           |

Safety analysis set: All subjects who received at least 1 infusion of blinatumomab.

ALL = acute lymphoblastic leukemia; MRD+ = minimal residual disease-positive; Ph- = Philadelphia chromosome-negative; Ph+ = Philadelphia chromosome-positive; R/R. =relapsed/refractory

Source: Modified from Table iss-06.2.2

## · Treatment-emergent Adverse Events Leading to Treatment Interruption and Discontinuation

For Study 20120216 (final analysis), adverse events leading to treatment interruption were reported in 17 subjects (37.8%), including 13 patients (28.9%) with SAEs.

The most frequently reported events leading to treatment interruption by SOC were in General Disorders and  Administration  Site  Conditions  SOC  and  Infections  and  infestations  SOC  (11.1%,  5/45  each). Adverse events leading to treatment interruption in ≥ 2 subjects were pyrexia (6.7%), and chills, device related infection, sepsis, ALT increased, and AST increased (4.4% for each). All other events leading to treatment interruption were reported in 1 subject each.

Twelve (12) patients (26.7%) presented with related TEAEs leading to treatment interruption (Table 45).

<div style=\"page-break-after: always\"></div>

Table 45: Related Treatment-Emergent Adverse Events Leading to Interruption of Investigational Product by System Organ Class and Preferred Terma (Full Analysis Set)

| System Organ Class Preferred Term                    | Blinatumumab (N = 45) n (%)   |
|------------------------------------------------------|-------------------------------|
| Number of subjects reporting treatment-emergent      | 12 (26.7)                     |
| adverse events                                       |                               |
| Cardiac disorders                                    | 1 (2.2)                       |
| Tachycardia                                          | 1 (2.2)                       |
| Gastrointestinal disorders                           | 1 (2.2)                       |
| Colitis                                              | 1 (2.2)                       |
| General disorders and administration site conditions | 5 (11.1)                      |
| Pyrexia                                              | 3 (6.7)                       |
| Chills                                               | 1 (2.2)                       |
| Non-cardiac chest pain                               | 1 (2.2)                       |
| Infections and infestations                          | 2 (4.4)                       |
| Device related infection                             | 1 (2.2)                       |
| Sepsis                                               | 1 (2.2)                       |
| Investigajions                                       | 2 (4.4)                       |
| Alanine aminotransferase increased                   | 2 (4.4)                       |
| Aspartate aminotransferase increased                 | 2 (4.4)                       |
| Nervous system disorders                             | 3 (6.7)                       |
| Aphasia                                              | 1 (2.2)                       |
| Encephalopathy                                       | 1 (2.2)                       |
|                                                      | 1 (2.2)                       |
| Skin snd subcutaneous tissue disorders               | 1 (2.2)                       |
| Erythema                                             | 1 (2.2)                       |

ln descending order of total frequency by preferred tem within system organ class Coded using MedDRA version19.1

Page 2of2

Program:/userdata/stat/amg103/onc/20120216/analysis/inal/tables/program/t-ae-rel.sas Output: t14-06-405-004-ae-reHinterp-50c-pt.irtf  (Date Generated: 17FEB17:00:54:54) Source Data: adam.adsl, adam.adae

Refering to Table 40, when the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the rates of treatment interruptions due to all adverse events, grade ≥ 3 adverse events, serious  adverse  events  and  fatal  adverse  events  were  similar.  In  addition,  the  rates  of  treatment interruption due to treatment-related events (all adverse events, grade ≥ 3  adverse  events,  serious adverse  events  and  fatal  adverse  events)  were  also  similar  regardless  of  Philadelphia  chromosome status.

The  most  frequently  reported  adverse  events  leading  to  treatment  interruption  in  Phi  neg  patients (subject incidence ≥ 2%) were pyrexia (2.7%), CRS (3.0%), and confusional state (2.1%).

## · Treatment Discontinuations due to Treatment-emergent Adverse Events

<div style=\"page-break-after: always\"></div>

In Study 20120216 primary analysis, adverse events leading to treatment discontinuation were reported in 3 subjects (6.7%) (Table 40) and included 1 event each of grade 4 neutropenia, grade 3 acute graft versus host disease, and grade 3 lung infection.

The serious adverse events of acute graft versus host disease and lung infection occurred within the induction phase of blinatumomab treatment. The event of neutropenia occurred during the consolidation phase of blinatumomab treatment. Events of neutropenia and acute graft versus host disease were considered related to treatment per the investigator's assessment.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the rates of treatment discontinuation due to all adverse events, grade ≥ 3 adverse events, serious adverse events and fatal adverse events were similar (Table 40). The rates of treatment discontinuation due to treatment-related events (all adverse events, grade ≥ 3 adverse events, serious adverse events and fatal adverse events) were also similar regardless of chromosome status.

The highest rate of adverse events leading to treatment discontinuation by SOC for adult subjects with Philadelphia-negative relapsed/refractory ALL was in Infections and Infestations (4.2%) . There was no specific  preferred  term  reported  for ≥ 2%  of  subjects  in  this  population  that  led  to  treatment discontinuation.  The  most  frequently  reported  event  leading  to  treatment  discontinuation  was encephalopathy (1.3%).

## 2.5.2.4. Events of Interest

Table 46: Summary of Treatment-emergent Events of Interest for Blinatumomab ALL Studies (Safety Analysis Set)

|                                                      | Adult R/R Ph+ ALL       | Adult R/R Ph- ALL MT103-211 MT103-206 00103311 (N = 528)   | Pediatric R/R ALL                 | RR ALL Pooled Total   | Adult MRD+ ALL MT103-202 MT103-203   | ALL Pooled All Studies (N= 843)   |
|------------------------------------------------------|-------------------------|------------------------------------------------------------|-----------------------------------|-----------------------|--------------------------------------|-----------------------------------|
| Event of Interest (Search StrategyType)              | 20120216 (N= 45) n (9%) | (Blinatumomab arm) n (%)                                   | MT103-205 20130320 (N= 133) n (%) | (N= 706) n (%)        | (N = 137) n (%)                      | n (%)                             |
| Neurologic Events (Amgen MedDRA Query/All terms      | 28 (62.2)               | 353 (66.9)                                                 | 69 (51.9)                         | 450 (63.7)            | 98 (71.5)                            | 548 (65.0)                        |
| Grade ≥3                                             | 6 (13.3)                | 73 (13.8)                                                  | 11 (8.3)                          | 90 (12.7)             | 22 (16.1)                            | 112(13.3)                         |
| Grade 2 4                                            | 0 (0.0)                 | 8 (1.5)                                                    | 1 (0.8)                           | 9 (1.3)               | 3 (2.2)                              | 12 (1.4)                          |
| Serious                                              | 6 (13.3)                | 70 (13.3)                                                  | 9 (6.8)                           | 85 (12.0)             | 31 (22.6)                            | 116 (13.8)                        |
| Fatal                                                | 0 (0.0)                 | 3 (0.6)                                                    | 0 (0.0)                           | 3 (0.4)               | 0 (0.0)                              | 3 (0.4)                           |
| Cytokine release syndrome (Amgen MedDRA              | 4 (8.9)                 | 75 (14.2)                                                  | 24 (18.0)                         | 103 (14.6)            | 4 (2.9)                              | 107 (12.7)                        |
| Query/Narrow)                                        |                         |                                                            |                                   |                       |                                      |                                   |
| Grade ≥3                                             | 0 (0.0)                 | 18 (3.4)                                                   | 9 (6.8)                           | 27 (3.8)              | 2 (1.5)                              | 29 (3.4)                          |
| Grade ≥4                                             | 0 (0.0)                 | 3 (0.6)                                                    | 4 (3.0)                           | 7 (1.0)               | (00) 0                               | 7 (0.8)                           |
| Serious                                              | 1 (2.2)                 | 15 (2.8)                                                   | 10 (7.5)                          | 26 (3.7)              | 2 (1.5)                              | 28 (3.3)                          |
| Infections (Ilnfections and InfestationsSystem Organ | 22 (48.9)               | 338 (64.0)                                                 | 61 (45.9)                         | 421 (59.6)            | 64 (46.7)                            | 485 (57.5)                        |
| Class)                                               |                         |                                                            |                                   |                       |                                      |                                   |
| Grade 23                                             | 11 (24.4)               | 183 (34.7)                                                 | 32 (24.1)                         | 226 (32.0)            | 16 (11.7)                            | 242 (28.7)                        |
| Grade ≥4                                             | 3 (6.7)                 | 80 (15.2)                                                  | 7 (5.3)                           | 90 (12.7)             | 4 (2.9)                              | 94 (11.2)                         |
| Serious                                              | 9 (20.0)                | 156 (29.5)                                                 | 26 (19.5)                         | 191 (27.1)            | 18 (13.1)                            | 209 (24.8)                        |
| Fatal                                                | 2 (4.4)                 | 55 (10.4)                                                  | 2 (1.5)                           | 59 (8.4)              | 1 (0.7)                              | 60 (7.1)                          |
| Elevated Liver Enzyme (MedDRA SMQ Liver related      | 8 (17.8)                | 121 (22.9)                                                 | 33 (24.8)                         | 162 (22.9)            | 17 (12.4)                            | 179 (21.2)                        |
| investigations, signs and symptoms/Narrow)           |                         |                                                            |                                   |                       |                                      |                                   |
| Grade ≥3                                             | 6 (13.3)                | 72 (13.6)                                                  | 23 (17.3)                         | 101 (14.3)            | 11 (8.0)                             | 112(13.3)                         |
| Grade 2 4                                            | 3 (6.7)                 | 14 (2.7)                                                   | 6 (4.5)                           | 23 (3.3)              | 6 (4.4)                              | 29 (3.4)                          |
| Serious                                              | 1 (2.2)                 | 9 (1.7)                                                    | 1 (0.8)                           | 11 (1.6)              | 5 (3.6)                              | 16 (1.9)                          |
| nfusion reactions (Amgen MedDRA QuerylNairrow)       | 22 (48.9)               | 268 (50.8)                                                 | 88 (66.2)                         | 378 (53.5)            | 124 (90.5)                           | 502 (59.5)                        |
| Grade ≥3                                             | 3 (6.7)                 | 41 (7.8)                                                   | 21 (15.8)                         | 65 (9.2)              | 14 (10.2)                            | 79 (8.4)                          |
| Grade 2 4                                            | 0 (0.0)                 | 2 (0.4)                                                    | 1 (0.8)                           | 3 (0.4)               | 1 (0.7)                              | 4 (0.5)                           |
| Serious                                              | 1 (2.2)                 | 13 (2.5)                                                   | 9(6.8)                            | 23 (3.3)              | 19 (13.9)                            | 42 (5.0)                          |

<div style=\"page-break-after: always\"></div>

| Tumour lysis syndrome (SMQ Tumor Lysis        | 0 (0.0)   | 23 (4.4)   | 4 (3.0)   | 27 (3.8)   | 0 (0.0)   | 27 (3.2)   |
|-----------------------------------------------|-----------|------------|-----------|------------|-----------|------------|
| Syndrome/Narrow)                              |           |            |           |            |           |            |
| Grade ≥3                                      | 0 (0.0)   | 15 (2.8)   | 3 (2.3)   | 18 (2.5)   | 0 (0.0)   | 18 (2.1)   |
| Grade ≥4                                      | 0 (0.0)   | 2 (0.4)    | 1 (0.8)   | 3 (0.4)    | 0 (0.0)   | 3 (0.4)    |
| Serious                                       | (0'0) 0   | 5 (0.9)    | 1 (0.8)   | 6 (0.8)    | 0 (0.0)   | 6 (0.7)    |
| Capillary leak syndrome (Amgen MedDRA         | (0'0) 0   | 1 (0.2)    | 6 (4.5)   | 7 (1.0)    | 1 (0.7)   | 8 (0.9)    |
| QuerylNarrow)                                 |           |            |           |            |           |            |
| Grade ≥3                                      | 0 (0.0)   | 1 (0.2)    | 2 (1.5)   | 3 (0.4)    | 0 (0.0)   | 3 (0.4)    |
| Grade ≥4                                      | 0 (0.0)   | 1 (0.2)    | 1 (0.8)   | 2 (0.3)    | 0 (0.0)   | 2 (0.2)    |
| Serious                                       | 0 (0.0)   | 1 (0.2)    | 2 (1.5)   | 3 (0.4)    | 0 (0.0)   | 3 (0.4)    |
| Medication errors (Amgen MedDRA Query/Broad)* | 1 (2.2)   | 20 (3.8)   | 6 (4.5)   | 27 (3.8)   | 6 (4.4)   | 33 (3.9)   |
| Grade ≥3                                      | 0 (0.0)   | 4 (0.8)    | 1 (0.8)   | 5 (0.7)    | 0 (0.0)   | 5 (0.6)    |
| Grade 2 4                                     | 0 (0.0)   | 2 (0.4)    | 0 (0.0)   | 2 (0.3)    | 0 (0.0)   | 2 (0.2)    |
| Serious                                       | 1 (2.2)   | 20 (3.8)   | 6 (4.5)   | 27 (3.8)   | 6 (4.4)   | 33 (3.9)   |
| Decreased immunoglobulins (Amgen MedDRA       | 4 (8.9)   | 62 (11.7)  | 14 (10.5) | 80 (11.3)  | 25 (18.2) | 105 (12.5) |
| QuerylNatrowja.b                              |           |            |           |            |           |            |
| Grade ≥3                                      | 0 (0.0)   | 12 (2.3)   | 3 (2.3)   | 15 (2.1)   | 7 (5.1)   | 22 (2.6)   |
| Grade ≥4                                      | 0 (0.0)   | 2 (0.4)    | 0 (0.0)   | 2 (0.3)    | 0 (0.0)   | 2 (0.2)    |
| Embolic and Thrombotic Events (MedDRA SMQ     | 3 (6.7)   | 42 (8.0)   | 11 (8.3)  | 56 (7.9)   | 7 (5.1)   | 63 (7.5)   |
| including DIC/Narrow)                         |           |            |           |            |           |            |
| Grade≥3                                       | 2 (4.4)   | 13 (2.5)   | 1 (0.8)   | 16 (2.3)   | 5 (3.6)   | 21 (2.5)   |
| Grade 24                                      | 0 (0.0)   | 4 (0.8)    | 1 (0.8)   | 5 (0.7)    | 2 (1.5)   | 7 (0.8)    |
| Serious                                       | 1 (2.2)   | 12 (2.3)   | 1 (0.8)   | 14 (2.0)   | 4 (2.9)   | 18 (2.1)   |
| Fatal                                         | 0(0.0)    | 2(0.4)     | 1 (0.8)   | 3(0.4)     | 0(0.0)    | 3 (0.4)    |
| Leukoencephalopathy (Amgen MedDRA             | 1 (2.2)   | 4 (0.8)    | 2 (1.5)   | 7 (1.0)    | 1 (0.7)   | 8 (0.9)    |
| Query/Broad)                                  |           |            |           |            |           |            |
| Grade 2 3                                     | 0 (0.0)   | 2 (0.4)    | 0 (0.0)   | 2 (0.3)    | 0 (0.0)   | 2(0.2)     |
| Grade ≥ 4                                     | 0 (0.0)   | 1 (0.2)    | 0 (0.0)   | 1 (0.1)    | 0 (0.0)   | 1 (0.1)    |
| Serious                                       | 0 (0.0)   | 2 (0.4)    | 0 (0.0)   | 2 (0.3)    | 1 (0.7)   | 3 (0.4)    |
| Neutropenia and Febrile neutropenia (Amgen    | 21 (46.7) | 213 (40.3) | 45 (33.8) | 279 (39.5) | 22 (16.1) | 301 (35.7) |
| MedDRA QuerylNarrow)                          |           |            |           |            |           |            |
| Grade ≥ 3                                     | 15 (33.3) | 196 (37.1) | 44 (33.1) | 255 (36.1) | 22 (16.1) | 277 (32.9) |
| Grade ≥ 4                                     | 3 (6.7)   | 80 (15.2)  | 25 (18.8) | 108 (15.3) | 17 (12.4) | 125 (14.8) |
| Serious                                       | 4 (8.9)   | 63 (11.9)  | 11 (8.3)  | 78 (11.0)  | 7 (5.1)   | 85 (10.1)  |
| Fatal                                         | 0 (0.0)   | 2 (0.4)    | 0 (0.0)   | 2 (0.3)    | 0 (0.0)   | 2(0.2)     |
| Lymphopenia (Amgen MedDRA Query/Narrow)       | 0 (0.0)   | 13 (2.5)   | 7 (5.3)   | 20 (2.8)   | 0 (6.6)   | 29 (3.4)   |
| Grade ≥ 3                                     | 0 (0.0)   | 11 (2.1)   | 6 (4.5)   | 17 (2.4)   | 9 (6.6)   | 26 (3.1)   |
| Grade ≥ 4                                     | 0 (0.0)   | 9 (1.7)    | 5 (3.8)   | 14 (2.0)   | 8 (5.8)   | 22 (2.6)   |
| Serious                                       | 0 (0.0)   | 1 (0.2)    | 0 (0.0)   | 1 (0.1)    | 6 (4.4)   | 7 (0.8)    |
| Pancreatitis(SMQ/Narrow)                      | 0 (0.0)   | 2 (0.4)    | 0 (0.0)   | 2 (0.3)    | 1 (0.7)   | 3 (0.4)    |
| Grade ≥ 3                                     | 0 (0.0)   | 2 (0.4)    |           |            | 0 (0.0)   | 2 (0.2)    |
| Serious                                       | 0 (0.0)   | 1 (0.2)    | (00)0     | 2 (0.3)    | 0 (0.0)   | 1(0.1)     |
|                                               |           |            | 0 (0.0)   | 1 (0.1)    |           |            |

ALL = acute lymphoblastic leukemia; DIC = disseminated intravascular coagulation; MedDRA = Medical Dictionary for Regulatory Activities; MRD+ = minimal residual disease-positive; NA = not applicable; Ph- = Philadelphia chromosome-negative; Ph+ = Philadelphia chromosome-positive; R/R = relapsed/refractory:

Safety analysis set: All subjects who received at least 1 infusion of blinatumomab.

SMQ = Standard MedDRA Query

Severity graded using Common Technical Criteria for Adverse Events, version 4.03.

No fatal adverse events were reported.

Adverse events coded using MedDRA version 18.1.

b No serious adverse events were reported.

Source: Modified from Table iss-06.6.1

cNo grade 2 4 adverse events were reported.

Page 3 of 3

<div style=\"page-break-after: always\"></div>

Table 47: Summary of Events of Interest by Philadelphia Chromosome Status for Blinatumomab ALL Studies (Safety Analysis Sets)

<!-- image -->

| Event of Interest                                                                                   | Any Grades EOI\"                                                                                     | Median Time to First Onset of Any Grades EO14e                                                      | Grade 2 3 EO1                                                                                       | Median Time to First Onset Grade23 Eolbe                                                            |
|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| ALL Classification (search strategy) Neurologic events (Amgen MedDRA Query)                         | ALL Classification (search strategy) Neurologic events (Amgen MedDRA Query)                         | ALL Classification (search strategy) Neurologic events (Amgen MedDRA Query)                         | ALL Classification (search strategy) Neurologic events (Amgen MedDRA Query)                         | ALL Classification (search strategy) Neurologic events (Amgen MedDRA Query)                         |
| Adult Ph+ R/R ALL Adult Ph- R/R ALL*                                                                | 62.2% 66.9%%                                                                                        | 8.5 days 6.0 days                                                                                   | 13.3% 13.8%6                                                                                        | 47.5 17.0                                                                                           |
| Cytokine release syndrome (Amgen MedDRA Query)                                                      | Cytokine release syndrome (Amgen MedDRA Query)                                                      | Cytokine release syndrome (Amgen MedDRA Query)                                                      | Cytokine release syndrome (Amgen MedDRA Query)                                                      | Cytokine release syndrome (Amgen MedDRA Query)                                                      |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL*                                                               | 8.97. 14.2%                                                                                         | 6.0 days 2.0 days                                                                                   | 0 3.4%                                                                                              | NA Not reported                                                                                     |
| Infections (Infections and Infestations System Organ Class)                                         | Infections (Infections and Infestations System Organ Class)                                         | Infections (Infections and Infestations System Organ Class)                                         | Infections (Infections and Infestations System Organ Class)                                         | Infections (Infections and Infestations System Organ Class)                                         |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL?                                                               | 48.9% 63.6%                                                                                         | 14.5 days 17.0 days                                                                                 | 24.4% 34.796                                                                                        | Not reported Not reported                                                                           |
| Elevated liver enzymes (MedDRA SMQ Liver-related investigations, Signs, and Symptoms narrow search) | Elevated liver enzymes (MedDRA SMQ Liver-related investigations, Signs, and Symptoms narrow search) | Elevated liver enzymes (MedDRA SMQ Liver-related investigations, Signs, and Symptoms narrow search) | Elevated liver enzymes (MedDRA SMQ Liver-related investigations, Signs, and Symptoms narrow search) | Elevated liver enzymes (MedDRA SMQ Liver-related investigations, Signs, and Symptoms narrow search) |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL*                                                               | 17.8% 22.9%                                                                                         | 2.0 days 3.0 days                                                                                   | 13.3%6 13.6%                                                                                        | Not reported Not reported                                                                           |
| Infusion reactions (Amgen MedDRA Query)                                                             | Infusion reactions (Amgen MedDRA Query)                                                             | Infusion reactions (Amgen MedDRA Query)                                                             | Infusion reactions (Amgen MedDRA Query)                                                             | Infusion reactions (Amgen MedDRA Query)                                                             |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL*                                                               | 48.9% 50.8%                                                                                         | 2.0 days 2.0 days                                                                                   | 6.7% 7.8%                                                                                           | Not reported Not reported                                                                           |
| Tumor lysis syndrome (MedDRA SMQ Tumor Lysis Syndrome)                                              | Tumor lysis syndrome (MedDRA SMQ Tumor Lysis Syndrome)                                              | Tumor lysis syndrome (MedDRA SMQ Tumor Lysis Syndrome)                                              | Tumor lysis syndrome (MedDRA SMQ Tumor Lysis Syndrome)                                              | Tumor lysis syndrome (MedDRA SMQ Tumor Lysis Syndrome)                                              |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL*                                                               | 4.4%                                                                                                | NA 3.0 days                                                                                         | D 2.8%                                                                                              | NA Not reported                                                                                     |
| Capillary leak syndrome (Narrow Search)                                                             | Capillary leak syndrome (Narrow Search)                                                             | Capillary leak syndrome (Narrow Search)                                                             | Capillary leak syndrome (Narrow Search)                                                             | Capillary leak syndrome (Narrow Search)                                                             |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL+                                                               | 0 0.2%                                                                                              | NA 2.0 days                                                                                         | D 0.2%                                                                                              | NA Not reporied                                                                                     |
| Medication errors (Amgen MedDRA Query)                                                              | Medication errors (Amgen MedDRA Query)                                                              | Medication errors (Amgen MedDRA Query)                                                              | Medication errors (Amgen MedDRA Query)                                                              | Medication errors (Amgen MedDRA Query)                                                              |
| Adult Ph+ R/R ALLa Adult Ph- R/R ALL*                                                               | 2.2%% 3.8%6                                                                                         | 9.0 days 7.0 days                                                                                   | 0 0.8%                                                                                              | NA Not reported                                                                                     |
| Decreased immunoglobulins (Narrow Search)                                                           | Decreased immunoglobulins (Narrow Search)                                                           | Decreased immunoglobulins (Narrow Search)                                                           | Decreased immunoglobulins (Narrow Search)                                                           | Decreased immunoglobulins (Narrow Search)                                                           |
| Adult Ph+ R/R ALL Adult Ph- R/R ALL                                                                 | 8.9%% 11.7%                                                                                         | 105.5 days 42.0 days                                                                                | 0 2.3%                                                                                              | NA Not reported                                                                                     |
| Embolic and thromboembolic events (including DlC) (MedDRA SMQ Embolic and Thrombotic Events)        | Embolic and thromboembolic events (including DlC) (MedDRA SMQ Embolic and Thrombotic Events)        | Embolic and thromboembolic events (including DlC) (MedDRA SMQ Embolic and Thrombotic Events)        | Embolic and thromboembolic events (including DlC) (MedDRA SMQ Embolic and Thrombotic Events)        | Embolic and thromboembolic events (including DlC) (MedDRA SMQ Embolic and Thrombotic Events)        |
| Adult Ph+ R/R ALL Adult Ph- R/R ALL                                                                 | 6.7% 8.0%%                                                                                          | 175.0 days 22.0 days                                                                                | 4.4% 2.5%                                                                                           | Not reported Not reported                                                                           |
| Leukoencephalopathy (Amgen Safety Database Review)                                                  | Leukoencephalopathy (Amgen Safety Database Review)                                                  | Leukoencephalopathy (Amgen Safety Database Review)                                                  | Leukoencephalopathy (Amgen Safety Database Review)                                                  | Leukoencephalopathy (Amgen Safety Database Review)                                                  |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL                                                                | 2.2% 0.8%                                                                                           | 23.0 days 24.0 days                                                                                 | D 0.4%                                                                                              | NA Not reported                                                                                     |
| Neutropenia and Febrile Neutropenia (Amgen MedDRA Query)                                            | Neutropenia and Febrile Neutropenia (Amgen MedDRA Query)                                            | Neutropenia and Febrile Neutropenia (Amgen MedDRA Query)                                            | Neutropenia and Febrile Neutropenia (Amgen MedDRA Query)                                            | Neutropenia and Febrile Neutropenia (Amgen MedDRA Query)                                            |
| Adult Ph+ R/R ALLd Adult Ph- R/R ALL*                                                               | 48.7%% 40.3%                                                                                        | 3.0 days 10.0 days                                                                                  | 33.3% 37.1%                                                                                         | Not reported Not reported                                                                           |
| Lymphopenia (Narrow Search) Adult Ph+ R/R ALL\" Adult Ph- R/R ALL*                                   | 0 2.5%                                                                                              | NA 2.0 days                                                                                         | D 2.1%                                                                                              | NA Not reported                                                                                     |
| Pancreatitis (Narrow Search)                                                                        | Pancreatitis (Narrow Search)                                                                        | Pancreatitis (Narrow Search)                                                                        | Pancreatitis (Narrow Search)                                                                        | Pancreatitis (Narrow Search)                                                                        |
| Adult Ph+ RIR ALL Adult Ph- R/R ALL*                                                                | 0 0.4%                                                                                              | NA 12.5 days                                                                                        | 0.4%                                                                                                | NA Not reported                                                                                     |

EOl version 3 was used for these analyses (MedDRA 18.1).

R/R = relapsed/refractory: SMQ = Standard MedDRA Query.

Safety analysis set: All subjects who received at least one infusion of blinatumomab.

Severily graded using CTCAE v 4.03

Only EOls with onset dates during the core study were considered.

Subjects who did not have any event are censored at the last assessment during the core study.

b Median time to first onset for those subjects who had the event of interest.

Including re-treatment period.

d The safety assessment of blinatumomab in adult subjects with Philadelphia-positive relapsedrefractory ALL is based on an analysis of safety data collected in phase 2 Study 20120216.

* The safety assessment of blinatumomab in adult subjects with Philadelphia-negative relapsed/refractory ALL is based on an analysis of safety data collected in Studies MT103-211, MT103-206, and 00103311. Source: Table iss-06.6.i: Table iss-06.10.1 to Table iss-06.10.14

Page 2 of 2

<div style=\"page-break-after: always\"></div>

## · Neurologic Adverse Events

The  analysis  of  adverse  events  suggestive  of  neurologic  and  psychiatric  events  was  based  on  a comprehensive  search  of  sponsor-defined  (AMQ)  high-level  group  terms  from  Nervous  Systems Disorders and Psychiatric Disorders SOCs (neurologic events from the AMQ search strategy).

In Study 20120216 primary analysis, 28 subjects (62.2%) were identified with experiencing at least 1 neurologic event (Table 46 ). The most frequently reported (≥ 10% subject incidence rate) neurologic events  (by  preferred  terms)  were  headache  (31.1%;  14/45  subjects),  paresthesia  (13.3%;  6/45 subjects),  and  confusional  state  (11.1%;  5/45  subjects).  The  median  time  to  the  first  onset  of  the identified neurologic events was 8.5 days and all events resolved. The median duration of neurologic events was 4.5 days.

Serious neurologic events were identified for 6 subjects in Study 20120216 primary analysis (13.3%: one of these subjects experienced tremor and encephalopathy, 2 additional subjects experienced tremor, 1 subject experienced depressed level of consciousness, 1 subject experienced hemiplegia, and 1 subject experienced aphasia. Events of serious encephalopathy, serious tremor, serious aphasia, and confusional state  led  to  treatment  interruption  for  1  subject  each.  No  neurologic  events  led  to  treatment discontinuation.

## · Cytokine Release Syndrome (CRS)

The analysis of adverse events suggestive of CRS events was based on a Sponsor predefined narrow search strategy of Cytokine Release Syndrome (AMQ).

For Study 20120216 primary analysis, a total of 4 subjects (8.9%) were identified with experiencing at least 1 CRS event (Table 46), with PTs CRS (6.7%; 3/45) and cytokine storm (2.2%; 1/45). None of the events identified were grade ≥ 3, led to treatment discontinuation or interruption, or were fatal. One of the events of CRS was considered serious for 1 subject. The median (range) time to the first onset of identified CRS events was 6.0 (1 to 52) days and all events had resolved. The duration of resolved CRS events (2 events) was 5.0 days.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 CRS event was similar (Table 46).

The types of CRS events reported were consistent among adult subjects with relapsed/refractory ALL, regardless of Philadelphia chromosome status.

The  median  time  to  first onset  of CRS  events  for adult subjects with Philadelphia-negative relapsed/refractory ALL was earlier than for adult subjects with Philadelphia-positive relapsed/refractory ALL (2.0 days versus 6.0 days, respectively).

In summary, the incidence of subjects identified with a CRS event, and the types of CRS events reported were comparable between the Philadelphia-positive and -negative relapsed/refractory ALL populations.

## · Infections

In Study 20120216 (primary analysis), a total of 22 subjects (48.9%) experienced at least 1 infection event (Table 46). The most frequently identified infection events (preferred terms) were device related infection (11.1%; 5/45), sepsis (8.9%; 4/45), and urinary tract infection (8.9%; 4/45). The median time to the first onset of infection event was 14.5 days and 2 infection events were unresolved .

Serious infection events were reported for 9 subjects (20.0%) and included the following: device-related infection and sepsis (6.7%; 3/45 for each), and catheter site infection, lung infection, neutropenic sepsis,

<div style=\"page-break-after: always\"></div>

pneumonia, septic shock, and urinary tract infection (2.2%; 1/45 for each). An event of lung infection in 1 subject led to treatment discontinuation. Device-related infection and sepsis led to interruption of treatment for 2 subjects each, sepsis led to interruption, and neutropenic sepsis led to interruption of treatment in 1 subject. Fatal events of sepsis and septic shock occurred in 1 subject each. The event of septic shock was considered related to treatment with blinatumomab (per the investigator's assessment.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared the incidence of subjects who experienced at least 1 infection event was ≥ 10% higher in the Philadelphianegative relapsed/refractory ALL  population (64.0%  versus  48.9%  in  the  Philadelphia-positive population).  The  median  time  to  first  onset  of  infection  events  for  adult  subjects  with  Philadelphianegative  relapsed/refractory  ALL  was  17.0  days  versus  14.5  days  for  the  Philadelphia-positive relapsed/refractory ALL population.

The rate of grade ≥ 3 adverse events in the Philadelphia-negative relapsed/refractory ALL population was more than 10% higher compared with the Philadelphia-positive population (34.7% versus 24.4%). The rates and types of serious infection events were comparable between the 2 relapsed/refractory ALL populations.  The  incidence  of  fatal  infection  events  was  also  comparable  regardless  of  chromosome status.

## · Elevated Liver Enzymes

Identification  of  elevated  liver  enzyme  events  in  Study  20120216  was  based  on  the  narrow  search strategy for the MedDRA SMQ Liver-related Investigations, Signs and Symptoms.

For Study 20120216 primary analysis, a total of 8 subjects (17.8%) were identified with experiencing at least 1 elevated liver enzyme event. The most frequently reported elevated liver enzyme events ( ≥ 10% subject incidence rate) were AST increased (13.3%; 6/45) and ALT increased (11.1%; 5/45). The median time to the first onset of elevated liver enzyme events was 2.0 days and all events resolved.

Serious elevated liver enzyme events were reported for 1 subject (2.2%) and included the events of ALT increased and AST increased. No fatal elevated liver enzyme events were reported.

No elevated liver enzyme events led to treatment discontinuation in Study 20120216. Events of ALT increased and AST increased led to interruption of treatment in 2 subjects; blood fibrinogen decreased and hepatic failure led to interruption of treatment in 1 subject each.

The subject with AST increased leading to hepatic failure had been hospitalized approximately 5 months after receiving the first treatment, to start cycle 4 of blinatumomab; however, due to hepatic disorder, the cycle was not started. Hospitalization continued, and the subject was reported as having hepatic disorder not otherwise specified (NOS). During hospitalization, the subject's AST was 88 U/L, AST 80 U/L, total bilirubin normal, and gammaglutamyltransferase (GGT) 70 U/L. The subject's event preferred term was later updated to hepatic failure, and history updated as having received an allogeneic HSCT from  an  unrelated  donor  (no  biopsy  performed).  Approximately  5.5  months  after  the  first  dose  of blinatumomab, the hepatic failure was reported to have resolved and the subject died later the same day, with cause of death described as a suspected brain infection. The investigator reported that there was not a reasonable possibility that the event hepatic disorder was related to blinatumomab treatment.

In Study 20120216 primary analysis, no subjects met the full parameters of Hy's law laboratory criteria on the same day during the study.

<div style=\"page-break-after: always\"></div>

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 elevated liver enzyme event were similar. Regardless of Philadelphia chromosome status, the median time to first onset of elevated liver enzyme events were similar for the adult relapsed/refractory ALL subjects and the types elevated liver enzyme adverse events were comparable across the studies examined.

The incidence rates of subjects identified with grade ≥ 3, and serious elevated liver enzyme events were similar in the adult relapsed/refractory ALL population, regardless of Philadelphia-chromosome status. No fatal elevated liver enzyme events were reported.

In the adult Philadelphia-negative relapsed/refractory ALL studies, 5.6% (15/267) of subjects in Study 00103311, 12.0% (27/225) of subjects in Study MT103-211, and 13.9% (5/36) of subjects in Study MT103-206 met the Hy's law laboratory criteria on any day.  These events consistent with Hy's law laboratory criteria generally occurred within the first 2 days of the start of blinatumomab treatment and were transient in nature, recovering to baseline levels within a few days. No subjects met the full criteria for Hy's law, since plausible alternative aetiologies or confounding factors were present that are known to be associated with the elevations in liver enzymes or hepatic dysfunction (eg, elevated liver enzymes at  baseline;  concomitant  therapy  with  medications  known  to  be  hepatotoxic;  a  setting  of  CRS  and macrophage activation syndrome).

## · Infusion Reactions

Potential infusion-related adverse events were identified by applying a AMQ narrow search strategy of preferred terms likely  associated  with  infusion  reactions.  A  preferred term  was  considered to  be  an infusion reaction if it occurred within 48 hours of the infusion.

In Study 20120216 primary analysis, 22 subjects (48.9%) were identified as experiencing at least 1 infusion  reaction  event  (Table  46).  The  most  frequently  reported  (incidence  rate ≥ 10%)  infusion reaction adverse event was pyrexia (40.0%; 18/45). The median time to the first onset of infusion reaction events was 2.0 days and all events were resolved.

No fatal infusion reaction events were reported. A serious infusion reaction event of CRS was reported for 1 subject. No subjects experienced an infusion reaction event that led to treatment. Events of pyrexia led to interruption of treatment in 3 subjects.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 infusion reaction event were similar. The types of infusion reaction events reported were consistent among adult subjects with relapsed/refractory ALL, regardless of Philadelphia chromosome status. The median time to onset of infusion reactions was the same in both populations (Table 47).

The incidence rates of grade ≥ 3 and serious infusion reaction events were also similar regardless of Philadelphia-chromosome status. No fatal infusion reaction events were reported.

## · Medication Errors

The analysis of adverse events suggestive of medication errors was based on a predefined broad search strategy (AMQ). In Study 20120216, overdose was defined as a dose of &gt; 10% higher than the intended blinatumomab dose. Guidance to the investigator was to report these errors as a serious adverse event.

An adverse event suggestive of a medication error event (grade 1 overdose) occurred in 1 subject (2.2%). Time to onset of this event was 9.0 days. This event of overdose was identified as serious that led to study drug interruption, but not treatment discontinuation. The event of overdose was reported to be resolved. No obvious signs or symptoms were present for this subject.

<div style=\"page-break-after: always\"></div>

In  Study  20120216 final  analysis  an  additional  subject  was  reported  to  have  experienced  a  serious medication error event (device infusion issue) that led to study drug interruption.

## · Decreased Immunoglobulins

Adverse events suggestive of decreased immunoglobulin events were identified based on an Amgen MedDRA Query (AMQ), narrow search strategy.

In Study 20120216 primary analysis, 4 subjects (8.9%) were identified with experiencing at least 1 immunoglobulin event; preferred terms for the reported events were hypogammaglobulinaemia (6.7%) and immunoglobulins decreased (2.2%). The median time to the first onset of decreased immunoglobulin events was 105.5 days and all events resolved. None of the events were grade ≥ 3,  serious,  led  to treatment discontinuation or interruption, or were fatal.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 decreased immunoglobulin event was similar. The types of immunoglobulin events reported were consistent among adult subjects with relapsed/refractory ALL, regardless of Philadelphia chromosome status. The median time to first onset of decreased immunoglobulin events for the adult Philadelphia-negative relapsed/refractory ALL studies was 42.0 days.

The rates of grade ≥ 3 decreased immunoglobulin events were comparable for the adult Philadelphiapositive and -negative relapsed/refractory ALL studies. No serious or fatal decreased immunoglobulin events were reported in the Philadelphia-negative relapsed/refractory ALL population.

## · Embolic and Thrombotic Events Including disseminated intravascular coagulation (DIC)

Adverse events suggestive of venous thrombosis and thromboembolic events were based on the narrow search strategy for the MedDRA SMQ Embolic and Thrombotic Events.

In Study 20120216 primary analysis, 3 subjects (6.7%) were identified with experiencing at least 1 embolic  and  thrombotic  event.  Reported  events  (1  of  each)  included  DIC,  thrombosis  in  device, hemiplegia, pulmonary embolism, and peripheral arterial occlusive disease. The median time to first onset of events suggestive of embolic and thrombotic events for Study 20120216 was 175.0 days.

The incidence rate of subjects identified with grade ≥ 3 embolic and thrombotic events was 2 subjects (4.4%), of which 1 event was reported as serious (2.2%). No fatal embolic or thrombotic events were identified in Study 20120216 primary analysis.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 embolic and thrombotic event was similar. The most commonly reported events in the Philadelphia-negative relapsed/refractory population included DIC  (1.1%)  and  deep  vein  thrombosis  1.1%.  The  median  time  to  first  onset  of  the  embolic  and thrombotic event in this population was 22.0 days.

The incidence rates of grade ≥ 3 and serious embolic and thrombotic events were comparable regardless of Philadelphia-chromosome status. Fatal embolic or thrombotic events were reported for 2 subjects (0.4%) in the adult Philadelphia-negative relapsed/refractory ALL studies.

## · Leukoencephalopathy

Data from Amgen Safety Database were reviewed to identify events reported as leukoencephalopathy, as  well  an  additional  review  of  any  serious  neurologic  events  to  identify  any  cases  that  contained descriptive content on magnetic resonance imaging (MRI) or computed tomography findings that might

<div style=\"page-break-after: always\"></div>

identify potential cases of leukoencephalopathy, which were not otherwise reported. In addition, a review of each case was made to determine if the diagnostic criteria for PML were present (clinical presentation, imaging findings, and cerebrospinal fluid PCR positive for John Cunningham Virus (JC Virus) (Keene et al, 2011).

In  Study  20120216  primary  analysis,  1  subject  (2.2%)  was  identified  as  experiencing  a  single leukoencephalopathy event. Time to onset of this event was 23.0 days. The event was not grade ≥ 3 or serious.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the safety profile regarding this AESI was similar.

## · Neutropenia and Febrile Neutropenia

Adverse events suggestive of neutropenia events were based on the AMQ, narrow search strategy.

In  Study  20120216  primary  analysis,  21  subjects  (46.7%)  were  identified  experiencing  at  least  1 neutropenia  event  (Table  46).  Neutropenia  events  (preferred  terms)  included  febrile  neutropenia (40.0%; 18/45), neutropenia (6.7%; 3/45), and neutropenic sepsis (2.2%; 1/45). The median time to first onset of neutropenia events was 3.0 days (Table 47) and all events were resolved.

Serious neutropenia events were identified for 4 subjects (8.9%); the event of febrile neutropenia was reported for all 4 subjects; and neutropenic sepsis in 1 of the subjects. An event of neutropenia in 1 subject led to treatment discontinuation. Events of febrile neutropenia and neutropenic sepsis led to interruption  of  treatment  in  1  subject  each.  No  fatal  neutropenia  events  were  reported  in  Study 20120216.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects with adverse events suggestive of neutropenia or febrile neutropenia was similar (Table 46). The median time to first onset for the adult Philadelphia-negative relapsed/refractory ALL subjects (10.0 days) was longer compared with the adult Philadelphia-positive relapsed/refractory ALL subjects (3.0 days) (Table 47) The rate of febrile neutropenia (by preferred term) was ≥ 10% higher in adult Philadelphia-positive relapsed/refractory ALL subjects compared with adult Philadelphia-negative relapsed/refractory ALL subjects (40.0% versus 24.4%, respectively), whereas the rate of neutropenia was ≥ 10% lower in adult Philadelphia-positive relapsed/refractory ALL subjects compared with adult Philadelphia-negative relapsed/refractory ALL subjects (6.7% versus 18.0%, respectively). Otherwise, the incidence of subjects identified with a neutropenia or febrile neutropenia event (all adverse events, grade ≥ 3, serious events, and fatal events) were comparable between the 2 populations.

## 2.5.2.5. Minimum Critical Toxicities

For  pooled  datasets,  analyses  of  minimum  critical  toxicities  were  conducted  for  the  ALL  pooled population.

## · Bone Marrow Toxicity (Cytopenias)

Adverse events suggestive of bone marrow cytopenia events are based on the narrow search strategy for the MedDRA SMQ Hematopoietic Cytopenias.

<div style=\"page-break-after: always\"></div>

In Study 20120216 primary analysis, 29 subjects (64.4%) were identified with experiencing at least 1 cytopenia  event.  The  most  frequently  identified  cytopenia  events  (preferred  terms)  were  febrile neutropenia (40.0%; 18/45) and thrombocytopenia (22.2%; 10/45).

A total of 24 subjects (53.3%) and 11 subjects (24.4%) were identified with grade ≥ 3 and grade ≥ 4 cytopenia  events,  respectively.  Serious  cytopenia  events  were  reported  for  4  subjects  (8.9%)  and included febrile neutropenia in all 4 subjects, and neutropenic sepsis and pancytopenia in 1 subject each.

An event of neutropenia in 1 subject led to treatment discontinuation. Events of febrile neutropenia and neutropenic sepsis led to interruption of treatment in 1 subject each. No fatal cytopenia events were reported in Study 20120216.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 cytopenia event were similar (64.4% versus 56.8%). The types of cytopenia events reported were similar in both relapsed/refractory populations; however, the event of febrile neutropenia had a higher incidence rate in subjects with Philadelphiapositive relapsed/refractory ALL compared with adult subjects with Philadelphia-negative relapsed/refractory ALL (40.0% versus 24.4%, respectively). The rates of all other cytopenia events were similar between the populations, regardless of chromosome status.

The rates of grade ≥ 3, grade ≥ 4, and serious cytopenia events were also comparable between the 2 relapsed/refractory  populations.  Fatal  bone  marrow  cytopenia  events  were  reported  for  4  subjects (0.8%) in the Philadelphia-negative relapsed/refractory ALL population.

## · Hepatotoxicity

For this variation application, potential hepatotoxicity was assessed similarly to the search strategy use in the initial MAA.

In Study 20120216 primary analysis, 11 subjects (24.4%) with Philadelphia-positive relapsed/refractory ALL were identified with experiencing at least 1 drug-related hepatotoxicity event. The most frequently reported  drug-related  hepatic  disorders  events  ( ≥ 2%  subject  incidence  rate)  were  AST  increased (13.3%),  ALT  increased  (11.1%),  blood  bilirubin  increased  (6.7%),  ascites  (2.2%),  hepatic  failure (2.2%), hepatocellular injury (2.2%), GGT increased (2.2%), and blood fibrinogen increased (2.2%).

The rates of identified grade ≥ 3 and grade ≥ 4 drug-related hepatotoxicity events were 15.6% and 6.7%, respectively. Serious drug-related hepatotoxicity events were identified in 2 subjects (4.4%).

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 drug-related hepatotoxicity event was similar (24.4% versus 29.0%). The types, and most frequently reported drug-related hepatic disorders events, were comparable in both adult relapsed/refractory ALL populations.

The rates of identified grade ≥ 3, grade ≥ 4, and serious drug-related hepatotoxicity events were also similar between the 2 populations, regardless of chromosome status. No fatal drug-related hepatotoxicity events were reported in either populations.

## · Nephrotoxicity

Potential  nephrotoxicity  was  assessed  for  the  adult  relapsed/refractory  ALL  population,  applying  the narrow search of MedDRA SMQ for Acute Renal Failure.

In Study 20120216 primary analysis, 1 subject (2.2%) was identified with experiencing a single acute renal failure event, with the preferred term of renal. The event was not grade ≥ 3 or serious.

<div style=\"page-break-after: always\"></div>

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 acute renal failure event was similar (2.2% versus 5.3%). The most frequently reported acute renal failure event in subjects with Philadelphianegative relapsed/refractory ALL (≥ 2% subject incidence rate) was acute kidney injury (2.8%).

The  rates  of  identified  grade  ≥  3  and  grade  ≥  4  acute  renal  failure  events  were  1.5%  and  0.2%, respectively. Serious acute renal failure events were identified in 5 subjects (0.9%). One fatal acute renal failure event (0.2%) was reported.

## · Arrhythmia, Convulsions, and Torsade de Pointes/QT Prolongation

To  identify  events  suggestive  of  cardiac  arrhythmias,  convulsions,  and  torsade  de  pointes/QT prolongation in the ALL pooled population, MedDRA SMQ narrow search strategies were utilized.

In Study 20120216 primary analysis, 3 subjects (6.7%) with Philadelphia-positive relapsed/refractory ALL were identified with experiencing at least 1 cardiac arrhythmia event; all 3 subjects experienced cardiac arrhythmia event of atrial fibrillation. The rate of identified grade ≥ 3 cardiac arrhythmia events was 2.2%. There were no serious or fatal cardiac arrhythmia events.

No convulsion or Torsade de pointes/QT prolongation events were identified in subjects with Philadelphiapositive relapsed/refractory ALL.

When the Philadelphia-positive and -negative relapsed/refractory ALL populations were compared, the incidence of subjects identified with experiencing at least 1 cardiac arrhythmia event was similar (6.7% versus 9.1%) . The most frequently reported cardiac arrhythmia event in subjects with Philadelphianegative relapsed/refractory ALL ( ≥ 2% subject incidence rate) was sinus tachycardia (5.3%). The rates of identified grade ≥ 3, grade ≥ 4, and serious cardiac arrhythmia events were 1.5%, 0.2%, and 0.9%, respectively. No fatal cardiac arrhythmia events were reported.

A  total  of  17  subjects  (3.2%)  were  identified  experiencing  at  least  1  convulsion  event  in  the  adult Philadelphia-negative relapsed/refractory ALL population. The most frequently reported convulsion event ( ≥ 2% subject incidence rate) was seizure (2.7%). The rates of identified grade ≥ 3,  grade ≥ 4,  and serious convulsion events were 1.5%, 0.2%, and 1.7%, respectively. No fatal convulsion events were reported.

In this  population, 6 subjects (1.1%) were identified experiencing at least 1 Torsade de pointes/QT prolongation event, of which 1 subject (0.2%) was identified as experiencing Torsade de pointes/QT prolongation event of Grade ≥ 3. No fatal Torsade de pointes/QT prolongation events were reported.

## · Immunogenicity

In Study 20120216 primary analysis, 29 subjects (64.4%) had a sample collected for antibody testing after blinatumomab was administered. None of these subjects tested positive for anti-blinatumomab antibodies.

In the Philadelphia-negative relapsed/refractory ALL studies, a total of 7 out of 422 subjects (3 subjects [1.7%]  in  Study  MT103-211,  and  4  subjects  [1.6%]  in  Study  00103311)  tested  positive  for  antiblinatumomab antibodies (Section 11.2 of 00103311 Primary Analysis CSR, EMEA/H/C/003731/II/0009).

To  date,  development  of  anti-drug  antibodies  (ADAs)  has  been  detected  in  9  subjects  across  all blinatumomab  studies.  Of  these  9  subjects,  7  subjects  were  identified  with  ADAs  that  had  in-vitro neutralizing activity. Among the 9 cases, 7 subjects achieved clinical response (CR/complete remission with partial hematological recovery [CRh*]) as defined in the respective protocols.

<div style=\"page-break-after: always\"></div>

Blinatumomab serum concentration levels in 2 out of 9 subjects were reduced.

## 2.5.2.6. Laboratory findings and vital signs

Shifts in grade from study baseline for clinical laboratory evaluations for Study 20120216 and the pooled adult Philadelphia-negative relapsed/refractory ALL population are provided in tables below.

## · Clinical Chemistry

Table 48 : Summary of Worst Clinical Chemistry Laboratory Toxicity Change From Baseline During the Core Study - Change of 3 Grades or More from Blinatumomab ALL Studies (Safety Analysis Set)

|                                       |                       |                               | Adult RIR Ph+ ALL       | Adult R/R Ph- ALL                                     | Pedlatrilc RIR ALL                 | RIR ALL               | Adult MRD+ ALL                      | Tolal                      |
|---------------------------------------|-----------------------|-------------------------------|-------------------------|-------------------------------------------------------|------------------------------------|-----------------------|-------------------------------------|----------------------------|
| Panel Laboratory Parameters CHEMISTRY | Dlrectlon of Toxlelty | Change In qrade from basellne | 20120216 [N - 45] n (%) | MT103-211 MT103-206 00103311(B1ln arm) (N - 528) n(%) | MT103-205 20130320 (N - 133) n (%) | Tolal (N - 706] n (%) | MT103-202 MT103-203 (N = 137) n (%) | All Sludles (N - 843) n(%) |
| Alanlne Amlno Transferase (uiL)       | Increase              | 3                             | 3 (6.7)                 | 25 (4.7)                                              | 10 (7.5)                           | 38 (5.4)              | 5(3.6)                              | 43 (5.1)                   |
|                                       | Increase              | 4                             | 0 (0.0)                 | 2 (0.4)                                               | 1 (0.8)                            | 3 (0.4)               | 1 (0.7)                             | 4 (0.5)                    |
| Albumln (g/L)                         | Decrease              | 3                             | 1 (2.2)                 | 3 (0.6)                                               | 1 (0.8)                            | 5 (0.7)               | 1 (0.7)                             | 6 (0.7)                    |
| Amylase (IU/L)                        | Increase              | 3                             | 0(0.0)                  | 4 (0.8)                                               | 0 (0.0)                            | 4 (0.6)               | 1 (0.7)                             | 5 [0.6]                    |
| Aspartate Amlno Transferase (UIL)     | Increase              | 3                             | 1(2.2)                  | 29 (5.5)                                              | 12 (9.0)                           | 42 (5.9)              | 3(2.2)                              | 45 (5.3)                   |
|                                       | Increase              | 4                             | 1 (2.2)                 | 5 (0.9)                                               | 1 (0.8)                            | 7 (1.0)               | 1 (0.7)                             | 8 (0.9)                    |
| Calclum (Corrected) (mmol/L)          | Decrease              | 3                             | 0 (0.0)                 | 7 (1.3)                                               | 0 (0.0)                            | 7 (1.0)               | 1 (0.7)                             | 8 (0.9)                    |
|                                       | Decrease              | 4                             | 0(0.0)                  | 0 (0.0)                                               | 0 (0.0)                            | 0 (0.0)               | 2 (1.5)                             | 2(0.2)                     |
| Gamma-Glulamyl Transterase (U/L)      | Increase              | 3                             | 2(4.4)                  | 20 (3.8)                                              | 1 (0.8)                            | 23 (3.3)              | 0 (0.0)                             | 23 (2.7)                   |
|                                       | Increase              | 4                             | 0 (0.0)                 | 2 (0.4)                                               | 0 (0.0)                            | 2 (0.3)               | 0 (0.0)                             | 2 (0.2)                    |
| Lpase (IU/L)                          | Increase              | 3                             | 0(0.0)                  | 11 (2.1)                                              | 0 (0.0)                            | 11 (1.6)              | 0 (0.0)                             | 11 (1.3)                   |
|                                       | Increase              | 4                             | 0 (0.0)                 | 2 (0.4)                                               | 0 (0.0)                            | 2 (0.3)               | 0 (0.0)                             | 2 (0.2)                    |
| Potasslum (mmol/L)                    | Decrease              | 3                             | 1 (2.2)                 | 28 (5.3)                                              | 21 (15.8)                          | 50 (7.1)              | 2 (1.5)                             | 52 (6.2)                   |
|                                       | Decrease              | 4                             | 0 (0.0)                 | 2 (0.4)                                               | 3 (2.3)                            | 5 (0.7)               | (0'0] o                             | 5 [0.6)                    |
| Total Bllnubln (umo/L)                | Increase Increase     | 3 4                           | 0 (0.0) 0 (0.0)         | 31 (5.9) 1 (0.2)                                      | 11 (8.3) 0 (0.0)                   | 42 (5.9) 1 (0.1)      | 3 (2.2) 0 (0.0)                     | 45 (5.3) 1 (0.1)           |

Source:Modifed from Table lss-07.3.1

<div style=\"page-break-after: always\"></div>

## · Important Hematology Laboratory Evaluations

Table 49: Summary of Worst Hematology Laboratory Toxicity Change From Baseline During the Core Study - Change of 3 Grades or More for Blinatumomab ALL Studies (Safety Analysis Set)

| Panel Laboratory Parameters       | Dlrectlon of toxlclty   | Chanqe In grade from basellne   | Adult RUR Ph+ ALL 20120216 (N = 45)   | Adull R/R Ph- ALL MT103-211 MT103-206 00103311(B1In am) (N - 528)   | Pedlatrlc RIR ALL. MT103-205 20130320 (N = 133) m(66)   | RUR ALL Tolal (N = 706) n()   | Adult MRD+ ALL MT103-202 MT103-203 (N = 137) n(%)   | All Studles (N - 843) n(6)   |
|-----------------------------------|-------------------------|---------------------------------|---------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------|-------------------------------|-----------------------------------------------------|------------------------------|
| HEMATOLOGY                        |                         |                                 | n(%)                                  | n (6)                                                               |                                                         |                               |                                                     |                              |
| Absolute Lymphocytes (10°IL)      | Decrease Decrease       | 4                               | 17 (37.8) 12 (26.7)                   | 165 (31.3) 133 (25.2)                                               | 41 (30.8) 20 (15.0)                                     | 223 (31.6) 165 (23.4)         | 46 (33.6) 30 (21.9)                                 | 269 (31.9) 195 (23.1)        |
| Absolute Neutrophlls (10°IL)      | Decrease                | 2                               | 8 (17.8)                              | 120 (22.7)                                                          | 33 (24.8)                                               | 128 (18.1)                    | 16 (11.7)                                           | 185 (21.9)                   |
| (10°/L)                           | Decrease                | 4                               | 7 (15.6)                              | 97 (18.4)                                                           | 24 (18.0)                                               | 161 (22.8)                    | 24 (17.5)                                           | 144 ([17.1)                  |
| Absolute Neutrophlls Granulocytes | Decrease                |                                 | 0 (0.0)                               | 35 (6.6)                                                            | 0 (0.0)                                                 | 35 (5.0)                      | 29 (21.2)                                           | 64 (7.6)                     |
| Hemoglobln (g/L)                  | Decrease                | 4                               | 0 (0.0)                               | 25 (4.7)                                                            | 0 (0.0)                                                 | 25 (3.5)                      | 16 (11.7)                                           | 41 (4.9)                     |
|                                   | Decrease                | 2                               | 0 (0.0)                               | 6 ([1.1]                                                            | 14 (10.5)                                               | 20 (2.8)                      | 0 (0.0)                                             | 20 (2.4)                     |
| Neutrophlls (10*lL)               | Decrease                | 4                               | (ool o                                | 0 (0.0)                                                             | 2 (1.5)                                                 | 2 (0.3)                       | 0 (0.0)                                             | 2 (0.2)                      |
|                                   | Decrease                | 3                               | 8 (17.8)                              | 64 (12.1)                                                           | 4 (3.0)                                                 | 76 (10.8)                     | 0 (0.0)                                             | 76 (9.0)                     |
|                                   | Decrease                | 4                               | 7 (15.6)                              | 58 (11.0)                                                           | 5 (3.8)                                                 | 70 (9.9)                      | 0 (0.0)                                             | 70 (8.3)                     |
| Platelets (10HL)                  | Decrease                |                                 | 6 (13.3)                              | 39 (7.4)                                                            | 13 (9.8)                                                | 58 (8.2)                      | 6 (4.4)                                             | 64 (7.6)                     |
|                                   | Decrease                | 4                               | 2 (4.4)                               | 10 (1.9)                                                            | 5 (3.8)                                                 | 17 (2.4)                      | 1 (0.7)                                             | 18 (2.1)                     |
| Whlle Blood Cells (10°IL)         | Decrease                | e                               | 11 (24.4)                             | 103 (19.5)                                                          | 31 (23.3)                                               | 145 (20.5)                    | 15 (10.9)                                           | 160 (19.0)                   |
|                                   | Decrease                | 4                               | 6 [13.3)                              | 63 (11.9]                                                           | 16 (12.0)                                               | 85 (12.0)                     | 6 (4.4)                                             | 91 (10.8)                    |

ALL - acute lymphoblastic leukemla; Blin - bllnatumomab; MRD+ - mlnlmal resldual disease-posiive; Ph- - Phladelphla chromosome-negative; Ph+ - Phlladelphla chromosome-posltive;RuR-relapsedirefractory

Source:Modifledfrom Table lss-07.3.1

## · Coagulation Laboratory Evaluations

In Study 20120216 primary analysis, the median changes in international normalized ratio (INR) from baseline to the end of cycle 1 (cycle 1, day 29) and cycle 2 (cycle 2, day 29) were 0.000 and -0.020, respectively. At the safety follow-up visit, the median change in INR from baseline was -0.040. The median changes in partial thromboplastin time (PTT) from baseline to the end of cycle 1 (cycle 1, day 29) and cycle 2 (cycle 2, day 29) were 3.050 and 3.000, respectively. At the safety follow-up visit, the median change in PTT from baseline was 1.150.

Data regarding changes in fibrinogen values from baseline are not available for Study 20160216.

Pooled data analyses for the adult Philadelphia-negative population are not available for INR and PTT values, as coagulation evaluations were not conducted in Study 00103311.

During the core phase of Study MT103-211 (N = 189), maximum INR value, maximum PTT values, and minimum fibrinogen concentrations were relatively stable over the treatment duration. The following shifts from grade &lt; 3 to grade ≥ 3 in fibrinogen values occurred during the core study: from grade 0 to grade 3 (0.5%; 1/196); from grade 1 to grade 4 (11.1%; 1/9); from grade 2 to grade 3 (20.0%; 1/5). Fibrinogen values were missing for 12 subjects from grade 0 to grade 3 (0.5% [1/196]); from grade 1 to grade 4 (11.1% [1/9]); from grade 2 to grade 3 (20.0% [1/5]). . In Study MT103-206, slight to no fluctuations were noted in coagulation laboratory values from baseline to the end of core study and to the end of follow-up period in subjects overall for prothrombin time/INR, PTT, and for fibrinogen from baseline to end of treatment cycle . Within this population, worsening shifts (decreases) of 3 grades from baseline fibrinogen values occurred in 3 subjects (0.6%). There were no 4 grade shifts from baseline fibrinogen in this population.

<div style=\"page-break-after: always\"></div>

## · Immunoglobulins

Only immunoglobulin G (IgG) evaluations were conducted as part of Study 20120216 primary analysis. Immunoglobulin A (IgA), immunoglobulin E (IgE) and immunoglobulin M (IgM) evaluations were only conducted in 1 Philadelphia-negative relapsed/refractory ALL study (Study MT103-206).

In Study 20120216 primary analysis, the median (range) IgG value at baseline was 5.650 g/L (2.970 to 10.360 g/L).

The median changes in IgG from baseline to the end of cycle 1 (cycle 1, day 29) and cycle 2 (cycle 2, day 29) were -0.850 g/L and -1.310 g/L, respectively. At the safety follow-up visit, the median change in IgG from baseline was -1.380 g/L.

Pooled  data  analyses  regarding  IgG  value  changes  from  baseline  in  the  adult  Philadelphia-negative population are not available. In Study MT103-206, the median (range) IgG baseline value was 5.680 g/L (1.94  to  11.40  g/L)  in  subjects  treated  with  blinatumomab.  The  median  change  in  IgG  value  from baseline to the end of cycle 1 (cycle 1, day 29), was -1.190 g/L (-5.36 to 3.61 g/L). The maximum change from baseline was at the end of cycle 6 (cycle 6, day 29) with a median (range) IgG value of 5.735 g/L (-6.51 to -4.96 g/L).

In Study 00103311, the median (range) IgG baseline value was 6.02 g/L (1.8 to 16.6 g/L) in subjects treated with blinatumomab. The median changes in IgG from baseline to the end of cycle 1 (cycle 1, day 29) and cycle 2 (cycle 2, day 29) were -1.35 g/L and -2.25 g/L, respectively. At the safety follow-up visit, the median change in IgG from baseline was -1.85 g/L. In Study MT103 211, the median minimum IgG concentration at baseline was 6.055 (range: 1.00 to 19.20 g/L). During the core study, IgG values decreased with increasing number of treatment cycles. The nadir of IgG concentration occurred at day 29 of cycle 4, with the lowest median IgG concentration of 2.680 g/L. At the end of the core study, the median minimum IgG concentration was 4.510 g/L.

## · Vital Signs, Physical Findings, and Other Observations Related to Safety

Abnormalities observed during Study 20120216 primary analysis included a high pulse rate in 15.6% of subjects, high or low blood pressure measurements (high systolic blood pressure in 11.1% of subjects, and low systolic blood pressure in 15.6% of subjects; high diastolic blood pressure in 4.4% of subjects and low diastolic blood pressure in 6.7% of subjects), increase or decrease in weight ( ≥ 10% increase from baseline in 11.1% of subjects and ≤ 10% increase from baseline in 6.7% of subjects) and increased body temperature of &gt; 39°C in 11.1% of subjects.

The analysis of vital signs results in the adult Philadelphia-negative relapsed/refractory ALL population is consistent with that previously reported. Compared with the adult Philadelphia-positive relapsed/refractory ALL subjects, this population had a higher incidence rate ( ≥ 10% difference) of body temperature &gt; 39 ° C (20.1% versus 11.1%), and low diastolic blood pressure (23.5% versus 6.7%). With  these  exceptions,  the  vital  sign  results  were  comparable  between  the  2  relapsed/refractory populations.

<div style=\"page-break-after: always\"></div>

## 2.5.2.7. Safety in special populations

The MAH provided TEAEs analysis by subgroup of age, sex, race, region, ECOG performance status, and renal function.

## · Age

In study 20120216, in order to allow comparison despite limited and imbalanced sample size, the MAH provided safety results comparing elderly ( ≥ 65 years; n = 12) and non-elderly (&lt; 65 years; n = 33) subjects in Study 20120216.

Table 50: Summary of Subject Incidence of Treatment-emergent Adverse Events for Age Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

|                                                       | Adult R/R Ph+ ALL        | Adult R/R Ph+ ALL        | Adult R/R Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab amm) (N = 528) n (%) (95% CI)   | Adult R/R Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab amm) (N = 528) n (%) (95% CI)   |
|-------------------------------------------------------|--------------------------|--------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
|                                                       | 65 years (N=33)          | 2 65 years (N = 12)      | 65 years (N = 459)                                                                           | ≥ 65 years (N = 69)                                                                          |
| All treatment-emergent adverse events (95% Cl)        | 33 (100.0) (89.4, 100.0) | 12 (100.0) (73.5, 100.0) | 456 (99.3) (98.1,99.9)                                                                       | 67 (97.1) (89.9, 99.6)                                                                       |
| Grade23                                               | 30 (90.9) (75.7. 98.1)   | 7 (58.3) (27.7, 84.8)    | 382 (83.2) (79.5, 86.5)                                                                      | 61 (88.4) (78.4. 94.9)                                                                       |
| Serious adverse events                                | 22 (66.7) (48.2, 82.0)   | 6 (50.0) (21.1, 78.9)    | 284 (61.9) (57.3,66.3)                                                                       | 51 (73.9) (61.9, 83.7)                                                                       |
| Leading to interruption of investigational product    | 12 (36.4) (20.4, 54.9)   | 4 (33.3) (9.9, 65.1)     | 140 (30.5) (26.3, 34.9)                                                                      | 35 (50.7) (38.4, 63.0)                                                                       |
| Leading to discontinuation of investigational product | 3(9.1) (1.9, 24.3)       | 0 (0.0) (0.0, 26.5)      | 70 (15.3) (12.1, 18.9)                                                                       | 13 (18.8) (10.4, 30.1)                                                                       |
| Fatal adverse events                                  | 5 (15.2) (5.1.31.9)      | 0 (0.0) (0.0, 26.5)      | 78 (17.0) (13.7, 20.7)                                                                       | 13 (18.8) (10.4, 30.1)                                                                       |

ALL = acute lymphoblastic leukemia; Ph+ = Philadelphia chromosome-positive; Ph- = Philadelphia

chromosome negative; R/R = relapsedlrefractory

Severity graded using Common Technical Criteria for Adverse Events v4.03.

Source: Table 11-1, Module 5.3.5.3

<div style=\"page-break-after: always\"></div>

The highest incidence rate of adverse events by SOC was General Disorders and Administration Site Conditions, for both subjects &lt; 65 years of age (28/33 subjects; 84.8%) and subjects ≥ 65 years of age (12/12 subjects; 100.0%). There was no discernable trend or pattern observed for events (by preferred term) that occurred by age.

In Study 20120216, grade ≥ 3 events (by preferred term) of anemia and aplasia occurred more frequently ( ≥ 10% difference) in elderly subjects, whilst febrile neutropenia, pain and ALT increased occurred more frequently in subjects &lt; 65 years of age; however, the 95% CIs overlapped substantially suggesting no statistically significant difference.

Table 51: Grade ≥ 3 Treatment-emergent Adverse Events by System Organ Class and Preferred Term in ≥ 10% of Subjects for Age Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

|                                                      | Adult RIR Ph+ ALL 20120216 (N= 45) n (%) (95% Cl)   | Adult RIR Ph+ ALL 20120216 (N= 45) n (%) (95% Cl)   | Adult RIR Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab am) (N = 528)) n (%) (95% CI)   | Adult RIR Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab am) (N = 528)) n (%) (95% CI)   |
|------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
|                                                      | < 65 years (N= 33)                                  | 265 years (N= 12)                                   | 65 years (N= 459)                                                                            | 2 65 years (N =69)                                                                           |
| Blood and lymphatic system disorders                 | 23 (69.7) (51.3, 84.4)                              | 5 (41.7) (15.2, 72.3)                               | 250 (54.5) (49.8, 59.1)                                                                      | 34 (49.3) (37.0, 61.6)                                                                       |
| Febrile neutropenia                                  | 11 (33.3) (18.0, 51.8)                              | 1 (8.3) (0.2, 38.5)                                 | 102 (22.2) (18.5, 26.3)                                                                      | 14 (20.3) (11.6, 31.7)                                                                       |
| Thrombocytopenia                                     | 7 (21.2) (9.0, 38.9)                                | 3 (25.0) (5.5, 57.2)                                | 59 (12.9) (9.9, 16.3)                                                                        | 6 (8.7) (3.3, 18.0)                                                                          |
| Anaemia                                              | 4(12.1) (3.4, 28.2)                                 | 3 (25.0) (5.5, 57.2)                                | 76 (16.6) (13.3, 20.3)                                                                       | 10 (14.5) (7.2. 25.0)                                                                        |
| Neutropenia                                          | 3 (8.1) (1.9, 24.3)                                 | 0 (0.0) (0.0, 26.5)                                 | 74 (16.1) (12.9, 19.8)                                                                       | 12 (17.4) (9.3, 28.4)                                                                        |
| Congenital, familial and genetic                     | 0 (0.0) (0.0, 10.6)                                 | 2 (16.7) (2.1, 48.4)                                | 6 (1.3) (0.5, 2.8)                                                                           | 0 (0.0) (0.0, 5.2)                                                                           |
| Aplasia                                              | 0 (0.0) (0.0, 10.6)                                 | 2 (16.7) (2.1, 48.4)                                | 4 (0.9) (0.2, 2.2)                                                                           | 0 (0.0) (0.0, 5.2)                                                                           |
| General disorders and administration site conditions | 9 (27.3) (13.3, 45.5)                               | 2 (16.7) (2.1, 48.4)                                | 77 (16.8) (13.5, 20.5)                                                                       | 14 (20.3) (11.6, 31.7)                                                                       |
| Pain                                                 | 4 (12.1) (3.4, 28.2)                                | 0 (0.0) (0.0, 26.5)                                 | 8 (1.7) (0.8, 3.4)                                                                           | 0 (0.0) (0.0, 5.2)                                                                           |
| Pyrexia                                              | 4 (12.1) (3.4, 28.2)                                | 1 (8.3) (0.2, 38.5)                                 | 37 (8.1) (5.7, 10.9)                                                                         | 4 (5.8) (1.6, 14.2)                                                                          |
| Infections and infestations                          | 9 (27.3) (13.3, 45.5)                               | 2 (16.7) (2.1, 48.4)                                | 157 (34.2) (29.9, 38.7)                                                                      | 26 (37.7) (26.3, 50.2)                                                                       |
| Device related infection                             | 3 (9.1) (1.9, 24.3)                                 | 0 (0.0) (0.0, 26.5)                                 | 14 (3.1) (1.7. 5.1)                                                                          | 7 (10.1) (4.2, 19.8)                                                                         |
| Investigations                                       | 8 (24.2) (11.1, 42.3)                               | 1 (8.3) (0.2, 38.5)                                 | 115 (25.1) (21.2, 29.3)                                                                      | 14 (20.3) (11.6, 31.7)                                                                       |
| Alanineaminotransferase increased                    | 5 (15.2) (5.1. 31.9)                                | 0 (0.0) (0.0, 26.5)                                 | 28 (6.1) (4.1, 8.7)                                                                          | 3 (4.3) (0.9. 12.2)                                                                          |
| Aspartate aminotransferase increased                 | 4 (12.1) (3.4. 28.2)                                | 1 (8.3) (0.2, 38.5)                                 | 18 (3.9) (2.3, 6.1)                                                                          | 2 (2.9) (0.4. 10.1)                                                                          |

ALL = acute lymphoblastic leukemia; Ph+=Philadelphia chromosome-positive; Ph-=Philadelphia chromosome negative; RuR = relapsedirefractory

Safety Analysis Set: All subjects who received at least 1 infusion of blinatumomab.

Adverse events coded using MedDRA version 18.1

Source: Modified from Table 11-3, Module 5.3.5.3

<div style=\"page-break-after: always\"></div>

Table 52: Treatment-emergent Adverse Events of Interest by Category and Preferred Term with Subject Incidence of ≥ 10% for any Age Subgroup - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

<!-- image -->

|                              | Adult R/R Ph+ ALL      | Adult R/R Ph+ ALL     | Adult R/R Ph- ALL                              | Adult R/R Ph- ALL                              |
|------------------------------|------------------------|-----------------------|------------------------------------------------|------------------------------------------------|
|                              | 20120216               | 20120216              | MT103-211 MT103-206 00103311 (Blinatumomab am) | MT103-211 MT103-206 00103311 (Blinatumomab am) |
|                              | (N= 45)                | (N= 45)               | (N = 528)                                      | (N = 528)                                      |
|                              | n (%6) (95% C1)        | n (%6) (95% C1)       | n (%) (95% C1)                                 | n (%) (95% C1)                                 |
| Event of Interest Category   | < 65 years             | 2 65 years            | 65 years                                       | ≥ 65 years                                     |
| Prefered Tem                 | N= 33                  | N= 12                 | N = 459                                        | N = 69                                         |
| Number of subjects reporting | 32 (97.0)              | 12 (100.0)            | 447 (97.4)                                     | 65 (94.2)                                      |
| Treatment Emergent Adverse   |                        | (73.5, 100.0)         |                                                |                                                |
|                              | (84.2, 99.9)           |                       | (95.5, 98.6)                                   | (85.8, 08.4)                                   |
| Event of Interest            | 4 (12.1)               | 0 (0.0)               | 62 (13.5) (10.5, 17.0)                         | 13 (18.8) (10.4, 30.1)                         |
| Cytokine release symdrome    | (3.4, 28.2) 3 (9.1)    | (0.0, 26.5)           | 56 (12.2)                                      | 12 (17.4)                                      |
| Cytokine release syndrome    |                        | 0 (0.0)               |                                                | (9.3, 28.4)                                    |
|                              | (1.9, 24.3)            | (0.0, 26.5)           | (9.3, 15.5)                                    |                                                |
| Decreased immunoglobulins    | 3 (9.1)                | 1 (8.3)               | 55 (12.0)                                      | 7 (10.1)                                       |
|                              | (1.8, 24.3)            | (0.2, 38.5)           | (9.2. 15.3)                                    | (4.2, 19.8)                                    |
| Elevated Liver Enzyme        | 7 (21.2)               |                       |                                                | (8.2, 26.7)                                    |
|                              | (9.0, 38.9)            | 1 (8.3) (0.2, 38.5)   | 110 (24.0) (20.1, 28.1)                        | 11 (15.9)                                      |
| Alanine aminotransferase     | 5 (15.2)               | 0 (0.0)               | 49 (10.7)                                      | 7 (10.1)                                       |
| increased                    | (5.1, 31.9)            | (0.0, 26.5)           | (8.0, 13.9)                                    | (4.2. 19.8)                                    |
| Aspartate aminotransferase   | 5 (15.2)               | 1 (8.3)               | 40 (8.7)                                       | 7 (10.1)                                       |
| increased                    | (5.1, 31.9)            | (0.2, 38.5)           | (6.3, 11.7)                                    | (4.2, 19.8)                                    |
| Embolic and thromboembolic   | 2 (6.1)                | 1 (8.3)               | 33 (7.2)                                       | 9 (13.0)                                       |
|                              |                        | (0.2, 38.5)           |                                                | [6.1, 23.3]                                    |
| events (including DIC)       | (0.7, 20.2)            |                       | (5.0, 9.9)                                     |                                                |
| Infections (continued)       | 17 (51.5)              | 5 (41.7)              | 296 (64.5)                                     | 42 (60.9)                                      |
|                              | (33.5, 69.2)           | (15.2, 72.3)          | (59.9, 68.9]                                   | (48.4, 72.4)                                   |
| Device related infection     | 5 (15.2)               | 0 (0.0)               | 22 (4.8)                                       | 8 (11.6)                                       |
|                              | (5.1, 31.9)            | (0.0, 26.5)           | (3.0, 7.2)                                     | (5.1, 21.6)                                    |
| Urinary tract infection      | 4 (12.1)               | 0 (0.0)               | 15 (3.3)                                       | 7 (10.1)                                       |
|                              | (3.4, 28.2)            | (0.0, 26.5)           | (1.8, 5.3)                                     | (4.2. 19.8)                                    |
| Staphylococcal infection     | 1 (3.0)                | 2 (16.7)              | 13 (2.8)                                       | 0 (0.0)                                        |
|                              | (0.1, 15.8)            | (2.1, 48.4)           | (1.5, 4.8)                                     | (0.0, 5.2)                                     |
| Oral candidiasis             | 0 (0.0)                | 2 (16.7)              | 11 (2.4)                                       | 2 (2.9)                                        |
| Infusion reactions (without  | (0.0, 10.6)            | (2.1, 48.4) 9(75.0)   | (1.2,4.2) 226 (49.2)                           | (0.4, 10.1) 42 (60.9)                          |
| considering duration)        | 13 (39.4) (22.9, 57.9) | (42.8, 04.5)          | (44.6, 53.9)                                   | (48.4, 72.4)                                   |
| Pyrexia                      | 10 (30.3)              | 8 (66.7)              | 178 (38.8)                                     | 33 (47.8)                                      |
|                              |                        | (34.9, 90.1)          | (34.3,43.4)                                    |                                                |
| Cyiokine release syndrome    | (15.6,48.7)            |                       | 42 (9.2)                                       | (35.6, 60.2) 11 (15.9)                         |
|                              | 1 (3.0)                | 0 (0.0)               | (6.7, 12.2)                                    | (8.2, 26.7)                                    |
|                              | (0.1, 15.8)            | (0.0, 26.5)           |                                                | 51 (73.9)                                      |
| Neurologic Events            | 20 (60.6)              | 8 (66.7)              | 302 (65.8) (61.3, 70.1)                        | (61.9. 83.7)                                   |
| Headache                     | (42.1, 77.1) 12 (36.4) | (34.9, 90.1) 2 (16.7) | 157 (34.2)                                     | 15 (21.7)                                      |
|                              |                        | (2.1, 48.4)           | (29.9, 38.7                                    |                                                |
|                              | (20.4, 54.9)           |                       | 26 (5.7)                                       | (12.7, 33.3) 2 (2.9)                           |
| Paraesthesia                 | 6 (18.2)               | 0 (0.0)               | (3.7, 8.2)                                     | (0.4, 10.1)                                    |
| Confusional state            | (7.0, 35.5) 2 (6.1)    | (0.0, 26.5) 3 (25.0)  | 22 (4.8)                                       | 5 (7.2)                                        |
|                              | (0.7,20.2)             | (5.5, 57.2)           | (3.0, 7.2)                                     | (2.4, 16.1)                                    |
| Dizziness                    | 2 (6.1)                | 2 (16.7)              | 42 (9.2)                                       | 10 (14.5)                                      |
|                              | (0.7, 20.2)            | (2.1, 48.4)           | (6.7. 12.2)                                    | (7.2, 25.0)                                    |
| Tremor                       | 2 (6.1)                | 2 (16.7)              | 65 (14.2)                                      | 10 (14.5)                                      |
|                              | (0.7. 20.2)            | (2.1, 48.4)           | (11.1, 17.7)                                   | (7.2,25.0)                                     |
| Aphasia                      | 1 (3.0)                | 1 (8.3)               | 10 (2.2)                                       | 7 (10.1)                                       |
|                              | (0.1, 15.8)            | (0.2,38.5)            | (1.1, 4.0)                                     | (4.2, 19.8)                                    |
| Insomnia                     | 1 (3.0)                | 2 (16.7)              | 52 (11.3)                                      | 9 (13.0)                                       |
|                              |                        |                       | (8.6, 14.6)                                    |                                                |
| Encephalopathy               | (0.1, 15.8) 0 (0.0)    | (2.1, 48.4) 1 (8.3)   | 10 (2.2)                                       | (6.1, 23.3) 8 (11.6)                           |
|                              |                        |                       | (1.1, 4.0)                                     |                                                |
|                              | (0.0, 10.6) 0 (0.0)    | (0.2, 38.5) 2 (16.7)  | 4 (0.9)                                        | (5.1, 21.6) 1 (1.4)                            |
| Nenvous system disorder      |                        |                       |                                                |                                                |
| Somnolence                   | (0.0, 10.6)            | (2.1, 48.4)           | (0.2,2.2)                                      | (0.0, 7.8)                                     |
|                              | 0 (0.0)                | 0 (0.0)               | 18 (3.9)                                       | 7 (10.1)                                       |
|                              | (0.0, 10.6)            | (0.0, 26.5)           | (2.3, 6.1)                                     | (4.2, 19.8)                                    |
| Neutropenia and Febrile      | 19 (57.6)              | 2 (16.7)              | 188 (41.0)                                     | 25 (36.2)                                      |
|                              |                        | (2.1, 48.4)           |                                                |                                                |
| neutropenia                  | (39.2.74.5)            |                       | [36.4,45.6)                                    | (25.0, 48.7)                                   |
| Febrile neutropenia          | 16 (48.5) (30.8, 66.5) | 2 (16.7) (2.1,48.4)   | 115 (25.1) (21.2, 29.3)                        | 14 (20.3) (11.6, 31.7)                         |
| Neutropenia                  | 3 (9.1) (1.9, 24.3)    | 0 (0.0) (0.0, 26.5)   | 83 (18.1) (14.7,21.9)                          | 12 (17.4) (9.3, 28.4)                          |

ALL = acute lymphoblastic leukemia; DIC = disseminated intravascular coagulation; Ph+ = Philadelphia chromosome-positive; Ph- = Philadelphia chromosome-negative; R/R = relapsed/refractory. Safety analysis set: All subjects who received at least one infusion of blinatumomab. Severily graded using Common Technical Criteria for Adverse Events v4.03. Source: Modified from Table 11-8, Module 5.3.5.3

Page 2 of 2

<div style=\"page-break-after: always\"></div>

## · Sex

Subgroup analysis was provided by sex, for study 20120216 and pooled adult RR ALL Phi neg patients, as summarized in tables below.

For study 20120216, the highest incidence rate of adverse events by SOC was General Disorders and Administration Site Conditions, for both male and female subjects (21/24 subjects; 87.5% and 19/21 subjects; 90.5%, respectively).

For serious adverse events by SOC, the highest incidence rate in male subjects was in Infections and Infestations (6/24 subjects; 25.0%), driven by PTs device related infection and sepsis (2/24 subjects; 8.3% for each). The highest incidence rate of serious adverse events by SOC in female subjects was observed in General Disorders and Administration Site Conditions and Nervous System Disorders (5/21 subjects; 23.8% for each), driven by non-cardiac chest pain and tremor, respectively ((2/21 subjects; 9.5% for each PT).

Table 53: Summary of Subject Incidence of Treatment-emergent Adverse Events for Sex Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

|                                                       | Adult R/R Ph+ ALL        | Adult R/R Ph+ ALL        | Adult R/R Ph-ALL MT103-211 MT103-206 00103311(Blinatumomab arm) (N=528) n (%6) (95% C1)   | Adult R/R Ph-ALL MT103-211 MT103-206 00103311(Blinatumomab arm) (N=528) n (%6) (95% C1)   |
|-------------------------------------------------------|--------------------------|--------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|                                                       | Female (N= 21)           | Male (N = 24)            | Female (N = 208)                                                                          | Male (N = 320)                                                                            |
| All treatment-emergent adverse events (95% C1)        | 21 (100.0) (83.9. 100.0) | 24 (100.0) (85.8, 100.0) | 207 (99.5) (97.4. 100.0)                                                                  | 316 (98.8) (96.8, 99.7)                                                                   |
| Grade 23                                              | 17 (81.0) (58.1, 94.6)   | 20 (83.3) (62.6, 95.3)   | 177 (85.1) (79.5, 89.6)                                                                   | 266 (83.1) (78.6, 87.1)                                                                   |
| Serious adverse events                                | 14 (66.7) (43.0, 85.4)   | 14 (58.3) (36.6, 77.9)   | 132 (63.5) (56.5,70.0)                                                                    | 203 (63.4) (57.9, 68.7)                                                                   |
| Leading to intemuption of investigational product     | 9 (42.9) (21.8, 66.0)    | 7 (29.2) (12.6, 51.1)    | 78 (37.5) (30.9,44.5)                                                                     | 97 (30.3) (25.3, 35.7)                                                                    |
| Leading to discontinuation of investigational product | 2 (9.5) (1.2, 30.4)      | 1 (4.2) (0.1, 21.1)      | 34 (16.3) (11.6, 22.1)                                                                    | 49 (15.3) (11.5, 19.7)                                                                    |
| Fatal adverse events                                  | 3 (14.3) (3.0, 36.3)     | 2 (8.3) (1.0, 27.0)      | 29 (13.9) (9.5. 19.4)                                                                     | 62 (19.4) (15.2, 24.1)                                                                    |

chromosome-negative; R/R = relapsed/refractory

ALL = acute lymphoblastic leukemia; Ph+ = Philadelphia chromosome-positive; Ph- = Philadelphia

Safety Analysis Set: All subjects who received at least 1 infusion of blinatumomab.

Severily graded using Common Technical Criteria for Adverse Events v4.03.

Source: Table 12-1, Module 5.3.5.3

<div style=\"page-break-after: always\"></div>

Table 54: Grade ≥ 3 Treatment-emergent Adverse Events by System Organ Class and Preferred Term in ≥ 10% of Subjects for Sex Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

|                                                | Adult R/RPh+ALL 20120216 (N=45)   | Adult R/RPh+ALL 20120216 (N=45)   | Adult R/R Ph-ALL MT103-211 MT103-206 00103311 (Blinatumomab am) (N= 528)   | Adult R/R Ph-ALL MT103-211 MT103-206 00103311 (Blinatumomab am) (N= 528)   |
|------------------------------------------------|-----------------------------------|-----------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
|                                                | Female (N= 21)                    | n (%6) (95% C1) Male (N= 24)      | Female (N= 208)                                                            | n (%6) (95% C1) Male (N= 320)                                              |
| Blood and lymphatic system disorders           | 12 (57.1) (34.0, 78.2)            | 16 (66.7) [44.7.84.4)             | 114 (54.8) (47.8, 61.7)                                                    | 170 (53.1) (47.5, 58.7)                                                    |
| Febrile neutropenia                            | 6 (28.6) (11.3, 52.2)             | 6 (25.0) (9.8, 46.7)              | 43 (20.7) (15.4, 26.8)                                                     | 73 (22.8) (18.3, 27.8)                                                     |
| Thrombocytopenia Anaemia                       | 4 (19.0) (5.4, 41.9) 2 (9.5)      | 6 (25.0) (9.8, 46.7) 5 (20.8)     | 31 (14.9) (10.4, 20.5) 40 (19.2)                                           | 34 (10.6) (7.5, 14.5) 46 (14.4)                                            |
| Neutropenia                                    | (1.2, 30.4) 1 (4.8)               | (7.1, 42.2) 2 (8.3) (1.0, 27.0)   | (14.1, 25.3) 35 (16.8)                                                     | (10.7, 18.7) 51 (15.9)                                                     |
| General disorders and                          | (0.1, 23.8)                       |                                   | (12.0, 22.6) 36 (17.3)                                                     | (12.1, 20.4)                                                               |
| administration site conditions Pain            | 7 (33.3) (14.6, 57.0) 3 (14.3)    | 4 (16.7) (4.7, 37.4) 1 (4.2)      | (12.4, 23.1) 5 (2.4)                                                       | 55 (17.2) (13.2, 21.8) 3 (0.9)                                             |
|                                                | (3.0, 36.3) 3 (14.3)              | (0.1, 21.1) 2 (8.3)               | (0.8, 5.5) 15 (7.2)                                                        | (0.2, 2.7) 26 (8.1)                                                        |
| Pyrexia                                        | (3.0, 36.3) 4 (19.0)              | (1.0, 27.0) 7 (29.2)              | (4.1, 11.6) 67 (32.2)                                                      | (5.4, 11.7)                                                                |
| Infections and Infestations Investigations     | (5.4, 41.9) 7 (33.3)              | (12.6, 51.1) 2 (8.3)              | (25.8, 39.0) 49 (23.6)                                                     | 116 (36.3) (31.0, 41.8) 80 (25.0)                                          |
| Alanine aminotransferase                       | (14.6, 57.0) 4 (19.0)             | (1.0, 27.0) 1 (4.2)               | (18.0, 29.9) 13 (6.3)                                                      | (20.4, 30.1) 18 (5.6)                                                      |
| increased Aspartate aminotransferase increased | (5.4,41.9) 4 (19.0)               | (0.1, 21.1) 1 (4.2)               | (3.4, 10.5) 14 (6.7)                                                       | (3.4, 8.7) 6 (1.9)                                                         |
| Metabolism and nutrition disorders             | (5.4,41.9) 3 (14.3)               | (0.1, 21.1)                       | (3.7, 11.0) 36 (17.3)                                                      | (0.7, 4.0)                                                                 |
|                                                | (3.0, 36.3)                       | 1 (4.2) (0.1, 21.1)               | (12.4, 23.1)                                                               | 65 (20.3) (16.0, 25.1)                                                     |
| tissue disorders                               | 2 (9.5)                           | 3 (12.5) (2.7, 32.4)              | 17 (8.2) (4.8, 12.8)                                                       | 29 (9.1)                                                                   |
| Musculoskeletal and connective                 | (1.2, 30.4)                       | 3 (12.5)                          | 32 (15.4)                                                                  | (6.2, 12.8)                                                                |
| Nervous system disorders                       | 4 (19.0)                          |                                   |                                                                            | 35 (10.9) (7.7.14.9)                                                       |
| Headache                                       | (5.4, 41.9)                       | (2.7, 32.4)                       | (10.8, 21.0)                                                               | 3(0.9)                                                                     |
|                                                | (00)0                             | 3 (12.5)                          | 7 (3.4)                                                                    |                                                                            |
| Respiratory. thoracic and                      | (0.0, 16.1)                       | (2.7, 32.4) 2 (8.3)               | (1.4, 6.8) 14 (6.7)                                                        | (0.2, 2.7)                                                                 |
| mediastinal disorders                          |                                   |                                   |                                                                            | 23 (7.2)                                                                   |
|                                                | 3 (14.3)                          |                                   |                                                                            |                                                                            |
|                                                | (3.0, 36.3)                       | (1.0, 27.0)                       | (3.7, 11.0)                                                                | (4.6, 10.6)                                                                |

chromosome-negative; R/R = relapsed/refractory

ALL = acute lymphoblastic leukemia; Ph+ = Philadelphia chromosome-positive; Ph- = Philadelphia

Safety Analysis Set: All subjects who received at least 1 infusion of blinatumomab.

Source: Modified from Table 12-3, Module 5.3.5.3

Adverse events coded using MedDRA version 18.1

## · Race

For Study 20120216 primary analysis, the sample sizes among the race categories for this subgroup analysis were imbalanced; 39 subjects (86.7%) were white and 6 subjects (13.3%) were other races (not otherwise specified). Further analyses by race were not possible for this population, due to the small sample size.

In the adult Philadelphia-negative relapsed/refractory ALL population, the sample sizes among the race categories were also imbalanced; 432 subjects (81.8%) were white and 96 subjects (18.2%) were other races. Although imbalances were observed, there were no differences of ≥ 10% in the rate of adverse events between the races.

## · Region

<div style=\"page-break-after: always\"></div>

For  Study  20120216  primary  analysis,  the  sample  sizes  among  the  regions  for  this  analysis  were imbalanced; 11 subjects (24.4%) were from the US and 34 subjects (75.6%) were from Europe. Subjects from the US, compared with subjects from Europe, had ≥ 10% higher incidence rates of grade ≥ 3 adverse events,  serious  adverse  events,  events  leading to  treatment  interruption,  and  fatal  adverse  events; however, the 95% CIs overlapped substantially suggesting no statistically significant difference. Rates of events leading to treatment discontinuation were comparable for subjects from the US and Europe.

Grade ≥ 3  events  occurring  with  a ≥ 10%  difference  between  regions  for  Philadelphia-positive relapsed/refractory ALL subjects included febrile neutropenia, anemia, leukocytosis, pain, device-related infection, sepsis, ALT increased, AST increased, platelet count decreased, WBC count decreased and respiratory failure (occurred more frequently in the US), and thrombocytopenia and pyrexia (occurred more frequently in Europe). Two serious events occurred with a ≥ 10% difference between subjects in the US and Europe (device-related infection [18.2%; 95% CI: 2.3, 51.8 versus 2.9%; 95% CI: 0.1, 15.3] and respiratory failure [18.2%; 95% CI: 2.3, 51.8 versus 0%; 95% CI: 0, 10.3The 95% CIs overlapped substantially for the above comparisons suggesting no statistically significant difference.

Table 55: Summary of Subject Incidence of Treatment-emergent Adverse Events by Region Subgroups Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

|                                                       | Adult R/R Ph+ ALL        | Adult R/R Ph+ ALL        | Adults R/R Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab amm) (N = 528)   | Adults R/R Ph- ALL MT103-211 MT103-206 00103311 (Blinatumomab amm) (N = 528)   |
|-------------------------------------------------------|--------------------------|--------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
|                                                       | US (N = 11)              | Europe (N= 34)           | US (N = 139)                                                                   | Europe (N = 329)                                                               |
| All treatment-emergent adverse events                 | 11 (100.0) (71.5, 100.0) | 34 (100.0) (89.7, 100.0) | 139 (100.0) (97.4, 100.0)                                                      | 325 (98.8) (96.9, 99.7]                                                        |
| Grade 2 3                                             | 10 (90.9) (58.7, 99.8)   | 27 (78.4) (62.1, 91.3)   | 123 (88.5) (82.0, 93.3)                                                        | 264 (80.2) (75.5, 84.4)                                                        |
| Serious adverse events                                | 8 (72.7) (39.0, 94.0)    | 20 (58.8) (40.7, 75.4)   | 96 (69.1) (60.7, 76.6)                                                         | 193 (58.7) (53.1, 64.0)                                                        |
| Leading to interuption of investigational             | 5 (45.5) (16.7, 76.6)    | 11 (32.4) (17.4, 50.5)   | 49 (35.3) (27.3, 43.8)                                                         | 103 (31.3) (26.3, 36.6)                                                        |
| Leading to discontinuation of investigational product | 1 (9.1) (0.2, 41.3)      | 2 (5.9) (0.7, 19.7)      | 24 (17.3) (11.4, 24.6)                                                         | 53 (16.1) (12.3, 20.5)                                                         |
| Fatal adverse events                                  | 3 (27.3) (6.0, 61.0)     | 2 (5.9) (0.7, 19.7)      | 27 (19.4) (13.2, 27.0)                                                         | 51 (15.5) (11.8, 19.9)                                                         |

Safety Analysis Set: All subjects who received at least 1 infusion of blinatumomab.

ALL = acute lymphoblastic leukemia; Ph+ = Philadelphia chromosome-positive; Ph- = Philadelphia chromosome-negative; R/R = relapsed/refractory

Severily graded using Common Technical Criteria for Adverse Events v4.03.

Source: Table 13-1, Module 5.3.5.3

60 subjects from the rest of wodd in Adult R/R Ph- ALL are not included in the table.

<div style=\"page-break-after: always\"></div>

Table 56: Grade ≥ 3 Treatment-emergent Adverse Events by System Organ Class and Preferred Term in ≥ 10% of Subjects for Region Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

|                                                                                          | Adult RIR Ph+ ALL 20120216       | Adult RIR Ph+ ALL 20120216            | Adult RIR Ph- ALL MT103-211 MT103-206 00103311 (Blnatumomab amm) (N=528) n (%) (95% C1)   | Adult RIR Ph- ALL MT103-211 MT103-206 00103311 (Blnatumomab amm) (N=528) n (%) (95% C1)   |
|------------------------------------------------------------------------------------------|----------------------------------|---------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|                                                                                          | US (N - 11)                      | Europe (N- 34]                        | US (N- 139)                                                                               | Europe (N- 329]                                                                           |
| Blood and lymphatic system                                                               | 10 (90.9)                        | 18 (52.9)                             | 75 (54.0)                                                                                 | 175 (53.2)                                                                                |
| dlsorders                                                                                | (58.7, 99.8)                     | (35.1, 70.2)                          | (45.3, 62.4]                                                                              | (47.6, 58.7)                                                                              |
| Febrle neutropenla                                                                       | 6 (54.5) (23.4, 83.3]            | 6 (17.6) [6.8, 34.5]                  | 46 (33.1) (25.4, 41.6)                                                                    | 53 (16.1) (12.3, 20.5)                                                                    |
| Anaemla                                                                                  | 3(27.3) (6.0, 61.0]              | 4 (11.8) [(3.3, 27.5]                 | 17 (12.2) (7.3, 18.9)                                                                     | 61 (18.5) (14.5, 23.2)                                                                    |
| Leukocytosls                                                                             | 2 (18.2) (2.3, 51.8) 1(9.1)      | 1(2.9) (0.1, 15.3) 9 (26.5)           | 2[1.4] (0.2, 5.1) 18 (12.9) (7.9, 19.7)                                                   | 5 (1.5) (0.5, 3.5)                                                                        |
| Thrombocytopenla Neutropenla                                                             | (0.2,41.3) 0 (0.0)               | (12.9, 44.4) 3[8.8) (1.9, 23.7)       | 20 (14.4) (9.0, 21.3)                                                                     | 44 ([13.4) (9.9, 17.5)                                                                    |
| Paln                                                                                     | (0.0, 28.5) 2 (18.2) (2.3, 51.8) | 9 (26.5) (12.9, 44.4)                 | 2(1.4)                                                                                    | 56 (17.0)                                                                                 |
| General dlsorders and admlnlstratlon slte condlilons                                     |                                  | 2 (5.9)                               | 24 (17.3) (11.4, 24.6)                                                                    | 56 (17.0) (13.1, 21.5)                                                                    |
| Pyrexla                                                                                  | 0(0.0)                           | 5 (14.7)                              | 6 [4.3]                                                                                   | 4 (1.2) (0.3, 3.1)                                                                        |
|                                                                                          | (2.3, 51.8)                      | (0.7, 19.7)                           | (0.2, 5.1)                                                                                | (13.1, 21.5)                                                                              |
|                                                                                          | 2 (18.2)                         |                                       |                                                                                           |                                                                                           |
|                                                                                          |                                  |                                       |                                                                                           | 32 (9.7)                                                                                  |
|                                                                                          | (0.0, 28.5)                      | (5.0, 31.1)                           | (1.6, 9.2)                                                                                | (6.7, 13.5)                                                                               |
| InfectlonsandInfestatlons                                                                | 5 (45.5) (16.7, 76.6)            | 6 (17.6)                              | 51 (36.7)                                                                                 | 107 (32.5) (27.5, 37.9)                                                                   |
| Devlce related Infecilon                                                                 | 2 (18.2) (2.3, 51.8)             | (6.6, 34.5] 1 (2.9) (0.1, 15.3)       | (28.7, 45.3) 5 (3.6)                                                                      | 12 (3.6) (1.9,6.3)                                                                        |
| Sepsls                                                                                   | 2 (18.2) (2.3, 51.8)             | 2(5.9) (0.7, 19.7)                    | (1.2, 8.2) 10 (7.2)                                                                       | 14 (4.3) (2.3, 7.0)                                                                       |
| Investlgatlons                                                                           | 6 (54.5) (23.4, 83.3) 4 (36.4)   | 3(8.8] (1.9, 23.7)                    | (3.5, 12.8)                                                                               | 64 (19.5) (15.3, 24.2)                                                                    |
| Increased Alanineaminotransferase Increased                                              | 3 (27.3) (6.0, 61.0)             | 2(5.9) (0.7, 19.7)                    | 11 (7.9)                                                                                  | 8 (2.4) (1.1, 4.7)                                                                        |
| Aspariale amlnotransferase                                                               | (10.9, 69.2)                     | 1.(2.9) (0.1, 15.3)                   | 45 (32.4) [24.7, 40.8)                                                                    |                                                                                           |
|                                                                                          | 2 (18.2)                         | 0(0.0)                                | (7.9, 19.7) 4 (2.9) (0.8, 7.2)                                                            | 9 (2.7)                                                                                   |
| Platelet count decreased                                                                 |                                  | (0.0, 10.3)                           | (4.0, 13.7) 18 (12.9)                                                                     | 10 (3.0) (1.5,5.5)                                                                        |
| Vascular dlsorders                                                                       | 1 (9.1)                          | 2(5.9) (0.7, 19.7) 0(0.0) (0.0, 10.3) | 53 (38.1) 18 (12.9) (7.9, 19.7) 17 (12.2) (7.3, 18.9]                                     | (1.3, 5.1) 14 (4.3)                                                                       |
| tlssue dlsorders Nervous system dlsorders Resplralory.thoraclc and medlastinal dlsorders |                                  | (5.0, 31.1)                           | (0.2, 5.1) 22 (15.8)                                                                      | 38 (11.6)                                                                                 |
| decreased                                                                                | 2 (18.2) [2.3, 51.8]             | 2(5.9) (0.7, 19.7)                    | (3.0, 11.9)                                                                               |                                                                                           |
|                                                                                          |                                  | [0.0, 10.3]                           | 9(6.5)                                                                                    |                                                                                           |
|                                                                                          | (2.3, 51.8) 2 (18.2)             |                                       |                                                                                           | (2.3, 7.0)                                                                                |
| Whlte blood cell count                                                                   |                                  | 0 (0.0)                               |                                                                                           |                                                                                           |
|                                                                                          | (2.3, 51.8) 2 (18.2)             |                                       |                                                                                           |                                                                                           |
| Metabollsm and nutrilondlsorders                                                         | (2.3, 51.8)                      |                                       | (30.0, 46.7)                                                                              | (8.3, 15.5)                                                                               |
| Hyperglycaemla                                                                           | 0 (0.0)                          | 0(0.0) [0.0, 10.3]                    |                                                                                           | 4 (1.2)                                                                                   |
|                                                                                          | (0.0, 28.5)                      |                                       |                                                                                           | (0.3, 3.1)                                                                                |
|                                                                                          |                                  | 3 (8.8) (1.9, 23.7]                   |                                                                                           | 24 (7.3)                                                                                  |
| Musculoskeletal andconneclve                                                             |                                  |                                       |                                                                                           |                                                                                           |
|                                                                                          |                                  |                                       | 18 (12.9)                                                                                 |                                                                                           |
|                                                                                          |                                  | 5 (14.7)                              |                                                                                           | (4.7, 10.7]                                                                               |
|                                                                                          | 2 (18.2) (2.3, 51.8)             |                                       | (7.9, 19.7)                                                                               | 45 (13.7)                                                                                 |
|                                                                                          |                                  |                                       |                                                                                           | (10.2, 17.9)                                                                              |
|                                                                                          | 3 (27.3)                         |                                       |                                                                                           | 17 (5.2)                                                                                  |
|                                                                                          | (6.0, 61.0)                      |                                       | 14 (10.1) (5.6, 16.3)                                                                     | (3.0, 8.1)                                                                                |
| Resplratory tallure                                                                      | 2 (18.2)                         |                                       | 2 (1.4)                                                                                   | 5(1.5)                                                                                    |
|                                                                                          | (2.3, 51.8)                      |                                       |                                                                                           | [0.5, 3.5)                                                                                |
|                                                                                          |                                  |                                       |                                                                                           | 11 (3.3)                                                                                  |
|                                                                                          |                                  | 3 (8.8)                               |                                                                                           |                                                                                           |
|                                                                                          | (0.2, 41.3)                      |                                       | (10.2,23.0)                                                                               | (1.7, 5.9]                                                                                |
|                                                                                          |                                  | (1.9, 23.7]                           |                                                                                           |                                                                                           |

ALL - acule lymphoblastlc leukemla; Ph+ - Phlladelphla chromosome-posltive; Ph- = Phlladelphla

Page 2 of 2

chromosome-negatlve; RilR - relapsed/refractory: US = Unlled States

Adverse events coded uslng MedDRA verslon 18.1

60 subjects from the rest of word In Adult RiR Ph- ALL are not Included In the table.

Source:Modliled from Table 13-3, Module 5.3.5.3

The MAH concluded that, although there were differences observed by region in Study 20120216 and between  the  2  relapsed/refractory  ALL  populations,  the  95%  CIs  overlapped  substantially  for  the comparisons suggesting no statistically significant difference. In addition, the imbalance in sample size within the populations does not allow for an adequate comparison.

<div style=\"page-break-after: always\"></div>

## · ECOG Performance Status

In Study 20120216, 16 subjects (35.6%) had a baseline ECOG status of 0, 20 subjects (44.4%) had a baseline ECOG status of 1, and 9 subjects (20.0%) had a baseline ECOG status of 2.

Table 57: Summary of Subject Incidence of Treatment-emergent Adverse Events for ECOG Performance Status Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

<!-- image -->

|                                                       | Adult RIR Ph+ ALL      | Adult RIR Ph+ ALL                                                 | Adult RIR Ph+ ALL     | Adults R/R Ph- ALL MT103-211 MT103-206 00103311 (Bllnatumomab amm)   | Adults R/R Ph- ALL MT103-211 MT103-206 00103311 (Bllnatumomab amm)   | Adults R/R Ph- ALL MT103-211 MT103-206 00103311 (Bllnatumomab amm)   |
|-------------------------------------------------------|------------------------|-------------------------------------------------------------------|-----------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
|                                                       | ECOG-D (N - 16)        | EC0G- 1 (N - 20)                                                  | EC0G-2 (N-9)          | ECOG-0 (N = 187)                                                     | EC0G-1 (N = 262)                                                     | ECOG-2 (N - 77)                                                      |
| All trealment-emerqent adverse events                 | 16 (100.0)             | 20 (100.0) (79.4, 100.0) (83.2, 100.0) (66.4, 100.0) (96.2, 99.9) | 9 (100.0)             | 185 (98.9)                                                           | 259 (98.9) [96.7,99.8]                                               | 77 (100.0) (95.3, 100.0)                                             |
| Grades 3                                              | 13 (81.3) (54.4, 96.0) | 18 (90.0) (68.3, 98.8)                                            | 6 (66.7) (29.9, 92.5) | 152 (81.3) (74.9, 86.6)                                              | 221 (84.4) (79.4, 68.5)                                              | 68 (88.3) (79.0, 94.5)                                               |
| Serlous adverse events                                | 10 (62.5) (35.4, 84.8) | 12 (60.0) (36.1, 80.9)                                            | 6 (66.7) (29.9, 92.5) | 108 (57.8) (50.3, 64.9)                                              | 166 (63.4) (57.2, 69.2)                                              | 60 (77.9) (67.0, 86.6)                                               |
| Leadinq to Intemupllon of Investlgatlonal product     | 5 (31.3) (11.0, 58.7)  | 7 (35.0) (15.4, 59.2)                                             | 4 (44.4) (13.7, 78.8) | 56 (29.9)                                                            | 91 (34.7) (23.5, 37.1)(29.0, 40.8)                                   | 27 (35.1) (24.5, 46.8)                                               |
| Leading to dlscontinuatlon of Investlgatlonal product | 1 (6.3) (0.2, 30.2)    | 2 (10.0) (1.2, 31.7)                                              | 0 (0.0) (0.0, 33.6)   | 21 (11.2) (7.1, 16.7)                                                | 44 (16.8) (12.5, 21.9)                                               | 18 (23.4) (14.5,34.4)                                                |
| Fatal adverse evenis                                  | 0(0.0) (0.0, 20.6)     | 3 (15.0) (3.2, 37.9)                                              | 2 (22.2) (2.8, 60.0)  | 13 (7.0) (3.8, 11.6)                                                 | 49 [18.7] (14.2, 24.0)                                               | 29 (37.7) (26.9,49.4)                                                |

Chromosome-positive; Ph- - Phlladelphla chromosome-negative; R/R -- relapsed/refraclory Severty graded using Common Technlcal Crilera for Adverse Evenis v4.03. Subjecis with mlsslng EcoG at baselne are not Included In the table. Source:Table 14-1,Module 5.3.5.3

The incidence of grade ≥ 3 events by preferred term occurring in ≥ 10% of subjects by ECOG status were presented  in  Table  above.  Some  differences  between  the  2  relapsed/refractory  populations  were observed; however, due to the small number of subjects within each ECOG performance status category for  Philadelphia-positive  subjects,  and  the  imbalance  in  number  of  subjects  within  each  ECOG performance status category for each population, an adequate comparison cannot be performed.

## · Renal Function

For  Study  20120216,  the  sample  sizes  among  renal  function  categories  for  this  analysis  were imbalanced; 31 subjects (68.9%) had normal renal function (CrCL ≥ 90 mL/min), 8 subjects (17.8%) had mild renal impairment (CrCL ≥ 60 mL/min to &lt; 90 mL/min), and 6 subjects (13.3%) had moderate renal impairment (CrCL ≥ 30 mL/min to &lt; 60 mL/min).

<div style=\"page-break-after: always\"></div>

Table 58 :  Summary  of  Subject  Incidence  of  Treatment-emergent  Adverse  Events  for  Renal  Function Subgroups - Adult Relapsed/Refractory ALL Populations (Safety Analysis Set)

<!-- image -->

|                                                       | Adult RIR Ph+ ALL                               | Adult RIR Ph+ ALL                             | Adult RIR Ph+ ALL                    | Adult R/R Ph-ALL                                                        | Adult R/R Ph-ALL                                                        | Adult R/R Ph-ALL                                                        |
|-------------------------------------------------------|-------------------------------------------------|-----------------------------------------------|--------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
|                                                       | 20120216 (N - 45) n (961(95% C1)                | 20120216 (N - 45) n (961(95% C1)              | 20120216 (N - 45) n (961(95% C1)     | MT103-211 MT103-206 00103311 (Blnalumomab amm) (N- 528) n (86) (95% C1) | MT103-211 MT103-206 00103311 (Blnalumomab amm) (N- 528) n (86) (95% C1) | MT103-211 MT103-206 00103311 (Blnalumomab amm) (N- 528) n (86) (95% C1) |
|                                                       | Nomal [N - 31)]                                 | Mlld (N- 8)                                   | Moderate [N- 6]                      | Nomal (N-417)                                                           | Mlld (N- 86]                                                            | Moderale (N- 22)                                                        |
| All treatment-emergen tadverse evenis Grade 23        | 31 (100.0) (88.8. 100.0) 25 (80.6) (62.5, 92.5) | 8 (100.0) (63.1, 100.0) 7 (87.5) (47.3, 99.7) | 6 (100.0) (54.1, 100.0) 5 (83.3)     | 414 (99.3) (97.9, 99.9) 345 (62.7)                                      | 84 (97.7) 74 (66.0)                                                     | 22 (100.0) (91.9, 99.7)(84.6, 100.0) 21 (95.5)                          |
| Serlous adverse evenis                                | 19 (61.3) (42.2, 78.2)                          | 3 (37.5) (8.5.75.5)                           | (35.9, 99.6) 6 (100.0) (54.1, 100.0) | (78.8, 86.2) 260 (62.4) (57.5, 67.0)                                    | (76.9, 92.6) 56 (65.1)                                                  | (77.2, 99.9) 17 (77.3) (54.1, 75.1) (54.6, 92.2)                        |
| Leadlng to Interupllon ot Invesilgatlonal             | 11 (35.5) (19.2, 54.6)                          | 2 (25.0) (3.2, 65.1)                          | 3 (50.0) (11.8, 88.2)                | 127 (30.5) (26.1, 35.1)                                                 | 34 (39.5)                                                               | 13 (59.1) (29.2, 50.7) (36.4, 79.3)                                     |
| product Leadlng to dlscontinuatlon of Investlgatlonal | 3(9.7) (2.0, 25.8)                              | 0 (0.0) (0.0, 36.9)                           | 0 (0.0) (0.0, 45.9)                  | 61 (14.6) [11.4, 18.4] (13.9, 32.3)                                     | 19 (22.1)                                                               | 3(13.6) (2.9, 34.9)                                                     |
| product Falal adverse evenis                          | 5 (16.1) 15.5.33.71                             | 0 (0.0) (0.0,36.9)                            | 0 (0.0) (0.0, 45.9]                  | 68 [16.3] (12.9,20.2)                                                   | 19 (22.1) (13.9, 32.3)                                                  | 3 (13.6) (2.9, 34.9)                                                    |

chromosome-negatlve; RiR. - relapsedirelractory

ALL - 3cute lymphoblastle leukemla; Ph+ = Phlladelphla chromosome-posltlve; Ph- - Phlladelphla

Renal Impalment measured by creatinlne clearance: nomal 2 90 mL/mln; mlld 2 60 to = 90 mL/mln; moderate ≥ 30 to ≤ 60 mLimln.

1isln aulaseg le elep nubjam bussjw oi anp yogeowssep juawjedwl leuau aullaseg buissjw ym sloelns were excluded.

Severty graded using Common Technlcal Crtera for Adverse Events v4.03.

Source:Table 15-1, Module 5.3.5.3

The incidence of grade ≥ 3 events by preferred term occurring in ≥ 10% of subjects by renal function were provided in Table above. Some differences between the 2 relapsed/refractory populations were observed;  however,  due  to  the  small  number  of  subjects  within  each  renal  function  subgroup  for Philadelphia-positive  subjects,  and  the  imbalance  in  number  of  subjects  within  each  renal  function subgroup for each population, an adequate comparison cannot be performed.

## · Use in Pregnancy and Lactation

Cumulatively, from clinical studies, there was 1 case of pregnancy reported in the long-term follow-up phase of a clinical trial. The case described a female with MRD-positive ALL who became pregnant 6 months after the last dose of blinatumomab in Study MT103-203. Approximately 5 months into the pregnancy, an ultrasound revealed normal results with no fetal abnormalities detected. The outcome of the pregnancy was a live birth at the gestational age of 37 weeks. The investigator reported that the infant did not have any complications, medical problems, or congenital anomalies.

Cumulatively,  from  non-study  sources,  there  were  2  cases  of  pregnancy  reported.  The  first  case described  a  male  patient  with  a  pregnant  partner  who  was  potentially  exposed  while  changing  the infusion bags. The birth outcome was unknown (lost to follow-up). The second case described an event of fetal death while a female patient was receiving blinatumomab. The case did not provide the patients age or obstetric history. The patient was diagnosed with B-ALL in July 2018. The patient was treated sequentially. However, the ALL was refractory to both. Subsequently, blinatumomab was started at 9 μg/day x 1 week, and the dose was escalated to 28 μg/day. On day 14 of blinatumomab treatment (approximately 26 weeks gestation), the patient had a 'spontaneous birth of a life-less child.' No details were provided as to fetal monitoring prior to the birth, autopsy, or pathology of fetus.

<div style=\"page-break-after: always\"></div>

## 2.5.3. Clinical safety in peadiatric RR Phi + ALL patients

The MAH cross-referenced to previous variation application in Pediatric Relapsed/Refractory ALL Variation Application (EMEA/H/C/003731/II/0018).

The MAH also summarized that three paediatric subjects with Philadelphia-positive relapsed/refractory ALL were enrolled in Study MT103-205. All 3 subjects were heavily pretreated for their disease with chemotherapy and HSCT conditioning regimens and received an allogeneic HSCT from an unrelated donor. Most adverse events experienced by these subjects were grades 1 or 2 in severity and the types of  adverse  events  were  consistent  with  those  reported  in  this  variation  application.  One  subject experienced grade 4 events of neutropenia and leukopenia, which resolved without dose interruption. A second  subject  experienced  grade  3  pyrexia  and  hyperglycemia,  which  resolved  without  dose interruption. The third subject had no grade ≥ 3 adverse events.

Table 59: Safety profile for Phi + paediatric patients, Study MT103-205

<!-- image -->

Llsling CSR 14-01-9; LIstlng 16-02-007-01 of MT103-205 Prmary Analysls CSR

<div style=\"page-break-after: always\"></div>

## 2.5.4. Clinical safety in adult MRD Phi + ALL patients

Safety  data  in  adult  MRD+  ALL  patients  were  included  in  tables  in  the  integrated  safety  summary, independently of Phi status.

## 2.5.5. Safety related to drug-drug interactions and other interactions

No  formal  drug  interaction  studies  have  been  conducted  with  blinatumomab.  Blinatumomab  is  a therapeutic protein and is not expected to affect cytochrome P450 enzyme activities and catabolism of other  proteins.  Blinatumomab  may induce transient cytokine elevations and the elevated cytokines, especially IL-6, may have suppressive effect on P450 enzymes. Evaluation of effect of cytokines on activities of P450 enzymes was conducted with a physiological-based PK model and results were provided in the original MAA submission and it was concluded that the blinatumomab mediated cytokine elevation, has a low potential to affect exposure levels of other drugs and the effect is inconsequential.

## 2.5.6. Post marketing experience

From the International Birth Date of 03 December 2014 to 02 December 2018 (data lock point for PBRER/PSUR #6), an estimated 7102 patients had been exposed to blinatumomab in the marketed setting (through commercialization and early access programs).

As of 02 December 2018, Amgen received, cumulatively, a total of 3196 serious adverse drug reactions (ADRs) in the postmarking setting, from spontaneous and solicited sources. In addition, 2093 nonserious ADRs were reported spontaneously.

Overall, among the 3916 total serious ADRs reported from spontaneous and solicited sources, the most frequently reported adverse reactions were from the SOCs of Nervous System Disorders (17.3%) and General Disorders and Administrative Site Conditions (15.7%). Serious ADRs with an event incidence 1% were: cytokine release syndrome (5.4%), pyrexia (5.1%), neurotoxicity (4.4%), death (4.0%), acute lymphocytic leukemia recurrent (3.2%), neutropenia (3.0%), seizure (2.1%), febrile neutropenia (1.9%),  sepsis  (1.6%),  acute  lymphocytic  leukemia  (1.6%),  blast  cell  count  increased  (1.6%), thrombocytopenia  (1.5%),  confusional  state  (1.2%),  disease  progression  (1.1%),  hospitalization (1.1%),  and  pneumonia  (1.0%).  These  events  are  consistent  with  the  known  safety  profile  of blinatumomab or representative of the underlying malignancy.

Overall, the safety information received in the postmarketing setting was consistent with the established safety profile and  cumulative  experience  of  blinatumomab.  The  overall  benefit-risk  profile of blinatumomab remains favorable in the approved indication.

As noted above, ADRs are reported from spontaneous and solicited sources; therefore, some patient details, such as Philadelphia chromosome status, may not have been reported. Thus, it is not possible to report ADRs  only for those patients who  received blinatumomab  for Philadelphia-positive relapsed/refractory ALL.

A cumulative summary of adverse reactions that have been reported for blinatumomab in the marketed setting is provided in PBRER/PSUR #4 (Procedure number: EMEA/H/C/PSUSA/00010460/201712).

<div style=\"page-break-after: always\"></div>

## · Investigator-sponsored Studies

Up to 22 February 2018, a total of 112 cases comprising of 265 serious and 12 nonserious adverse events from investigator-sponsored studies were available in the Amgen safety database. Adverse events with an event incidence ≥ 1% were: febrile neutropenia (6.9%); sepsis (5.0%); device related infection (3.2%), seizure (2.9%); lung infection (2.5%); confusional state and lymphocyte count decreased (2.2% each); blood creatinine increased, CRS, hypotension and pyrexia (1.8% each); and ALT increased, AST increased,  encephalopathy,  hypokalaemia,  hypoxia,  pain,  platelet  count  decreased  and  respiratory failure  (1.4%  each).  These  events  are  consistent  with the  known  safety  profile  of  blinatumomab  or representative of the underlying malignancy.

## 2.5.7. Discussion on clinical safety

This safety analysis provides safety data from Study 20120216, the phase 2, open-label, single-arm, multicenter study of blinatumomab in adult subjects with Philadelphia-positive relapsed/refractory ALL. This review also includes safety results from pooled studies of adult subjects with Philadelphia-negative relapsed/refractory ALL) (Studies 00103311, MT103-211, and MT103-206 [N = 528]).

In study 20120216, patients completed a median of 2 cycles, with a mean exposure of 59,88 days. Exposure was similar among pooled RR Phi neg adult studies and peadiatric studies, despite a median of 1 cycle. Baseline demographic and disease characteristics were similar between study 20120216 and pooled ALL RR Phi neg ALL studies. However, it should be noted that patients in study 20120216 were older (median age of 55.0 years, vs 37.5), with most of patients in this study aged 55 and over (51.1%). In study 20120216, a higher proportion of patients had PNN &lt; 500/µL (42.2 % vs 30.5%) and prior HSCT (44.4% vs 34.2%).

All 45 patients presented with at least 1 TEAE, including 28 subjects with serious TEAE (62.2%). Most frequently  reported  TEAEs  were  pyrexia  (57.8%),  febrile  neutropenia  (40.0%),  headache  (31.1%), anaemia (28.9%), thrombocytopenia (22.2%), bone pain (20.0%), and diarrhoea (20.0%). The safety profile raised in RR Phi + adults ALL patients in study 20120216 was similar to RR Phi neg adults ALL pooled patients. It should anyway be noted that the frequency of febrile neutropenia was higher in Phi + subjects (40.0% vs 24.4%).

The most frequently reported grade 3/ 4 TEAEs were febrile neutropenia (26.7%), thrombocytopenia (22.2%), anaemia (15.6%), and pyrexia, ALT increased, and AST increased (11.1% each). The safety profile remained similar in terms of grade 3/ 4 AEs between adult RR ALL Phi + and Phi neg patients. However, the frequency of grade 3 /4 thrombocytopenia was higher in Phi + patients (22.2 vs 12.3%) while a higher frequency of grade 3 /4 neutropenia was observed in Phi neg patients (6.7 vs 16.3%).

The frequency of treatment-related AEs was 91.1%, higher than in pooled adult RR Phi neg patients (84.7%), with a similar trend in related AEs reported except for the higher frequency of related febrile neutropenia (24.4 vs 12.7%)..

A total of 6 fatal AEs were reported, including 1 case of treatment-related fatal sepsis. No unexpected trend in fatal AEs was reported, nor new safety signal. Moreover, 62.2% of patients presented with SAEs, driven by febrile neutropenia (8.9%), sepsis, device related infection and tremor (6.7% each). When compared to adult RR Phi neg ALL pooled patients, no unexpected trend in SAEs was reported, nor new safety signal.

No unexpected trend in AEs leading to treatment interruption was observed in study 20120216, nor while comparing both Phi + and Phi neg RR ALL adult populations.

<div style=\"page-break-after: always\"></div>

There was no discernable trend or pattern observed for events (by preferred term) by region.

Regarding TEAEs leading to treatment discontinuation, 3 patients (6.7%) presented with such TEAEs in study 20120216, including 2 related TEAEs neutropenia and acute graft versus host disease.  The global trend in reporting of TEAEs leading to treatment discontinuation was similar between Phi + and Phi neg RR ALL adult populations.

There were no events leading to treatment interruption, events leading to treatment discontinuation, or fatal events (by preferred term) with ≥ 10% difference between subjects from the US and Europe in Study 20120216.

The related case of acute GvHD reported in study 20120216 should be kept in mind. It concerns a 62 year old female patient, who presented with acute GvHD (skin stage 3, bowel stage 2, liver stage 0, grading 3) one month after treatment initiation. No other case of acute GvHD was reported in this study, and  this  AE  is  not  included  in  the  SmPC  nor  in  the  current  RMP.  It  should  be  noted  that  a noninterventional PASS is planned (20170610) in US and EU, which will cover this risk: '100-day survival and  risk  of  developing  acute  graft  versus  host  disease  (aGvHD)  in  relapsed/refractory  acute lymphoblastic  leukemia  (ALL)  after  allogeneic  stem  cell  transplant:  blinatumomab  vs  chemotherapy induction'.

Prespecified AESIs were neurologic events, cytokine release syndrome (CRS), infections, elevated liver enzymes, infusion reactions, tumor lysis syndrome (TLS), capillary leak syndrome (CLS), medication errors, decreased immunoglobulins, embolic and thrombotic events (including disseminated intravascular coagulation [DIC]), leukoencephalopathy including progressive multifocal leukoencephalopathy (PML), neutropenia and febrile neutropenia, lymphopenia, immunogenicity, and pancreatitis.

Additionally, the following minimum critical toxicities were reviewed: bone marrow toxicity (cytopenias), hepatotoxicity,  nephrotoxicity,  and  torsade  de  pointes/QT  prolongation,  cardiac  arrhythmias,  and convulsion.

The impact of immunogenicity on safety was evaluated through medical review and assessment of the type and severity of adverse events, potential infusion reactions, and number of doses received while on study for blinatumomab-treated antibody-positive subjects. In those assessments, no evidence of an altered safety profile was observed for subjects who tested positive for anti-blinatumomab antibodies.

No unexpected safety signal was raised from these AESIs and critical toxicities.

However, some clarifications were requested by the MAH. Taking into account the delayed median time to onset (TTO) observed in Phi + patients for decreased immunoglobulin (105.5 days vs 42.0), embolic and thrombotic events (175 days vs 22 days), neurologic events (8.5 vs 6 days) and Cytokine release syndrome (6 vs 2 days), these delayed AEs occurrences were thus further discussed. The MAH considered that despite differences in median TTO, min-max intervals of TTOs for each of these AESIs in Phi+ RR ALL adult subjects are included in min-max intervals raised in Phi- RR ALL adult subjects. Thus, the MAH does not consider these differences in median TTO to be significant. High variability with very limited sample size in Phi + RR ALL subjects is acknowledged. One could also consider Q1-Q3 intervals, wider in Phi+ RR ALL adult patients and out of Q1-Q3 intervals in Phi - RR ALL adult patients (refer to detailed tables provided in response document). For example, in Embolic and Thrombotic Events, Q1-Q3 interval was 11.0, 53.0 in Phi neg RR ALL adult patients (n=41), vs 44.0, 206.0 in Phi+ RR ALL adult patients (n=3). For Decreased Immunoglobulins, Q1-Q3 interval was 29.0, 85.0 in Phi neg RR ALL adult patients (n=61), vs 46.0, 144.0 in Phi+ RR ALL adult patients (n=4).  However, considering the very limited sample size, no strong comparison could be raised and MAH conclusion is acknowledged.

<div style=\"page-break-after: always\"></div>

Moreover, the MAH was asked to further discuss the increased risk of febrile neutropenia and its earlier onset (3 days vs 10 days) in Phi + patients, including potential causes for such higher incidence. The MAH discussed the differences observed in the onset of neutropenia and febrile neutropenia, between Phi + and Phi- subjects. The MAH considered that Amgen SMQ results should be taken into account, rather than isolated PT for this AE with several related PTs. This is endorsed.

A lower incidence of CRS events was observed in Ph+ (8.9%) than in Ph- (14.2%) R/R ALL subjects and this is  unexpected due to the higher burden of baseline disease with bone marrow blasts ≥50% by central laboratory assessments in 75.6% of Philadelphia-positive relapsed/refractory ALL versus 65.6% of Philadelphia-negative relapsed/refractory ALL. Therefore the MAH was asked to discuss the reasons of  this  apparent  inconsistency  specifying  how  many  subjects  in  Study  20120216  underwent  to  premedication and/or pre-phase treatment with dexamethasone. Data provided by the MAH suggest that the lower incidence of CSR in the Ph-positive ALL population could be in part due to the major proportion of patients receiving pre-phase treatment, however the very low sample size of this study population does not allow to draw firm conclusions. Moreover, all 4 subjects in the Ph-positive ALL population and the majority of patients (71,5%) in the Ph-negative ALL population whit CSR, had baseline bone marrow ≥ 50% by central laboratory assessments, suggesting, as expected, that regardless of population, the rate of treatment-emergent CRS was highest among subjects with baseline blast counts ≥ 50%, and this is  agreed.  Finally,  while  the  onset  time  of  CRS  is  6.0  days  for  subjects  with  relapsed/refractory Philadelphia-positive ALL, 4 subjects with this disease experienced CRS, which represents 5.1% (4/79) of  the  total  subjects  with  relapsed/refractory  ALL  and  3.6%  (4/111)  of  the  total  subjects  with  ALL. Therefore, the MAH considers that the small number of subjects with relapsed/refractory Philadelphiapositive ALL that had CRS is not sufficient to update the time to on onset of CRS for the Summary of Product Characteristics, and this is considered acceptable.

A similar rate of embolic and thrombotic events was reported in Ph+ (6.7%) and Ph- relapsed/refractory ALL studies (8%), with a later onset (175 days vs 22 days). The majority of events were grade ≥ 3 and 1 event was reported as serious (2.2%). Thromboembolic events (including DIC) are already included in the RMP as an important potential risk. DIC is already included in the 4.4 section of the SmPC as mostly associated to CSR and this is acceptable.

The incidence and types of subjects identified with experiencing at least 1 drug-related hepatotoxicity event was similar (24.4% versus 29.0%) in both adult relapsed/refractory ALL populations. However, grade ≥4 and serious events were more common in Philadelphia -positive (6.7% and 4.4%, respectively) than  in -negative (3% and 2.1%, respectively) relapsed/refractory ALL populations. Also related AST and  ALT increased (11.1% each vs 8% and 7.6, respectively, all of grade ≥ 3) were more common. A higher incidence of serious and grade ≥4 hepatotoxicity events is unexpected due to the baseline minor hepatic impairment of Ph+ adult R/R ALL subjects (AST or ALT &gt; 3 x ULN or Total Bilirubin &gt; 1.5 x ULN: 6.7%) compared to Ph- adult R/R ALL subjects (AST or ALT &gt; 3 x ULN or Total Bilirubin &gt; 1.5 x ULN: 16.9%). A higher incidence of serious and grade ≥4 hepatotoxicity events is unexpected due to the baseline minor hepatic impairment of Ph+ adult R/R ALL subjects (AST or ALT &gt; 3 x ULN or Total Bilirubin &gt; 1.5 x ULN: 6.7%) compared to Ph- adult R/R ALL subjects (AST or ALT &gt; 3 x ULN or Total Bilirubin &gt; 1.5 x ULN: 16.9%). The MAH confirmed the higher incidence of rates (more than double) of grade ≥ 4 and serious hepatotoxic events in Ph positive compared to Ph negative patients, even though no hepatotoxic events were fatal and no new safety signal was observed, which is reassuring. A possible explanation of this unexpected discrepancy in frequencies between the two populations has not been proposed by the MAH, however the above reported data have been described in the 4.8 section of the SmPC under the paragraph ' Description of selected adverse reactions' and this is considered acceptable.

<div style=\"page-break-after: always\"></div>

In Study 20120216 3 patients (6.7%) experienced no serious or fatal cardiac arrhythmia event of atrial fibrillation. Although, cardiac arrhythmia evens were in general more common in Philadelphia-negative (9.1%) compared to -positive (6.7%) relapsed/refractory ALL populations, the incidence of atrial fibrillation was lower in Ph- relapsed/refractory ALL patients (0.9%). Further information about the three patients experiencing atrial fibrillation in Study 20120216 were requested, in order to better understand the potential correlation to blinatumomab administration and to update the 4.8 section of the SmPC including also atrial fibrillation. Narratives for 3 subjects who had atrial fibrillation were provided. Atrial fibrillation occurred while on treatment in two patients and two days after the last dose of blinatumomab in the third patient (Subject 21626001001), who was the only one with a past history of atrial fibrillation. Blinatumomab administration was not interrupted due to these events. The investigator deemed each event of all three patients as non-serious and not related to blinatumomab and possible other contribution factors to the arrhythmia event are reported in each patient. Even if in principle the time to event in subject 21625003003 and subject 21633004004 (day 4 and day 8 of cycle 1, respectively) could suggest a possible causal relationship with blinatumomab, this hypothesis seems to be weakened by other past and concurrent confounding factors, age of subjects, previous treatment (eg. TKIs) as well as by the investigator judgment of not relationship with study drug. Therefore, at this time and in absence of signals from other blinatumomab studies, firm conclusion cannot be drawn. The MAH is recommended to follow-up these events (ADR of arrhythmia, including atrial fibrillation) by routine pharmacovigilance activity in the post-marketing setting across different Blincyto indications.

Despite limited sample size, a subgroup analysis by age was provided by the MAH for adult RR ALL patients, Phi + (study 20120216) and Phi neg (pooled studies) for the following subgroups: age, sex, race, region, ECOG performance status, and renal function.

In study 20120216, the global safety profile and main AEs was similar between both age groups, except for febrile neutropenia (all TEAEs), surprisingly higher in non-elderly patients (33.3% vs 8.3%). While comparing the global safety profile among ≥65 years patients, the frequency of grade ≥3 TEAEs and SAEs was lower in Phi + patients (58.3% vs 88.4%; and 50.0% vs 73.9% respectively).

Considering AEs of special interest, among adult RR Phi + ALL patients (study 20120216), a higher frequency of elevated hepatic enzymes (21.2% vs 8.3%) and febrile neutropenia (57.6% vs 16.7%) was noted in non-elderly patients vs elderly, while infusion reactions were higher in elderly patients (39.4 vs 75.0%), driven by pyrexia. Comparing AEs of special interest among both age groups between Phi + and Phi neg patients, no significant difference was noted considering crossing CIs and limited sample size.

No significant difference in safety profile was evidenced in the other subgroups analysis, among adult RR Phi + ALL patients as well as when compared to adult RR Phi neg ALL patients.

The MAH summarized that three paediatric subjects with Philadelphia-positive relapsed/refractory ALL were enrolled in Study MT103-205. Most adverse events experienced by these subjects were grades 1 or 2 in severity and the types of adverse events were consistent with those reported in this variation application. No unexpected safety signal was raised from grade 3/ 4 AEs reported in these 3 patients. However, no conclusion on the safety profile in this target population could be drawn based on this very limited safety population.

The MAH provided pooled treatment-related safety data for the 10 subjects with Philadelphia-positive ALL from Studies MT103-203 and MT103-202. No new safety signal was identified in this indication.

<div style=\"page-break-after: always\"></div>

Sections  4.4  and  4.8  of  the  SmPC  have  been  updated  to  reflect  new  safety  information  from  this submission.

## 2.5.8. Conclusions on clinical safety

No unexpected safety signal was raised in patients from study 201202176, when compared to pooled safety data in adult Phi - RR ALL patients. No new safety signal was identified from the pooled treatmentrelated  safety  data  for  the  10  subjects  with  Philadelphia-positive  ALL  from  Studies  MT103-203  and MT103-202.

Based on the information concerning three Phi + paediatric patients, no unexpected safety signal was raised. However, no conclusion on the safety profile in this target population could be drawn based on this very limited safety population.

The MAH will provide further safety data from the following studies as detailed in the PhV plan:

- Study 20180130:  Evaluation of long-term safety in pediatric patients with B-precursor ALL who have been treated with either blinatumomab or chemotherapy followed by transplantation.
- Observational Cohort Study 20170610:  Overall survival and incidence of adverse events in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: induction with blinatumomab vs chemotherapy
- Observational Cohort Study 20180138:  Long-term follow-up of adult relapsed refractory patients enrolled in Study 00103311
- A Randomized, Open-label, Controlled phase 3 Adaptive Study 20120215:  A randomized, open-label, controlled phase 3 adaptive trial to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BiTE  ) antibody blinatumomab as consolidation therapy versus conventional chemotherapy in pediatric patients with high-risk first relapse of B-precursor acute lymphoblastic leukemia (ALL)

## 2.5.9. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted/was requested to submit an RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 12 is acceptable.

The CHMP endorsed the Risk Management Plan version 12 with the following content:

## Safety concerns

| Important identified risks   | Neurologic events Opportunistic Infections   |
|------------------------------|----------------------------------------------|
|                              | Cytokine release                             |
|                              | syndrome                                     |

<div style=\"page-break-after: always\"></div>

|                           | Medication errors                                                                         |
|---------------------------|-------------------------------------------------------------------------------------------|
| Important potential risks | Hematopoietic stem cell transplantation-related toxicity in children                      |
| Missing information       | Use in patients after recent HSCT                                                         |
|                           | Recent or concomitant treatment with other anti-cancer therapies (including radiotherapy) |
|                           | Recent or concomitant treatment with other immunotherapy                                  |
|                           | Long-term safety and efficacy                                                             |
|                           | Development impairment in children including neurological, endocrine, and immune system   |
|                           | Subsequent relapse of leukemia in children including in the central nervous system        |
|                           | Long-term toxicity in children                                                            |
|                           | Secondary malignant formation in children                                                 |

No new safety concerns were added as a result of this extension of indication. The list of safety concerns remains unchanged.

## Pharmacovigilance plan

| Study Status                                                                                                               | Summary of Objectives                                                                                                                                                                               | Safety Concerns Addressed                                                                                                                                                                                                                                                              | Milestones                                                                                                                 | Due Dates                                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                          | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                             | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization       |
| Observatio nal Patient Study Study 20150136 : An observatio nal study of blinatumo mab                                     | Primary objective: • To characterize the safety profile of blinatumomab in routine clinical practice in countries in the EU • To estimate the frequency and types of blinatumomab medication errors | Neurologic events, opportunistic infections, cytokine release syndrome, medication errors, use in patients after recent HSCT, recent or concomitant treatment with other anti-cancer therapies (including radiotherapy), recent or concomitant treatment with other immunotherapy, and | Protocol v1.1, dated 06 Septembe r 2016                                                                                    | Submission: 22 January 2016 Pharmacovig ilance Risk Assessment Committee (PRAC) adoption of draft protocol on 02 Septemb er 2016 |

<div style=\"page-break-after: always\"></div>

| safety and effectiven ess, utilization and treatment practices Ongoing   | identified in patient charts Secondary objectives: • To estimate the incidence of other serious adverse events, ie, serious adverse events not included in the primary objective • To evaluate safety and effectiveness endpoints among patient subgroups defined by demographic and clinical factors • To characterize the effectiveness of blinatumomab in routine clinical practice   | long-term safety and efficacy   | Interim Final report   | Enrollment update will be provided in each PSUR/Period ic Benefit- Risk Evaluation Report (PBRER) Annual interim reports will be provided with correspondin g PSUR/PBRER starting with PSUR/PBRER #3 Anticipated Q4 2022   |
|--------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Study

Status

## Summary of Objectives

## Safety Concerns Addressed

Milestones   Due Dates

Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization (continued)

<div style=\"page-break-after: always\"></div>

| Study 20180130: Evaluation of long-term safety in pediatric patients with B-precursor ALL who have been treated with either blinatumomab or chemotherapy followed by transplantation. Planned   | Primary objective: • To estimate incidence of neuropsychomotor developmental impairment, endocrine impairment, neurological impairment, and immune system impairment (including auto-immune disorders and vaccine failure)   | Hematopoietic stem cell transplantation-related toxicity in children Long-term safety and efficacy Development impairment in children including neurological, endocrine, and immune system Subsequent relapse of leukemia in children including in the central nervous system Long-term toxicity in children Secondary malignant formation in children   | Final Protocol Interim Analysis Final CSR   | Q1 2020 Every 2 years from start of data collection Q3 2038   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------------------------|

| Study Status                                                                                                                                                                                                                                                     | Summary of Objectives                                                                                                                | Safety Concerns Addressed                                     | Milestones                                                    | Due Dates                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                        | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Observational Cohort Study Study 20170610: Overall survival and incidence of adverse events in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: induction with blinatumomab vs chemotherapy Planned | Primary objective: • Describe 100-day and mortality • Estimate the incidence of graft versus host disease (GVHD) (acute and chronic) | Long-term safety and efficacy                                 | Final Protocol Interim CSR Final CSR                          | Anticipated Q1 2020 Q2 2025 Anticipated Q1 2030               |
|                                                                                                                                                                                                                                                                  |                                                                                                                                      |                                                               | Protocol                                                      | Q3 2019                                                       |

<div style=\"page-break-after: always\"></div>

| Observational Cohort Study Study 20180138: Long-term follow-up of adult relapsed refractory patients enrolled in Study 00103311 Planned   | To describe additional long-term overall survival of patients in Study 00103311   | Long-term safety and efficacy   | Final CSR   | Anticipated Q4 2020   |
|-------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|---------------------------------|-------------|-----------------------|

| Study Status                                                                                                                                                                                                                                                                                                                                                                                                                           | Summary of Objectives                                                                             | Safety Concerns Addresse d                                                | Miles tone s                                                              | Due Dates                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities (continued)                                                                                                                                                                                                                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities (continued)                         | Category 3 - Required additional pharmacovigilance activities (continued) | Category 3 - Required additional pharmacovigilance activities (continued) | Category 3 - Required additional pharmacovigilance activities (continued) |
| A Randomized, Open-label, Controlled phase 3 Adaptive Trial Study 20120215: A randomized, open-label, controlled phase 3 adaptive trial to investigate the efficacy, safety, and tolerability of the bi-specific T-cell engager (BiTE  ) antibody blinatumomab as consolidation therapy versus conventional chemotherapy in pediatric patients with high-risk first relapse of B-precursor acute lymphoblastic leukemia (ALL) Ongoing | To evaluate EFS in the blinatumomab arm versus EFS in the standard consolidation chemotherapy arm | Long-ter m safety and efficacy                                            | CSR                                                                       | July 2024                                                                 |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Safety Concerns Addressed                                                 | Mileston es                                                               | Due Dates                                                                 |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities (continued)                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities (continued)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Category 3 - Required additional pharmacovigilance activities (continued) | Category 3 - Required additional pharmacovigilance activities (continued) | Category 3 - Required additional pharmacovigilance activities (continued) |
| Cross-sectional Survey (Study 20150228): A cross-sectional survey of patients and caregivers receiving blinatumomab in routine clinical practice in Europe to evaluate the effectiveness of aRMMs. Ongoing | Primary objective: • To describe receipt of the educational materials and knowledge about key safety messages in the educational materials, among patients with Ph - R/R B-cell precursor ALL receiving Blincyto and their caregivers Secondary objective: • To describe behaviors, outline in the educational materials, by patients with Ph - R/R B-precursor ALL receiving Blincyto and their caregivers • To describe the level of understanding of key safety messages in the educational materials, among patients with Ph - R/R B-precursor ALL receiving Blincyto and their caregivers • To describe usage of the educational materials, among patients with Ph - R/R B-cell precursor ALL receiving Blincyto and their caregivers | Neurologic events, medication errors                                      | Final report                                                              | Anticipat ed Q3 2019                                                      |

| Study           |                                         | Safety Concerns Addressed        | Mileston es   | Du e Dat   |
|-----------------|-----------------------------------------|----------------------------------|---------------|------------|
|                 | Summary of Objectives                   |                                  |               | es         |
| Status          |                                         |                                  |               |            |
| Required        | additional pharmacovigilance activities |                                  |               |            |
| Category 3 -    |                                         |                                  |               |            |
| Study 20130320: | Primary objective:                      | (continued) Long-term safety and |               | Q2         |
|                 | To estimate the incidence of            | efficacy                         | Protocol      | 201        |
|                 |                                         |                                  |               | 8          |
|                 | treatment-emergent and                  |                                  |               |            |

<div style=\"page-break-after: always\"></div>

| An open-label, multicenter, expanded access protocol of blinatumomab for the treatment of pediatric and adolescent subjects with relapsed and/or refractory B-precursor acute lymphoblastic leukemia (ALL) Ongoing   | treatment-related adverse events during treatment with blinatumomab in pediatric and adolescent subjects with B- precursor ALL in second or later bone marrow relapse, in any marrow relapse after alloHSCT, or refractory to other treatments   | Final CSR   | Q2 203 4   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------------|

No changes to the pharmacoviglinace plan were made as a result of this extension of indication.

## Risk minimisation measures

<div style=\"page-break-after: always\"></div>

| Safety Concern             | Risk Minimization Measures                                                                                                                                                                                                                                                                                              | Pharmacovigilance Activities                                                                                                                                                                                                                       |
|----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks | Important Identified Risks                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                    |
| Neurologic events          | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4 • SmPC Section 4.7 • SmPC Section 4.8 • PIL Section 2 • PIL Section 4 Additional risk minimization measures: • Educational materials for physicians, nurses, pharmacists and patients (including caregivers) and patient alert card (see Part | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136 • Cross-sectional patient and caregiver survey Study 20150228 |
| Opportunistic infections   | Routine risk minimization measures: • SmPC Section 4.4 • SmPC Section 6.6 • PIL Section 4 Additional risk minimization measures:                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136                                                               |
| Cytokine release syndrome  | Routine risk minimization measures: • SmPC Section 4.2 • SmPC Section 4.4 • SmPC Section 4.5 • SmPC Section 4.8 • SmPC Section 5.1 • SmPC Section 5.3 • PIL Section 4 Additional risk minimization measures:                                                                                                            | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136                                                               |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                       | Risk Minimization Measures                                                                                                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                       |
|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Identified Risks (continued)                               | Important Identified Risks (continued)                                                                                                                                                                                                                                                                             | Important Identified Risks (continued)                                                                                                                                                                                                             |
| Medication errors                                                    | Routine risk minimization measures: • SmPC Section 4.4 • SmPC Section 4.9 • SmPC Section 6.6 Additional risk minimization measures: • Educational Materials for Physicians, Pharmacists, Nurses, and Patients (Including Caregivers). In addition, patients will also receive a patient alert card (see Part V.2). | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational Patient Study 20150136 • Cross-sectional patient and caregiver survey Study 20150228 |
| Important Potential Risks                                            | Important Potential Risks                                                                                                                                                                                                                                                                                          | Important Potential Risks                                                                                                                                                                                                                          |
| Hematopoietic stem cell transplantation-related toxicity in children | Routine risk minimization measures: • None Additional risk minimization measures: • None                                                                                                                                                                                                                           | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130                                                                |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                            | Risk Minimization Measures                                                               | Pharmacovigilance Activities                                                                                                                                                         |
|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information                                                                       |                                                                                          |                                                                                                                                                                                      |
| Use in patients after recent HSCT                                                         | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136 |
| Recent or concomitant treatment with other anti-cancer therapies (including radiotherapy) | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136 |
| Recent or concomitant treatment with other immunotherapy                                  | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational patient Study 20150136 |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                          | Risk Minimization Measures                                                               | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information (continued)                                                         | Missing Information (continued)                                                          | Missing Information (continued)                                                                                                                                                                                                                                                                                                                                                     |
| Long-term safety and efficacy                                                           | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • An expanded access Study 20130320 • An open-label, controlled Study 20120215 • Observational patient Study 20150136 • Observational cohort Study 20170610 • Observational cohort Study 20180130 • Retrospective long-term follow-up |
| Development impairment in children including neurological, endocrine, and immune system | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130                                                                                                                                                                                                 |
| Subsequent relapse of leukemia in children including in the central nervous system      | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| Safety Concern                            | Risk Minimization Measures                                                               | Pharmacovigilance Activities                                                                                                                                                        |
|-------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Missing Information (continued)           | Missing Information (continued)                                                          | Missing Information (continued)                                                                                                                                                     |
| Long-term toxicity in children            | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort                |
| Secondary malignant formation in children | Routine risk minimization measures: • None Additional risk minimization measures: • None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: • None Additional pharmacovigilance activities: • Observational cohort Study 20180130 |

No changes were made to the risk minimisation measures as part of this extension of indication.

Measures already in place remain sufficient to mitigate the risks of Blycento in all indications.

## 2.7. Update of the Product information

As a consequence of this extension of indication, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Acute lymphoblastic leukemia is a rare aggressive cancer of the blood and bone marrow. The majority

<div style=\"page-break-after: always\"></div>

of ALL cases are B-lineage, Philadelphia-negative ALL. The Philadelphia chromosome is observed in 3% to 5% of children and 20% to 30% of adults with B-cell precursor ALL and associated with a poorer prognosis.

## 3.1.2. Available therapies and unmet medical need

Allogeneic hematopoietic stem cell transplantation (HSCT) is recommended in first remission for patients with Philadelphia-positive ALL. Since the introduction of TKIs, the objective response rates are similar between subjects with Philadelphia-negative ALL and subjects with Philadelphia-positive ALL (Thomas et al, 2004; Yanada and Naoe, 2006); however, duration of response and relapse-free survival (RFS) have remained short in ALL Phi+ patients.

Recently, 2 non-TKI treatments were approved for the treatment of relapsed or refractory ALL that included Philadelphia-positive ALL subjects in the pivotal trials. Inotuzumab ozogamicin (Besponsa) is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor ALL; adult patients with Philadelphia-positive relapsed or refractory B-cell precursor ALL should have failed treatment with at least 1 TKI. Tisagenlecleucel (Kymriah) is indicated for the treatment of pediatric and young adult patients up to 25 years of age with B-cell ALL that is refractory, in relapse post-transplant, or in second or later relapse.

With  the  limited  options  described  above,  treatment  of  Philadelphia-positive  ALL  patients  who  are resistant to or relapse after first-line therapy remains challenging.

## 3.1.3. Main clinical studies

The main pivotal study 20120216 is a Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE® Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive Bprecursor  Acute  Lymphoblastic  Leukemia  (Alcantara  Study).  The  primary  endpoint  was  the  rate  of CR/CRh* within the first two cycles of blinatumomab. OS, complete MRD response rate, RFS and DoR were investigated as secondary endpoints. A total of 45 patients were included (FAS). Only 6 of them could complete the end of the consolidation phase (13.3%), and 8 patients completed the study (17.8%). Most  of  patients  (n=37;  82.2%)  discontinued  study,  all  due  to  death.  However,  only  3  patients discontinued the treatment due to death. Most of treatment discontinuations were due to progression without prior CR/CRh/Cri (n=12), followed by requirement for alternative therapy (n=7) and intention to receive HSCT (n=6).

A retrospective historical cohort was carried out in a similar population (study 20160462) and with similar endpoints, in  order  to  provide  comparative  data  with  standard  of  care.  The  study  included  patients diagnosed between 2000 through end of data collection in 2017, and thus covered the same time period than the pivotal study. Most of patients were RR to at least 1 G2 TKI (94.5%). However, none had previously received imatinib treatment.

A Propensity Score Analysis was performed to estimate the association between receipt of blinatumomab and OS and CR/CRh* outcomes among patients with Philadelphia-positive relapsed or refractory ALL. The primary endpoint of propensity score analysis was based on OS comparison.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

In the main pivotal study (20120216) a total of 16 patients presented with CR/CRh (35.6%; [21.9%, 51.2%]) within the first 2 cycles of blinatumomab treatment, including 14 with CR (31.1%; [18.2-46.6]). One additional patient achieved a CR/CRh* after the first 2 cycles.

Following a subgroup analysis, an increase in CR/CRh rate was observed with increasing number of previous TKI lines, from 14.3% with 1TKI, 33.3% with 2 TKI up to 47.1% with 3 TKI. CI remained over the 10 % cut-off in subgroups with 2 and 3 TKI. These results, added to current treatment guidelines in ALL Phi + patients, reinforce the limited target indication after at least 2 TKI.

MRD response was coherent with results obtained with the primary endpoint, with 40% of patients in MRD response, all MRD CR. 12/14 patients in CR achieved MRD CR, and 2/2 in CRh achieved MRD CR. MRD CR was also observed in 4 patients who did not achieve CR/CRh.

Estimated median RFS from the 16 patients who achieved CR/CRh* after 2 cycles was 6.8 months (95% CI: 4.4, NE). Five subjects (31.3%) remained relapse free at the time of last response evaluation.

Median time to haematological relapse in CR/CRh patients was coherent with RFS results (6.8 months; 95% CI: 4.5, NE).

Median OS was 9.0 months (95% CI: 5.7, 13.5), with 8 patients alive at the time of the last follow-up date and a median FU of 25.1 months. Among the 10 patients with T315i Bcr-abl mutation, median OS was 12.7 months [4.2, 18.1].

Subgroups analysis also showed an increasing median OS with increasing number of prior TKI, up to 12.6 months [4.2, 20.6] in patients with 3 or more prior TKIs.

A total of 9 subjects (9/45, 20.0%) had an allogeneic HSCT during the study, including 7 who achieved CR/CRh* in the first 2 cycles (7/16 subjects, 43.8%). The KM estimate of median survival after HSCT was 15.9 months (95% CI: 2.1, 16.9).

A historical control study (Study 20160462) and a propensity score analysis were conducted to estimate the effects of blinatumomab compared with standard of care ALL therapy for treatment of Philadelphiapositive relapsed/refractory ALL. Balance between 20120216 population and 20160462 was obtained by applying inverse probability of treatment weights (IPTW) calculated from a propensity score model. In order to avoid statistical limitations due to limited sample size in both studies, a Bayesian augmentation approach was applied to the endpoint analyses, using key efficacy outcomes from a previous randomized trial in adult Philadelphia-negative relapsed/refractory subjects, Study 00103311.

Based on non-Bayes IPTW for OS, adjusted hazard ratio was 0.81 (95% CI: 0.57, 1.15). Once Bayesaugmented, adjusted hazard ratio reached significant value of 0.77 (95% CI: 0.61, 0.96), in favour of blinatumomab treatment.

## 3.3. Uncertainties and limitations about favourable effects

No difference in median OS was observed with or without censoring at time of HSCT. Uncertainty remains on a risk of detrimental long term effect of blinatumomab treatment on OS after HSCT considering also that  all  4  patients  who  received  HSCT  without  additional  treatment  had  died  at  17  months. Study 20170610  will  provide  more  data  on  the  overall  survival  in  relapsed/refractory  B-cell  acute lymphoblastic leukemia (ALL) patients after allogeneic stem cell transplant: induction with blinatumomab vs chemotherapy (see RMP).

<div style=\"page-break-after: always\"></div>

## 3.4. Unfavourable effects

The MAH provided safety data in adult RR Phi + ALL patients, and pooled safety data in adult RR Phi neg ALL patients.

In study 20120216, all 45 patients presented with at least 1 TEAE, including 28 subjects with serious TEAE (62.2%). Most frequently reported TEAEs were pyrexia (57.8%), febrile neutropenia (40.0%), headache (31.1%), anaemia (28.9%), thrombocytopenia (22.2%), bone pain (20.0%), and diarrhoea (20.0%). The safety profile raised in RR Phi + adults ALL patients in study 20120216 was similar to RR Phi neg adults ALL pooled patients. It should anyway be noted that the frequency of febrile neutropenia was higher in Phi + subjects (40.0% vs 24.4%).

In study 20120216, the most frequently reported grade 3/ 4 TEAEs were febrile neutropenia (26.7%), thrombocytopenia (22.2%), anaemia (15.6%), and pyrexia, ALT increased and AST increased (11.1% each). The safety profile remained similar in terms of grade 3/ 4 AEs between adult RR ALL Phi + and Phi neg patients. However, the frequency of grade 3 /4 thrombocytopenia was higher in Phi + patients (22.2 vs 12.3%) while a higher frequency of grade 3 /4 neutropenia was observed in Phi neg patients (6.7 vs 16.3%).

In RR adult Phi + ALL (study 20120216), the frequency of treatment-related AEs was 91.1%, higher than in pooled adult RR Phi neg patients (84.7%), with a similar trend in related AEs reported except for the higher frequency of related febrile neutropenia (24.4 vs 12.7%).

A total of 6 fatal AEs were reported, including 1 case of treatment-related fatal sepsis. 62.2% of patients presented with SAEs, driven by febrile neutropenia (8.9%), sepsis, device related infection and tremor (6.7% each). When compared to adult RR Phi neg ALL pooled patients, no unexpected trend in SAEs was reported, nor new safety signal.

No unexpected trend in AEs leading to treatment interruption was observed in study 20120216, nor when comparing both Phi + and Phi neg RR ALL adult populations.

Prespecified AESIs were neurologic events, cytokine release syndrome (CRS), infections, elevated liver enzymes, infusion reactions, tumor lysis syndrome (TLS), capillary leak syndrome (CLS), medication errors, decreased immunoglobulins, embolic and thrombotic events (including disseminated intravascular coagulation [DIC]), leukoencephalopathy including progressive multifocal leukoencephalopathy (PML), neutropenia and febrile neutropenia, lymphopenia, immunogenicity, and pancreatitis. Additionally, the following minimum critical toxicities were reviewed: bone marrow toxicity (cytopenias), hepatotoxicity, nephrotoxicity, and torsade de pointes/QT prolongation, cardiac arrhythmias, and convulsion.

Overall, no unexpected safety signal was raised from these AESIs and critical toxicities.

A similar rate of embolic and thrombotic events were reported in Ph+ (6.7%) and Ph- relapsed/refractory ALL studies (8%), with a later onset (175 days vs 22 days). The majority of events were grade ≥ 3 and 1 event was reported as serious (2.2%). Thromboembolic events (including DIC) are included in the RMP as an important potential risk.

In Study 20120216 3 patients (6.7%) experienced non serious or fatal cardiac arrhythmia event of atrial fibrillation. The incidence of atrial fibrillation was lower in Ph- relapsed/refractory ALL patients (0.9%).

Overall safety of Blincyto in this study was in line with the known safety profile for Blincyto.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

This safety assessment is based on indirect comparison with known safety profile for blinatumomab in pooled adult RR Phi neg ALL patients, due to the non-comparative design of the pivotal study for this extension of indication in adult RR Phi + ALL patients. Moreover, the interpretation of the safety data and the comparison between the adult Ph-positive and Ph-negative relapsed/refractory ALL populations is limited by the low number of patients included in Study 20120216.

Regarding TEAEs leading to treatment discontinuation, 3 patients (6.7%) presented with such TEAEs in study 20120216, including 2 related TEAEs neutropenia and a case of acute graft versus host disease. A non-interventional PASS is planned (20170610) in US and EU, which will cover the risk: '100-day survival and  risk  of  developing  acute  graft  versus  host  disease  (aGvHD)  in  relapsed/refractory  acute lymphoblastic  leukemia  (ALL)  after  allogeneic  stem  cell  transplant:  blinatumomab  vs  chemotherapy induction' (see RMP).

The observed higher incidence of serious and grade ≥ 4 hepatotoxicity events in Ph+ ALL patients is unexpected due to the baseline minor hepatic impairment of Ph+ adult R/R ALL subjects compared to Ph- adult R/R ALL subjects.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

Table 60. Effects Table for blinatumomab in adult RR Phi + ALL patients, after at least 2 TKIs and without alternative therapeutic option (data cut-off: 20 May 2015 ).

| Effect   | Short description                                                          | Unit               | Treatment                              | Historical Control   | Propensity score analysis                                                                                                              | Uncertainties / Strength of evidence                                                                             | References         |
|----------|----------------------------------------------------------------------------|--------------------|----------------------------------------|----------------------|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|--------------------|
|          | Favourable Effects                                                         | Favourable Effects | Favourable Effects                     | Favourable Effects   | Favourable Effects                                                                                                                     | Favourable Effects                                                                                               | Favourable Effects |
| CR/CRh   | proportion of subjects who achieved CR/CRh within 2 cycles of blinatumomab | Rate               | Blincyto: 35.6% [21.9%, 51.2%]         | SoC: 27.27%          | HR for CR/CRh* (95% CI), non-Bayes IPTW: 1.54 (95% CI: 0.61, 3.89) HR for CR/CRh* (95% CI), Bayes augmented: 1.70 (95% CI: 0.94, 2.94) | Limited population Non comparative study Non-significant propensity score analysis                               |                    |
| RFS      | Relapse free survival                                                      | Months             | Blincyto: Median: 6.8 months [4.4, NE] | SoC: NA              |                                                                                                                                        | Limited population Non comparative study 5 subjects (31.3%) relapse free at the time of last response evaluation |                    |
| OS       | overall survival                                                           | Months CI          | Blincyto: 9.0 5.7, 13.5                | SoC: 6.0 4.4, 9.2    | HR for OS (95% CI), non-Bayes IPTW: 0.81 (95% CI: 0.57, 1.15) HR for OS (95% CI), Bayes augmented: 0.77 (95% CI: 0.61, 0.96)           | Limited population Non comparative study Favourable trend in propensity score analysis                           |                    |

<div style=\"page-break-after: always\"></div>

| Effect                                | Short description    | Unit                                       | Treatment                                                       | Historical Control                   | Propensity score analysis   | Uncertainties / Strength of evidence                                                                                                                                                                               | References           |
|---------------------------------------|----------------------|--------------------------------------------|-----------------------------------------------------------------|--------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|
| allogeneic HSCT and 100-day mortality |                      | Rate (n=45) 100- day mortali ty rate (n=4) | Blincyto: 20.0% 25.0% ( 95% CI: 3.9%, 87.2%)                    | SoC: NA                              |                             | Limited population Non comparative study No difference in OS with or without censoring at time of HSCT All 4 patients dead at 17 months. KM estimated median survival after HSCT: 15.9 months (95% CI: 2.1, 16.9). |                      |
|                                       | Unfavourable Effects | Unfavourable Effects                       | Unfavourable Effects                                            | Unfavourable Effects                 | Unfavourable Effects        | Unfavourable Effects                                                                                                                                                                                               | Unfavourable Effects |
| treatment -related AEs                |                      |                                            | Blincyto, Phi +: 91.1%                                          | Blincyto, Phi - (pooled data): 84.7% |                             | similar trend Higher frequency of related febrile neutropenia (24.4 vs 12.7%)                                                                                                                                      |                      |
| Fatal AEs                             |                      |                                            | Blincyto, Phi +: 6 fatal AEs, including 1 related fatal sepsis. | Blincyto, Phi - (pooled data): 17,2% |                             |                                                                                                                                                                                                                    |                      |
| SAEs                                  |                      |                                            | Blincyto, Phi +: 62.2%                                          | Blincyto, Phi - (pooled data): 63.4% |                             | similar trend                                                                                                                                                                                                      |                      |

Abbreviations: AE: adverse event, CI: confidence interval, CR: complete response, CRh: complete response with partial hematologic recovery; OS: overall survival, HR; hazard ratio, RFS: relapse free survival, SOC: standard of care

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Based on 45 patients included in the pivotal, single-arm study, CR/CRh was obtained in 35.6% of patients [21.9%, 51.2%] within the first 2 cycles of blinatumomab treatment, including 31.1% with CR [18.246.6].  Estimated median RFS from the 16 patients who achieved CR/CRh* after 2 cycles was 6.8 months (95% CI: 4.4, NE). Five subjects (31.3%) remained relapse free at the time of last response evaluation. Median OS was 9.0 months (95% CI: 5.7, 13.5), with 8 patients alive at the time of the last follow-up date and a median FU of 25.1 months. A total of 9 subjects (9/45, 20.0%) had an allogeneic HSCT during the study. The KM estimate of median survival after HSCT was 15.9 months (95% CI: 2.1, 16.9).

No unexpected safety signal was raised in patients from study 201202176, when compared to pooled safety data in adult Phi - RR ALL patients. Overall safety of Blincyto in this study was in line with the known safety profile of the product.

## 3.7.2. Balance of benefits and risks

Considering the unmet medical need for the treatment of Philadelphia-positive ALL adult patients who are resistant to or relapse after first-line therapy and despite the methodological limitations of the noncomparative study the clinical relevance of results presented in these patients is endorsed.

Risk benefit balance of Blincyto in the claimed indication in RR Phi + adult patients is considered positive

## 3.7.3. Additional considerations on the benefit-risk balance

NA

## 3.8. Conclusions

The overall B/R of Blincyto as monotherapy in the treatment of adult patients with Phi + RR ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options is positive.

The overall B/R of Blincyto for the treatment as monotherapy of paediatric patients with Philadelphiapositive relapsed/refractory ALL remains undetermined.

The overall B/R of Blincyto for the treatment of adult patients in first or second hematologic CR with Philadelphia-positive MRD-positive ALL remains undetermined.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and

<div style=\"page-break-after: always\"></div>

therefore recommends by consensus the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

To modify the approved therapeutic indication to include the treatment of Philadelphia chromosome positive CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adult patients with relapsed or refractory ALL who have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the PL are updated accordingly. The updated RMP version 10.0 has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Blincyto is not similar to Xaluprine, Besponsa, Iclusig and Kymriah within the meaning of Article 3 of Commission Regulation (EC) No. 847/200. See appendix 1

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Blincyto EMEA/H/C/003731/II/0030